[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2245
1. Verschuere J, Decroo T, Lim D, Kindermans JM, Nguon C, Huy R, Alkourdi Y, Peeters Grietens K, Gryseels C: Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. Malar J; 2017 Feb 17;16(1):81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study.
  • BACKGROUND: Despite emerging drug resistance in Cambodia, artemisinin-based combination therapy (ACT) is still the most efficacious therapy.
  • ACT is available free of charge in the Cambodian public sector and at a subsidized rate in the private sector.
  • Initial treatment options consist of cheap and accessible home-based care (manual therapy, herbs and biomedical medication) targeting single symptoms.
  • CONCLUSIONS: Cambodian perceptions of illness that focus on single symptoms and their perceived severity may lead to the identification of one or multiple illnesses at the same time, rarely suspecting malaria from the start and implying different patterns of health seeking behaviour and treatment choice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2014 Jul 31;371(5):411-23 [25075834.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):455-67 [19641202.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2006 Nov;100(11):1019-24 [16765399.001]
  • [Cites] PLoS One. 2013 Nov 11;8(11):e80343 [24244678.001]
  • [Cites] Parassitologia. 1998 Jun;40(1-2):217-29 [9653747.001]
  • [Cites] Malar J. 2008 May 29;7:96 [18510724.001]
  • [Cites] Malar J. 2014 Oct 06;13:394 [25288380.001]
  • [Cites] Sci Rep. 2015 Nov 23;5:16837 [26593245.001]
  • [Cites] Malar J. 2016 May 20;15(1):282 [27206729.001]
  • [Cites] BMC Public Health. 2007 Sep 24;7:262 [17892564.001]
  • [Cites] Trop Med Int Health. 2004 Dec;9(12):1241-6 [15598255.001]
  • [Cites] Microbiol Spectr. 2016 Jun;4(3):null [27337450.001]
  • [Cites] Science. 2010 May 14;328(5980):866-71 [20466925.001]
  • [Cites] Malar J. 2016 Aug 26;15(1):434 [27562347.001]
  • [Cites] Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):39-50 [25897063.001]
  • [Cites] Lancet Infect Dis. 2012 Nov;12(11):820-2 [22940026.001]
  • [Cites] Clin Infect Dis. 2010 Dec 1;51(11):e82-9 [21028985.001]
  • [Cites] Trop Med Int Health. 2001 Nov;6(11):845-8 [11703837.001]
  • [Cites] Malar J. 2014 Sep 30;13:385 [25266007.001]
  • [Cites] Malar J. 2015 Jun 20;14:252 [26088924.001]
  • [Cites] Lancet Infect Dis. 2002 Apr;2(4):209-18 [11937421.001]
  • (PMID = 28212641.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Ganfon H, Diallo T, Nanga C, Coulibaly N, Benao V, Ekanmian G, Sandouidi A, Daniel Garcia E: Private pharmacy staff in five main towns in Benin, Burkina Faso, and Mali: knowledge and practices concerning malaria care in 2014. Med Sante Trop; 2017 Jun 01;27(2):164-169

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Connaissances et pratiques de la prise en charge du paludisme par le personnel des pharmacies privées de cinq grandes villes du Bénin, Burkina Faso et Mali en 2014.
  • A pretested questionnaire was administered to the supervisor present in each pharmacy at the time of the survey.
  • Data were collected by local students in the first quarter of 2014.
  • Among the participants, 84% knew about the national malaria control program, and 77.7% about artemisinin-based combination therapy (ACT), while 38.8% knew the national protocols.
  • Licensed pharmacists had a better knowledge of ACT than their assistants, and training improved knowledge of treatment for uncomplicated malaria episodes.
  • They are ready to advise ACT when appropriate after rapid detection tests.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28655677.001).
  • [ISSN] 2261-2211
  • [Journal-full-title] Medecine et sante tropicales
  • [ISO-abbreviation] Med Sante Trop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Keywords] NOTNLM ; ACT / Malaria / West Africa / practices / private pharmacies
  •  go-up   go-down


3. Wang X, Wu X, Liu K, Xia L, Lin X, Liu W, Gao Z: Topical cryoanesthesia for the relief of pain caused by steroid injections used to treat hypertrophic scars and keloids. Medicine (Baltimore); 2017 Oct;96(43):e8353
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The procedure is, however, quite painful and is unpopular with patients because of this.
  • The onset of the analgesic effect is also slow, which means that the use of topical anesthetics is time-consuming in clinical practice.We hypothesized that a commercially available cryotip could be used to provide fast-acting topical cryoanesthesia that would reduce the pain associated with steroid injections.Thirty patients with hypertrophic scars or keloids were enrolled in the study.
  • The degree of pain was evaluated in each case using the visual analogue scale (VAS) and the verbal descriptor scale (VDS), together with any side-effects caused by application of the cryotip.The VAS pain scores showed a statistically significant (P < .01) difference between the pretreated and the control scars (pain scores 7.87 ± 1.31 and 2.7 ± 1.37, respectively).
  • The VDS pain scores also showed a statistically significant (P < .01) difference between the pretreated and the control scars.
  • [MeSH-major] Anesthetics, Local / administration & dosage. Cryoanesthesia / instrumentation. Glucocorticoids / administration & dosage. Pain / drug therapy. Triamcinolone Acetonide / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Cicatrix, Hypertrophic / drug therapy. Female. Humans. Injections, Intralesional / adverse effects. Injections, Intralesional / methods. Keloid / drug therapy. Male. Middle Aged. Pain Measurement. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29069016.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Glucocorticoids; F446C597KA / Triamcinolone Acetonide
  •  go-up   go-down


Advertisement
4. Baumert TF, Jühling F, Ono A, Hoshida Y: Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med; 2017 Mar 14;15(1):52
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New direct-acting antivirals substantially improved the cure rate to above 90%.
  • Direct-acting antivirals may affect cancer development and recurrence, which needs to be determined in further investigation.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / virology. Hepatitis C / complications. Hepatitis C / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / virology
  • [MeSH-minor] Hepacivirus / physiology. Humans. Interferons / therapeutic use. Liver Cirrhosis / drug therapy. Liver Cirrhosis / pathology. Liver Cirrhosis / virology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2016 Jun;64(6):1217-23 [27059129.001]
  • [Cites] Int J Med Sci. 2014 May 07;11(7):707-12 [24843320.001]
  • [Cites] J Hepatol. 2017 Jan;66(1):153-194 [27667367.001]
  • [Cites] J Infect Dis. 2016 Mar 15;213(6):966-74 [26582959.001]
  • [Cites] Clin Infect Dis. 2016 Aug 15;63(4):528-31 [27225242.001]
  • [Cites] J Med Virol. 2011 Jun;83(6):1016-22 [21503914.001]
  • [Cites] J Hepatol. 2017 Mar;66(3):504-513 [27818234.001]
  • [Cites] J Viral Hepat. 2015 Dec;22(12):983-91 [26482547.001]
  • [Cites] J Infect Dis. 2016 Jan 15;213(2):216-23 [26223768.001]
  • [Cites] Gastroenterology. 2016 Oct;151(4):633-636.e3 [27373513.001]
  • [Cites] J Gastroenterol Hepatol. 2015 Dec;30(12 ):1768-74 [26094738.001]
  • [Cites] Lancet Infect Dis. 2016 Sep;16(9):e196-201 [27421993.001]
  • [Cites] Liver Int. 2016 Dec;36(12 ):1793-1799 [27254286.001]
  • [Cites] Am J Med. 1982 Dec;73(6):883-8 [7148881.001]
  • [Cites] Liver Int. 2009 Jan;29(1):126-32 [18492017.001]
  • [Cites] Gastroenterology. 2016 Jul;151(1):70-86 [27080301.001]
  • [Cites] Hepatol Res. 2016 Nov 10;:null [27859993.001]
  • [Cites] J Hepatol. 2016 Oct;65(1 Suppl):S2-S21 [27641985.001]
  • [Cites] J Gastroenterol Hepatol. 2016 Aug 30;:null [27577675.001]
  • [Cites] J Hepatol. 2017 Jan;66(1):19-27 [27545496.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):727-33 [27349488.001]
  • [Cites] Medicine (Baltimore). 2016 Jul;95(27):e4157 [27399135.001]
  • [Cites] Hepatology. 2016 Nov;64(5):1442-1450 [27015107.001]
  • [Cites] Clin Infect Dis. 2016 Sep 15;63(6):723-9 [27282709.001]
  • [Cites] Oncology. 2016;90(3):167-75 [26901157.001]
  • [Cites] J Med Virol. 2017 Mar;89(3):476-483 [27531586.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):734-40 [27288051.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):859-60 [27392425.001]
  • [Cites] Clin Infect Dis. 2016 Mar 15;62(6):683-94 [26787172.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):719-26 [27084592.001]
  • [Cites] Lancet Infect Dis. 2016 Jun;16(6):735-45 [27301929.001]
  • [Cites] J Gastroenterol Hepatol. 2015 Jul;30(7):1183-9 [25678094.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):856-8 [27318327.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):741-7 [27388925.001]
  • [Cites] J Gastroenterol. 2014 Nov;49(11):1504-13 [24317936.001]
  • [Cites] Clin Gastroenterol Hepatol. 2010 Nov;8(11):924-33; quiz e117 [20713178.001]
  • [Cites] N Engl J Med. 2016 Oct 27;375(17 ):1699-1701 [27783921.001]
  • [Cites] J Hepatol. 2014 Jul;61(1):67-74 [24613362.001]
  • [Cites] J Hepatol. 2016 Dec;65(6):1086-1093 [27569777.001]
  • [Cites] Hepatology. 2016 Jul;64(1):130-7 [26946190.001]
  • [Cites] Lancet. 2015 Mar 21;385(9973):1124-35 [25687730.001]
  • [Cites] Nat Med. 2013 Jul;19(7):850-8 [23836235.001]
  • [Cites] Viruses. 2015 Dec 04;7(12):6346-59 [26690198.001]
  • [Cites] J Antimicrob Chemother. 2016 Jul;71(7):1943-7 [27073265.001]
  • [Cites] J Hepatol. 2014 Sep;61(3):538-43 [24905492.001]
  • [Cites] J Gastroenterol Hepatol. 2016 May;31(5):1009-15 [26584407.001]
  • [Cites] Gastroenterology. 2017 Jan;152(1):142-156.e2 [27641509.001]
  • [Cites] Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37 [23460056.001]
  • [Cites] Cancer Cell. 2016 Dec 12;30(6):879-890 [27960085.001]
  • [Cites] N Engl J Med. 2014 Apr 24;370(17):1576-8 [24720678.001]
  • [Cites] J Hepatol. 2016 Feb;64(2):326-32 [26386160.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):148-56 [15770398.001]
  • [Cites] Aliment Pharmacol Ther. 2017 Jan;45(1):160-168 [27790734.001]
  • [Cites] BMC Gastroenterol. 2014 Aug 07;14:137 [25100159.001]
  • [Cites] Hepatology. 2012 Jun;55(6):1652-61 [22213025.001]
  • [Cites] Gastroenterology. 2015 Nov;149(6):1471-1482.e5; quiz e17-8 [26255044.001]
  • [Cites] Gastroenterology. 2011 Mar;140(3):840-9; quiz e12 [21129375.001]
  • [Cites] J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9 [25055928.001]
  • [Cites] Gastroenterology. 2015 Jul;149(1):190-200.e2 [25754160.001]
  • [Cites] Expert Rev Vaccines. 2016 Dec;15(12 ):1535-1544 [27267297.001]
  • [Cites] J Infect Public Health. 2016 Jul-Aug;9(4):389-95 [26148849.001]
  • [Cites] Liver Int. 2014 Nov;34(10):1447-51 [24840955.001]
  • [Cites] J Hepatol. 2016 Dec;65(6):1272-1273 [27524465.001]
  • [Cites] J Hepatol. 2015 Dec;63(6):1323-33 [26220749.001]
  • [Cites] J Hepatol. 2014 Nov;61(1 Suppl):S79-90 [25443348.001]
  • [Cites] J Clin Oncol. 2016 May 20;34(15):1787-94 [27044939.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Jul;12(7):1186-95 [24321207.001]
  • [Cites] Clin Gastroenterol Hepatol. 2016 Nov;14 (11):1662-1666.e1 [27211502.001]
  • [Cites] J Antimicrob Chemother. 2012 Nov;67(11):2766-72 [22899800.001]
  • [Cites] Hepatology. 2014 Nov;60(5):1767-75 [24839253.001]
  • [Cites] Liver Int. 2016 Jun;36(6):817-26 [26787002.001]
  • [Cites] J Hepatol. 2017 Mar;66(3):485-493 [27780714.001]
  • [Cites] J Hepatol. 2014 Sep;61(3):530-7 [24824282.001]
  • (PMID = 28288626.001).
  • [ISSN] 1741-7015
  • [Journal-full-title] BMC medicine
  • [ISO-abbreviation] BMC Med
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK099558
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  • [Keywords] NOTNLM ; Direct-acting antivirals / Hepatitis C virus / Hepatocellular carcinoma / Interferon / Sustained virologic response
  •  go-up   go-down


5. Macià I Garau M: Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother; 2017 Mar-Apr;22(2):86-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiobiology of stereotactic body radiation therapy (SBRT).
  • Stereotactic body radiotherapy delivers high doses of radiation to small and well-defined targets in an extreme hypofractionated (and accelerated) scheme with a very high biological effectiveness obtaining very good initial clinical results in terms of local tumor control and acceptable rate of late complications.
  • Only through a better understanding of how high doses of ionizing radiation act, clinicians will know exactly what we do, allowing us in the future to refine our treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 2012 Mar;177(3):311-27 [22229487.001]
  • [Cites] Semin Radiat Oncol. 2015 Jan;25(1):54-64 [25481267.001]
  • [Cites] Radiother Oncol. 1999 Dec;53(3):219-26 [10660202.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3381-4 [19661360.001]
  • [Cites] J Appl Clin Med Phys. 2011 Feb 08;12(2):3368 [21587185.001]
  • [Cites] Radiat Oncol. 2008 Oct 31;3:36 [18976463.001]
  • [Cites] Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):446-53 [26696785.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1761-9 [7153088.001]
  • [Cites] Science. 2003 May 16;300(5622):1155-9 [12750523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):323-7 [20832663.001]
  • [Cites] Radiother Oncol. 2014 Mar;110(3):499-504 [24630539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8 [18755555.001]
  • [Cites] JAMA. 2010 Mar 17;303(11):1070-6 [20233825.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):437-47 [15170446.001]
  • [Cites] Acta Oncol. 1988;27(2):131-46 [3390344.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1026-32 [15519771.001]
  • [Cites] Sci Transl Med. 2015 Mar 11;7(278):278ra34 [25761890.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] J Thorac Oncol. 2009 Aug;4(8):976-82 [19633473.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):11-3 [25835617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):242-9 [15093921.001]
  • [Cites] Future Oncol. 2014 Dec;10(15):2319-28 [25525842.001]
  • [Cites] Sci Transl Med. 2012 Jun 6;4(137):137ra74 [22674552.001]
  • [Cites] Acta Oncol. 2006;45(7):831-7 [16982547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):344-50 [25636759.001]
  • [Cites] Lancet Oncol. 2009 Jul;10(7):718-26 [19573801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):254-62 [24411596.001]
  • [Cites] Cancer Lett. 2015 Jan 1;356(1):82-90 [24125863.001]
  • [Cites] Radiology. 1972 Oct;105(1):135-42 [4506641.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1579-84 [19255320.001]
  • [Cites] Radiother Oncol. 2009 Dec;93(3):408-13 [19454366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Phys Med Biol. 2006 Jun 7;51(11):2813-23 [16723768.001]
  • [Cites] Front Oncol. 2012 Aug 07;2:88 [22891162.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):336-42 [23433800.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):751-9 [3350731.001]
  • [Cites] Cancer. 2011 Sep 1;117(17):4060-9 [21432842.001]
  • [Cites] Cell. 2011 Mar 4;144(5):646-74 [21376230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82 [19251380.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Apr;37(4):469-71 [6968732.001]
  • [Cites] J Radiat Res. 2016 Aug;57 Suppl 1:i76-i82 [27006380.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53 [18990511.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):549-62 [7558943.001]
  • [Cites] Radiat Res. 2000 Mar;153(3):295-304 [10669551.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):89-91 [16098459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):847-52 [18262098.001]
  • [Cites] Pract Radiat Oncol. 2012 Oct-Dec;2(4):288-95 [24674167.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1585-91 [19255313.001]
  • [Cites] Br J Radiol. 1953 May;26(305):234-41 [13042090.001]
  • [Cites] Annu Rev Immunol. 2013;31:51-72 [23157435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):757-64 [26530743.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4833-9 [17050868.001]
  • [Cites] Radiother Oncol. 2009 Jun;91(3):360-8 [19410314.001]
  • [Cites] Semin Radiat Oncol. 2008 Oct;18(4):240-3 [18725110.001]
  • [Cites] Ann Surg Oncol. 2011 Apr;18(4):1081-7 [21046264.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):164-70 [11134209.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1159-60 [23517805.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1572-8 [19255321.001]
  • [Cites] Semin Radiat Oncol. 2008 Oct;18(4):234-9 [18725109.001]
  • [Cites] Semin Radiat Oncol. 2015 Apr;25(2):93-9 [25771413.001]
  • [Cites] Cancer. 2012 Apr 15;118(8):2078-84 [22009495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1047-57 [22284028.001]
  • [Cites] Pract Radiat Oncol. 2015 Sep-Oct;5(5):282-5 [26127008.001]
  • [Cites] Blood. 2009 Jul 16;114(3):589-95 [19349616.001]
  • [Cites] Med Phys. 2010 Aug;37(8):4078-101 [20879569.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93 [20350791.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):117-23 [8365932.001]
  • [Cites] Acta Oncol. 2006;45(7):823-30 [16982546.001]
  • [Cites] J Neurosurg Spine. 2007 Aug;7(2):151-60 [17688054.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1006-11 [23102838.001]
  • [Cites] Radiat Oncol J. 2015 Dec;33(4):265-75 [26756026.001]
  • [Cites] N Engl J Med. 2012 Mar 8;366(10 ):925-31 [22397654.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):478-84 [22386374.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):18-9 [23608235.001]
  • [Cites] Radiother Oncol. 2009 Jun;91(3):307-13 [19321217.001]
  • (PMID = 28490978.001).
  • [ISSN] 1507-1367
  • [Journal-full-title] Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
  • [ISO-abbreviation] Rep Pract Oncol Radiother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Radiobiology / SBRT / Stereotactic body radiation therapy
  •  go-up   go-down


6. Zhou B, Liao Y, Guo Y, Tarner IH, Liao C, Chen S, Kermany MH, Tu H, Zhong S, Chen P: Adoptive Cellular Gene Therapy for the Treatment of Experimental Autoimmune Polychondritis Ear Disease. ORL J Otorhinolaryngol Relat Spec; 2017;79(3):166-177
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adoptive Cellular Gene Therapy for the Treatment of Experimental Autoimmune Polychondritis Ear Disease.
  • In the past, the clinical therapy for autoimmune diseases, such as autoimmune polychondritis ear disease, was mostly limited to nonspecific immunosuppressive agents, which could lead to variable responses.
  • Currently, gene therapy aims at achieving higher specificity and less adverse effects.
  • However, IL-12p40-transduced T cells suppressed IFN-γ and augmented IL-4 production, indicating their potential to act therapeutically by interrupting Th1-mediated inflammatory responses via augmenting Th2 responses.
  • These results indicate that the local delivery of IL-12p40 by T cells could inhibit CIAPED by suppressing autoimmune responses at the site of inflammation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28463837.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Adoptive cellular gene therapy / Autoimmune polychondritis ear disease / IL-12p40
  •  go-up   go-down


7. Rupreht RR, Mozetič-Francky B, Francky A, Matis M, Škoberne M, Galvani V, Malovrh T, Kotnik V, Šerbec VČ: Murine monoclonal antibodies directed against human recombinant Macrophage Migration Inhibitory Factor. Pflugers Arch; 2000 Jan;440(Suppl 1):R078-R080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Macrophage Migration Inhibitory Factor (MIF) is a crucial component of the immune system acting together with glucocorticosteroids to regulate immunity and inflammation.
  • Due to the newest findings that a local MIF expression is up regulated in allograft rejection and in glomerulonephritis, an interest in MIF research is increasing and is focused on possibilities of anti-MIF treatment.In the present work new murine monoclonal antibodies (MAbs) directed against human recombinant MIF (hrMIF) are described. hrMIF protein used for the immunisation was tested for its biological activity and has evident macrophage migration inhibitory activity.
  • Anti-MIF MAb designated as Ml inhibited MIF activity in the test, which was performed in the 48 well Boyden chamber system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28008489.001).
  • [ISSN] 1432-2013
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Key words MIF / anti-MIF MAb / anti-MIF therapy / immune response
  •  go-up   go-down


8. Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L, ACT II study group: Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol; 2017 Mar;18(3):347-356
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
  • Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after chemoradiotherapy.
  • METHODS: The previously reported ACT II trial was a phase 3 randomised trial of patients of any age with newly diagnosed, histologically confirmed, squamous cell carcinoma of the anus without metastatic disease from 59 centres in the UK.
  • We randomly assigned patients (by minimisation) to receive either intravenous mitomycin (one dose of 12 mg/m<sup>2</sup> on day 1) or intravenous cisplatin (one dose of 60 mg/m<sup>2</sup> on days 1 and 29), with intravenous fluorouracil (one dose of 1000 mg/m<sup>2</sup> per day on days 1-4 and 29-32) and radiotherapy (50·4 Gy in 28 daily fractions); and also did a second randomisation after initial therapy to maintenance chemotherapy (fluorouracil and cisplatin) or no maintenance chemotherapy.
  • The primary outcome was complete clinical response (the absence of primary and nodal tumour by clinical examination), in addition to overall survival and progression-free survival from time of randomisation.
  • Our data suggests that the optimum time for assessment of complete clinical response after chemoradiotherapy for patients with squamous cell carcinoma of the anus is 26 weeks from starting chemoradiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Chemoradiotherapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Dose Fractionation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Prognosis. Remission Induction. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
  • [Cites] Gastrointest Cancer Res. 2014 Jan;7(1):4-14 [24558509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] BMC Cancer. 2011 Feb 03;11:55 [21291546.001]
  • [Cites] Ann Oncol. 2014 Sep;25 Suppl 3:iii10-20 [25001200.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Br J Cancer. 2010 Mar 30;102(7):1123-8 [20354531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1467-78 [20605354.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):715-21 [20171812.001]
  • [Cites] Oncology. 1993;50(1):14-7 [8421594.001]
  • [Cites] J Natl Compr Canc Netw. 2010 Jan;8(1):106-20 [20064293.001]
  • [Cites] Eur Radiol. 2011 Apr;21(4):776-85 [20890758.001]
  • [Cites] Am J Obstet Gynecol. 2011 Jun;204(6):466-78 [21752752.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):780-4 [15966204.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):66-72 [22592047.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e173-80 [22436791.001]
  • [Cites] J Clin Oncol. 2012 Jun 1;30(16):1941-8 [22529257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1316-24 [16169674.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet Oncol. 2013 May;14 (6):516-24 [23578724.001]
  • [CommentIn] Strahlenther Onkol. 2017 Jul;193(7):593-594 [28523338.001]
  • (PMID = 28209296.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. McArthur TA, Narducci CA, Lander PH, Lopez-Ben R: Percutane Image-Guided Cryoablation of Painful Osseous Metastases: A Retrospective Single-Center Review. Curr Probl Diagn Radiol; 2017 Jul - Aug;46(4):282-287
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this institutional review board-approved, health insurance portability and accountability act-compliant study, we retrospectively searched our department׳s picture archiving system for patients who underwent computed tomography (CT)-guided percutaneous cryoablation for treatment of painful metastatic osseous disease over a 6-year period (1/1/2005-12/31/2011).
  • The preprocedure and postprocedure images and imaging reports, primary tumor type, CT-guided cryoablation procedure details, treated tumor response, immediate and 3-month postprocedure complications, reported pain response to cryoablation, postprocedural tumor imaging characteristics, and imaging response of noncryoablated systemically treated metastatic lesions were reviewed in patients with metastatic osseous disease who underwent cryoablation.
  • RESULTS: All 16 patients reported improvement in pain within 1 week after the procedure and at 3-month clinical follow-up.
  • A total of 6.2% had tumor growth and 93.8% had tumor arrest or shrinkage on follow-up CT, although all study patients had progression of noncryoablated metastases at other sites despite systemic therapy.
  • A total of 62.5% of patients with posttreatment contrasted CT demonstrated marginal enhancement at the ablation site, although only single patient had interval growth.
  • CONCLUSION: Most of our patients had tumor arrest or shrinkage on follow-up imaging, despite progression of noncryoablated metastases treated with preprocedure and postprocedure systemic therapy.
  • Radiation therapy, chemotherapy, and analgesics have a moderate failure rate and require repeat treatments where quality of life is the foremost objective.
  • CT-guided cryoablation is a safe palliative treatment to reduce pain in patients with painful osseous metastatic disease, achieve effective local tumor control, and in some cases, provide a curative option for a target lesion.
  • [MeSH-major] Bone Neoplasms / secondary. Bone Neoplasms / surgery. Cryosurgery / methods. Radiography, Interventional. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Pain Measurement. Quality of Life. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28034477.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sugarbaker PH: Strategies to improve local control of resected pancreas adenocarcinoma. Surg Oncol; 2017 Mar;26(1):63-70
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to improve local control of resected pancreas adenocarcinoma.
  • The disease has an anatomic location that makes it difficult for the surgeon to maintain adequate margins of resection and prevent tumor spillage at the time of resection.
  • A regional chemotherapy treatment that consists of hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine and long-term normothermic intraperitoneal chemotherapy (NIPEC-LT) gemcitabine for 6 months postoperatively is suggested as a new treatment that has demonstrated decreases in local-regional failure and promises to more adequately target micrometastases in the peritoneal space, in the liver and lymph nodes.
  • Long-term intraperitoneal gemcitabine may act on micrometastases in the liver through absorption into the portal vein blood and the lymph nodes as a result of gemcitabine absorption by subperitoneal lymphatic channels.
  • The use of HIPEC and NIPEC-LT gemcitabine may improve local control of resected pancreas cancer.
  • [MeSH-major] Adenocarcinoma / prevention & control. Pancreatectomy. Pancreatic Neoplasms / prevention & control
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28317586.001).
  • [ISSN] 1879-3320
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Gemcitabine / Hyperthermic perioperative chemotherapy (HIPEC) / Intraoperative radiation therapy / Intraperitoneal port / Pancreaticoduodenectomy / Total pancreatectomy / Whipple procedure
  •  go-up   go-down


11. Kanda S, Narita S, Komine N, Kitajima S, Yamauchi M, Sugita A, Saito Y, Habuchi T: [A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy]. Hinyokika Kiyo; 2016 Dec;62(12):647-650
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy].
  • We present a case of gigantic prostate tumor in a patient with castration-resistant prostate cancer with successful local control by external-beam radiation therapy.
  • He achieved a PSA nadir at 4 months after the initial androgen deprivation therapy and was diagnosed with castration-resistant prostate cancer three years later.
  • Abdominal computed tomography scan showed a gigantic prostatic mass occupying the whole pelvic cavity along with multiple lymph node, bone and liver metastases.
  • He underwent external beam radiation therapy (60 Gy) to the prostate, which brought about excellent local control with a 96.7% shrinkage of tumor at 2 months after radiation therapy.
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Male. Proton Therapy. Tomography, X-Ray Computed. Treatment Outcome. Urinary Retention / etiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28103659.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Li X, Chan NS, Tam AW, Hung IFN, Chan EW: Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis; 2017 May 17;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
  • The purpose of this investigation was to evaluate the budget impact and cost-effectiveness of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection in Hong Kong.
  • A decision analytic model was developed to compare short-term costs and health outcomes of patients with chronic HCV genotype 1 infection in Hong Kong who were treated with an interferon (INF)-based treatment (dual therapy of pegylated interferon and ribavirin) or DAA-based treatments (sofosbuvir or ledipasvir/sofosbuvir or ombitasvir/paritaprevir/ritonavir plus dasabuvir).
  • The incremental cost-effective ratios of DAA-based treatments ranged from $9724 to $29,189 per treatment success, which were all below the cost-effectiveness threshold of local GDP per capita ($42,423 in 2015).
  • Introducing DAAs to the public hospital formulary yields a considerable budget increase but is still economically favorable to the local government.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2012 Dec 26;308(24):2584-93 [23268517.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):787-800 [26289734.001]
  • [Cites] JAMA. 2014 Aug 13;312(6):631-40 [25117132.001]
  • [Cites] AIDS Patient Care STDS. 2014 Jan;28(1):4-9 [24428794.001]
  • [Cites] Value Health. 2014 Jan-Feb;17(1):5-14 [24438712.001]
  • [Cites] J Hepatol. 2016 Feb;64(2):301-307 [26476290.001]
  • [Cites] Int J Med Sci. 2006;3(2):47-52 [16614742.001]
  • [Cites] Hepatology. 2013 Jun;57(6):2164-70 [23280550.001]
  • [Cites] Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5 [22715208.001]
  • [Cites] Clinicoecon Outcomes Res. 2012;4:349-59 [23180971.001]
  • [Cites] Ann Intern Med. 2015 Mar 17;162(6):407-19 [25775313.001]
  • [Cites] Eur J Clin Pharmacol. 2017 Jan;73(1):1-14 [27757504.001]
  • [Cites] N Engl J Med. 2014 May 15;370(20):1889-98 [24725239.001]
  • [Cites] Lancet. 2012 Dec 15;380(9859):2095-128 [23245604.001]
  • [Cites] BMC Res Notes. 2014 Apr 24;7:266 [24758162.001]
  • [Cites] P T. 2014 Jul;39(7):517 [25083130.001]
  • [Cites] Clin Infect Dis. 2016 May 1;62(9):1066-71 [26908799.001]
  • [Cites] N Engl J Med. 2011 Mar 31;364(13):1207-17 [21449784.001]
  • [Cites] J Med Econ. 2015 ;18(10 ):838-49 [25903830.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):471-85 [23199506.001]
  • [Cites] J Med Econ. 2015;18(9):678-90 [25891129.001]
  • [Cites] Pharmacoeconomics. 2015 Dec;33(12 ):1255-68 [26105525.001]
  • [Cites] N Engl J Med. 2014 May 22;370(21):1973-82 [24725237.001]
  • [Cites] J Med Virol. 2006 May;78(5):574-81 [16555294.001]
  • [Cites] Gut. 2015 Aug;64(8):1277-88 [25311032.001]
  • [Cites] Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):285-94 [26327360.001]
  • [Cites] N Engl J Med. 2011 Mar 31;364(13):1195-206 [21449783.001]
  • [Cites] PLoS One. 2015 May 14;10(5):e0126984 [25974722.001]
  • [Cites] Aliment Pharmacol Ther. 2015 Mar;41(6):544-63 [25619871.001]
  • [Cites] Aliment Pharmacol Ther. 2014 Sep;40(6):657-75 [25065960.001]
  • [Cites] Clin Infect Dis. 2015 Jul 15;61(2):157-68 [25778747.001]
  • [Cites] J Med Econ. 2015;18(7):502-11 [25763827.001]
  • [Cites] PLoS One. 2015 Dec 31;10(12):e0145953 [26720298.001]
  • [Cites] Gastroenterology. 2014 Aug;147(2):359-365.e1 [24818763.001]
  • [Cites] World J Gastroenterol. 2013 Oct 28;19(40):6703-9 [24187444.001]
  • [Cites] J Hepatol. 2014 Nov;61(1 Suppl):S45-57 [25086286.001]
  • [Cites] Curr Opin Infect Dis. 2015 Dec;28(6):563-71 [26524328.001]
  • [Cites] Gastroenterol Hepatol (N Y). 2007 Jun;3(6 Suppl 20):4-32 [23329897.001]
  • (PMID = 28516201.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Aldridge A, Dowd W, Bray J: The relative impact of brief treatment versus brief intervention in primary health-care screening programs for substance use disorders. Addiction; 2017 Feb;112 Suppl 2:54-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND PARTICIPANTS: A total of 9029 patients with both baseline and follow-up interviews were identified in the US Government Performance and Results Act (GPRA) data from October 2004 and February 2008.
  • Using a propensity score framework, multiple generalized linear mixed models and a local linear matching method with a difference in difference estimator, patients from the BI group that resemble BT patients were used to determine the relative treatment effect of BT.
  • A total of 3218 of these US patients with baseline and follow-up interviews were used in the final analysis sample after the propensity score-matching procedure (1448 patients assigned to a BI service category and 1770 assigned to a BT service category).
  • BT was found to reduce the frequency of use of illicit drugs at follow-up by 0.634 days more than BI (P < 0.05).
  • Higher severity patients assigned to BT had a decrease in days of illicit drug use of 1.765 (P < 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Society for the Study of Addiction.
  • (PMID = 28074568.001).
  • [ISSN] 1360-0443
  • [Journal-full-title] Addiction (Abingdon, England)
  • [ISO-abbreviation] Addiction
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Brief intervention / SBI / SBIRT / brief therapy / brief treatment / illicit drugs / propensity score / quasi-experimental
  •  go-up   go-down


14. Yoo ER, Perumpail RB, Cholankeril G, Jayasekera CR, Ahmed A: The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C. Telemed J E Health; 2017 Oct;23(10):870-873

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C.
  • PURPOSE: Recently, we reported the successful application of task-shifting to improve the management of patients with chronic hepatitis C virus (HCV) infection receiving treatment with direct-acting antiviral (DAA) agents in underserved areas of California.
  • A nonphysician healthcare provider worked in close conjunction with a hepatologist to monitor the patients during the course of antiviral therapy.
  • We exclusively used our institution-based, secured e-health portal as the means of communication with the local staff and patients in outreach clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28375820.001).
  • [ISSN] 1556-3669
  • [Journal-full-title] Telemedicine journal and e-health : the official journal of the American Telemedicine Association
  • [ISO-abbreviation] Telemed J E Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; e-health / healthcare access / hepatitis C virus / task-shifting / telemedicine
  •  go-up   go-down


15. Leone M, Giustiniani A, Cecchini AP: Cluster headache: present and future therapy. Neurol Sci; 2017 May;38(Suppl 1):45-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster headache: present and future therapy.
  • Cluster headache attacks need fast-acting abortive agents because the pain peaks very quickly; sumatriptan injection is the gold standard acute treatment.
  • Steroids are very effective; local injection in the occipital area is also effective but its prolonged use needs caution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2016 May 3;86(18):1676-82 [27029635.001]
  • [Cites] Brain Res. 2008 Feb 27;1196:22-32 [18221935.001]
  • [Cites] Neurology. 2000 Mar 28;54(6):1382-5 [10746617.001]
  • [Cites] Cephalalgia. 2017 Apr;37(5):423-434 [27165493.001]
  • [Cites] Cephalalgia. 1989 Sep;9(3):195-8 [2507161.001]
  • [Cites] Eur J Neurol. 2007 Sep;14(9):1008-15 [17718693.001]
  • [Cites] Headache. 1989 Mar;29(3):167-8 [2708046.001]
  • [Cites] N Engl J Med. 1991 Aug 1;325(5):322-6 [1647496.001]
  • [Cites] Cephalalgia. 1996 Nov;16(7):494-6 [8933994.001]
  • [Cites] Cochrane Database Syst Rev. 2015 Dec 28;(12):CD005219 [26709672.001]
  • [Cites] Acta Neurol Scand. 1993 Jul;88(1):63-9 [8396833.001]
  • [Cites] Cephalalgia. 2015 Apr;35(4):317-26 [24958681.001]
  • [Cites] Brain. 1994 Jun;117 ( Pt 3):427-34 [7518321.001]
  • [Cites] Headache. 2004 May;44 Suppl 1:S20-30 [15149490.001]
  • [Cites] Cephalalgia. 2004;24 Suppl 1:9-160 [14979299.001]
  • [Cites] Lancet Neurol. 2012 Aug;11(8):708-19 [22814542.001]
  • [Cites] J Headache Pain. 2013 Oct 21;14:86 [24144382.001]
  • [Cites] Cephalalgia. 2000 Mar;20(2):85-91 [10961763.001]
  • [Cites] Neurology. 2003 Feb 25;60(4):630-3 [12601104.001]
  • [Cites] Cephalalgia. 2002 Nov;22(9):730-9 [12421159.001]
  • [Cites] Headache. 1991 Sep;31(8):525-32 [1960057.001]
  • [Cites] PLoS One. 2016 Mar 18;11(3):e0150334 [26990646.001]
  • [Cites] Headache. 1981 Jul;21(4):132-9 [7021473.001]
  • [Cites] Ann Neurol. 2004 Oct;56(4):488-94 [15455406.001]
  • [Cites] Neurology. 2010 Oct 26;75(17):1520-6 [20975053.001]
  • [Cites] Headache. 2007 Jan;47(1):81-9 [17355498.001]
  • [Cites] Pain. 2009 Nov;146(1-2):84-90 [19679396.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1948 Mar 3;23(5):105-8 [18905478.001]
  • [Cites] Headache. 2004 Mar;44(3):249-55 [15012663.001]
  • [Cites] Cephalalgia. 2017 Jul;37(8):756-763 [27250232.001]
  • [Cites] Drugs. 1972;3(3):159-203 [4403890.001]
  • [Cites] Pain. 2013 Jan;154(1):89-94 [23103434.001]
  • [Cites] Headache. 1990 Jun;30(7):411-7 [2205598.001]
  • [Cites] Reg Anesth Pain Med. 2001 Jul-Aug;26(4):373-5 [11464360.001]
  • [Cites] J Headache Pain. 2010 Feb;11(1):23-31 [19936616.001]
  • [Cites] Neurology. 2003 Apr 22;60(8):1360-2 [12707445.001]
  • [Cites] Neurology. 2015 Mar 24;84(12):1249-53 [25713002.001]
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3589-93 [16571767.001]
  • [Cites] Cephalalgia. 2003 Dec;23(10):1001-2 [14984235.001]
  • [Cites] Neurology. 2007 Aug 14;69(7):668-75 [17698788.001]
  • [Cites] Cephalalgia. 2013 Jul;33(10):816-30 [23314784.001]
  • [Cites] Curr Pain Headache Rep. 2010 Apr;14(2):140-4 [20425203.001]
  • [Cites] Cephalalgia. 2014 Nov;34(13):1100-10 [24740514.001]
  • [Cites] Lancet Neurol. 2015 Nov;14(11):1091-100 [26432181.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(4):382-90 [26879279.001]
  • [Cites] Cephalalgia. 1986 Mar;6(1):51-4 [3516408.001]
  • [Cites] Pain. 2005 Nov;118(1-2):92-6 [16202532.001]
  • [Cites] Cephalalgia. 2002 Apr;22(3):205-8 [12047460.001]
  • (PMID = 28527055.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Keywords] NOTNLM ; CGRP / Cluster headache / Drugs / Neurostimulation / Treatment
  •  go-up   go-down


16. Di CY, Wan Z, Lin WH: [Efficacy and safety of Rivaroxaban anticoagulant therapy in the treatment of atrial fibrillation cryoablation]. Zhonghua Yi Xue Za Zhi; 2017 Sep 05;97(33):2591-2594
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of Rivaroxaban anticoagulant therapy in the treatment of atrial fibrillation cryoablation].
  • <b>Objective:</b> To observe the efficacy and safety of the novel oral anticoagulant Rivaroxaban for anticoagulation therapy in patients with nonvalvular atrial fibrillation (AF) during cryoablation.
  • <b>Methods:</b> A total of 137 AF patients from October 2013 to December 2016 underwent cryoablation were divided into two groups according to the application of anticoagulant drugs: Rivaroxaban group (65 cases) and Heparin group (72 cases).
  • Rivaroxaban group: oral administration of Rivaroxaban 20 mg, once a day, was started 3 days before the cryoablation, no anticoagulant was additionally added during cryoablation, the activated clotting time (ACT) was measured, and oral administration of Rivaroxaban was continued for 3 months after cryoablation.
  • Heparin group: oral administration of Rivaroxaban 20 mg, once a day, was stopped 24 hours before the cryoablation, heparin (100 U/kg) anticoagulation was given during cryoablation, ACT was controlled between 250 and 300 seconds, and oral administration of Rivaroxaban was continued for 3 months after cryoablation.
  • The ACT results, the incidence of bleeding and thromboembolic events between the two groups were compared.
  • <b>Results:</b> The ACT result between the two groups were with statistically significance[(110±16) vs (323±61) seconds, <i>P</i>=0.000)].
  • The bleeding events for Rivaroxaban group were two cases of local hematoma of the femoral vein puncture site, with the incidence rate of 3.1%(2/65); Heparin group were two cases of local hematoma of the femoral vein puncture site, and one case of epistaxis, with the incidence rate of 4.2%(3/72), with no statistical significance(<i>P</i>=0.549) between the two groups.
  • <b>Conclusion:</b> Rivaroxaban is safe and effective for anticoagulation therapy in patients with atrial fibrillation cryoablation.
  • <b>目的:</b> 观察新型口服抗凝药利伐沙班用于非瓣膜性心房颤动(房颤)患者冷冻消融术中抗凝治疗的安全性和有效性。 <b>方法:</b> 入选2013年10月至2016年12月于泰达国际心血管病医院行冷冻消融的房颤患者137例,根据冷冻消融术中应用抗凝药物分为两组:利伐沙班组(65例)和普通肝素组(72例)。利伐沙班组:术前3 d开始口服利伐沙班20 mg,每天一次,术日不停药,术中不再追加抗凝药物,测试活化凝血时间(ACT),术后继续口服3个月。普通肝素组:术前3 d开始口服利伐沙班20 mg,每天一次,术前24 h停药,术中给予普通肝素(100 U/kg)抗凝,监测ACT,控制在250~300 s之间,术后继续口服利伐沙班3个月。比较两组患者冷冻消融术中ACT以及术中及术后住院期间出血、血栓栓塞事件的发生率有无差别。 <b>结果:</b> 两组患者ACT差异具有统计学意义[(110±16)s比(323±61)s,<i>P</i>=0.000],两组患者出血事件利伐沙班组2例均为股静脉穿刺部位局部血肿,发生率为3.1%(2/65);普通肝素组2例为股静脉穿刺部位局部血肿,1例为术后鼻出血,发生率为4.2%(3/72),差异无统计学意义(<i>P</i>=0.549);利伐沙班组术中和术后未发生血栓栓塞事件,普通肝素抗凝组1例患者术后抗凝桥接期发生小脑血栓栓塞事件。 <b>结论:</b> 利伐沙班用于心房颤动冷冻消融术中抗凝安全有效。.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28881533.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; Anticoagulants / Atrial fibrillation / Catheter Ablation / Cryotherapy / Rivaroxaban
  •  go-up   go-down


17. Eng C, Xing Y, You YN, Chang GJ, Das P, Phillips J, Wolff RA, Rodriguez-Bigas MA, Ohinata A, Crane CH: Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective. J Clin Oncol; 2011 Feb;29(4_suppl):482

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C was evaluated with 5-FU in 2 large phase III studies (RTOG 98-11 and ACT II) to establish superiority over 5-FU/MMC.
  • RTOG 98-11 reported reduced colostomy-free survival (CFS) in the C-induction arm; no differences were noted in the ACT II study.
  • The log-rank test was used to compare OS among these subgroups.
  • After a median follow up of 8.6 years, 14 pts (8%) developed local recurrence; 11 received salvage surgery.
  • Platinum-based therapy for anal cancer appears to be an acceptable alternative to MMC and should be considered as a standard option for locally advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985490.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A: Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. Int J Cancer; 2017 Oct 01;141(7):1458-1468
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
  • Systemic high dose interleukin-2 (IL-2) postconditioning has long been utilized in boosting the efficacy of T cells in adoptive cell therapy (ACT) of solid tumors.
  • The resulting severe off-target toxicity of these regimens renders local production at the tumor an attractive concept with possible safety gains.
  • We evaluated the efficacy and safety of intratumorally administered IL-2-coding adenoviruses in combination with tumor-infiltrating lymphocyte therapy in syngeneic Syrian hamsters bearing HapT1 pancreatic tumors and with T cell receptor transgenic ACT in B16.OVA melanoma bearing C57BL/6 mice.
  • In both models, local production of IL-2 successfully replaced the need for systemic recombinant IL-2 (rIL-2) administration and increased the efficacy of the cell therapy.
  • In summary, local IL-2 production results in efficacy and safety gains in the context of ACT.
  • [MeSH-major] Adenoviridae / metabolism. Immunotherapy, Adoptive / methods. Interleukin-2 / biosynthesis. Lymphocytes, Tumor-Infiltrating / immunology. Melanoma, Experimental / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adoptive Transfer / methods. Animals. B-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Movement / immunology. Cricetinae. Disease Models, Animal. Female. Forkhead Transcription Factors / immunology. Genetic Vectors. Inflammation Mediators / blood. Interleukin-2 Receptor alpha Subunit / immunology. Lung / blood supply. Lung / pathology. Macrophages / immunology. Male. Mesocricetus. Mice. Mice, Inbred C57BL. Random Allocation. Recombinant Proteins / administration & dosage. Recombinant Proteins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 UICC.
  • (PMID = 28614908.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Inflammation Mediators; 0 / Interleukin-2; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Recombinant Proteins
  • [Keywords] NOTNLM ; T cell therapy / adoptive cell therapy / immunotherapy / interleukin-2 / oncolytic adenovirus
  •  go-up   go-down


19. Pissulin CN, de Souza Castro PA, Codina F, Pinto CG, Vechetti-Junior IJ, Matheus SM: GaAs laser therapy reestablishes the morphology of the NMJ and nAChRs after injury due to bupivacaine. J Photochem Photobiol B; 2017 Feb;167:256-263

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GaAs laser therapy reestablishes the morphology of the NMJ and nAChRs after injury due to bupivacaine.
  • BACKGROUND: Local anesthetics are used to relieve pre- and postoperative pain, acting on both sodium channels and nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (NMJ).
  • Bupivacaine acts as a non-competitive antagonist and has limitations, such as myotoxicity, neurotoxicity, and inflammation.
  • Low-level laser therapy (LLLT) has anti-inflammatory, regenerative, and analgesic effects.
  • Next, the animals were divided into a Control group (C) and a Laser group (LLLT).
  • The maximum diameters of the NMJs were lower in the Bupi (15.048±1.985) and LLLT/Bupi subgroups (15.456±1.983) compared to the Cl (18.502±2.058) and LLLT/Cl subgroups (19.356±2.522) (p<0.05).
  • There was an increase in the perimeter of the LLLT/Bupi subgroup (150.33) compared to the Bupi subgroup (74.69) (p<0.01) observed by confocal microscopy.
  • There was also an increase in the relative planar area of the NMJ after LBI (8.75) compared to CBupi (4.80) (p<0.01).
  • There was an increase in protein expression of the ε subunit after application of LLLT (13.055) compared to Bupi (0.251) (p<0.01).
  • Taken together, the present experiments indicate that there was a positive association of the α and γ subunits (p<0.05).
  • CONCLUSIONS: These results demonstrate that LLLT at the dose used in this study reduced structural alterations in the NMJ and molecular changes in nAChRs triggered by bupivacaine, providing important data supporting the use of LLLT in therapeutic protocols for injuries triggered by local anesthetics.
  • [MeSH-major] Anesthetics, Local / adverse effects. Bupivacaine / adverse effects. Lasers, Semiconductor. Low-Level Light Therapy. Neuromuscular Junction / radiation effects. Receptors, Nicotinic / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier B.V. All rights reserved.
  • (PMID = 28088107.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Receptors, Nicotinic; Y8335394RO / Bupivacaine
  • [Keywords] NOTNLM ; Bupivacaine / Low-level light therapy / Neuromuscular junction / Nicotinic acetylcholine receptor
  •  go-up   go-down


20. TuŢă LA, Boşoteanu M, Dumitru E, Deacu M: Complicated diverticulitis in a de novo kidney transplanted patient. Rom J Morphol Embryol; 2017;58(1):249-253

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complicated diverticulitis in a de novo kidney transplanted patient.
  • It mainly presents as sigmoid diverticulitis, but severe complications, like bleedings, infections and colon perforation may occur, frequently due to immunosuppressive therapy.
  • Moreover, antibiotherapy and hemostatics may not efficiently control evolution in such cases.
  • We report a 55-year-old patient who underwent de novo renal transplantation one year ago and recently developed a severe diverticular bleeding complicated by hemorrhagic shock.
  • Due to his immunocompromised status and unfavorable evolution under hemostatics, recombinant coagulation factor VIIa (rFVIIa) was given to avoid surgery.
  • Unfortunately, after three weeks, lower quadrant pain, tenderness, abdominal distention, and fever occurred, in spite of immunosuppressive drug changing and adequate conservative therapy.
  • Abdominal computed tomography (CT) scan revealed complicated diverticulitis, so patient underwent surgery, with partial colectomy, followed by total recovery.
  • Treatment options, usually based on our local resources and expertise, considered conservatory therapy as the first choice, keeping surgical maneuvers just as a rescue solution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28523327.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


21. Holvoet T, Devriese S, Castermans K, Boland S, Leysen D, Vandewynckel YP, Devisscher L, Van den Bossche L, Van Welden S, Dullaers M, Vandenbroucke RE, De Rycke R, Geboes K, Bourin A, Defert O, Hindryckx P, De Vos M, Laukens D: Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor. Gastroenterology; 2017 Oct;153(4):1054-1067
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor.
  • Because systemic ROCK inhibition causes cardiovascular side effects, we evaluated the effects of a locally acting ROCK inhibitor (AMA0825) on intestinal fibrosis.
  • RESULTS: ROCK is expressed in fibroblastic, epithelial, endothelial, and muscle cells of the human intestinal tract and is activated in inflamed and fibrotic tissue.
  • AMA0825 reduced TGFβ1-induced activation of myocardin-related transcription factor (MRTF) and p38 mitogen-activated protein kinase (MAPK), down-regulating matrix metalloproteinases, collagen, and IL6 secretion from fibroblasts.
  • CONCLUSIONS: Local ROCK inhibition prevents and reverses intestinal fibrosis by diminishing MRTF and p38 MAPK activation and increasing autophagy in fibroblasts.
  • Overall, our results show that local ROCK inhibition is promising for counteracting fibrosis as an add-on therapy for CD.
  • [MeSH-major] Ileum / drug effects. Inflammatory Bowel Diseases / prevention & control. Intestinal Obstruction / prevention & control. Myofibroblasts / drug effects. Protein Kinase Inhibitors / pharmacology. rho-Associated Kinases / antagonists & inhibitors
  • [MeSH-minor] Adoptive Transfer. Animals. Autophagy / drug effects. Case-Control Studies. Collagen / metabolism. Dextran Sulfate. Disease Models, Animal. Enzyme Activation. Fibrosis. Humans. Interleukin-6 / metabolism. Male. Matrix Metalloproteinases / metabolism. Mice, Inbred C57BL. Signal Transduction / drug effects. T-Lymphocytes / immunology. T-Lymphocytes / transplantation. Time Factors. Tissue Culture Techniques. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28642198.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Protein Kinase Inhibitors; 0 / interleukin-6, mouse; 9007-34-5 / Collagen; 9042-14-2 / Dextran Sulfate; EC 2.7.11.1 / rho-Associated Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Keywords] NOTNLM ; Colitis / Epithelial-to-Mesenchymal Transition / Mesenchymal Cells / Stenosis
  •  go-up   go-down


22. Priya SR, Dravid CS, Digumarti R, Dandekar M: Targeted Therapy for Medullary Thyroid Cancer: A Review. Front Oncol; 2017;7:238

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted Therapy for Medullary Thyroid Cancer: A Review.
  • The 10-year overall survival (OS) rate of patients with localized disease is around 95% while that of patients with regional stage disease is about 75%.
  • Adjuvant external radiation confers local control but not improved OS.
  • The management of residual, recurrent, or metastatic disease till a few years ago was re-surgery with local measures such as radiation.
  • The development of targeted therapy has brought in a major advantage in management of such patients.
  • In addition, several drugs acting on other steps of the molecular pathway are being investigated with promising results.
  • Targeted radionuclide therapy also provides an effective treatment option with good quality of life.
  • This review covers the rationale of targeted therapy for MTC, present treatment options, drugs and methods under investigation, as well as an outline of the adverse effects and their management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2014 Dec;92 (3):194-207 [25028151.001]
  • [Cites] Thyroid. 2015 Jun;25(6):567-610 [25810047.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):363-74, viii [18502331.001]
  • [Cites] J Cutan Pathol. 2010 Dec;37(12):1237-40 [19615004.001]
  • [Cites] Cancer. 2016 Dec 15;122(24):3856-3864 [27525386.001]
  • [Cites] J Clin Oncol. 2012 Mar 10;30(8):871-7 [22312105.001]
  • [Cites] Thyroid. 2008 May;18(5):587 [18466083.001]
  • [Cites] Thyroid. 2014 Jun;24(6):1062-6 [24499195.001]
  • [Cites] J Surg Res. 2010 Apr;159(2):640-4 [19394967.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1336-41 [15709206.001]
  • [Cites] Endocr Pathol. 2000 Spring;11(1):19-30 [12114654.001]
  • [Cites] J Clin Endocrinol Metab. 2011 Apr;96(4):997-1005 [21289252.001]
  • [Cites] Thyroid. 2010 Aug;20(8):863-71 [20615131.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1529-39 [18316578.001]
  • [Cites] Neuroendocrinology. 2009;90(4):323-48 [19468197.001]
  • [Cites] Biochem Pharmacol. 2010 Sep 1;80(5):613-23 [20519133.001]
  • [Cites] Eur J Endocrinol. 2016 Sep;175(3):173-80 [27283290.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):681-8 [8314345.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Endocr Relat Cancer. 2016 Jun;23(6):R287-97 [27185870.001]
  • [Cites] J Appl Toxicol. 2012 Dec;32(12):945-51 [22961481.001]
  • [Cites] Cancer Treat Rev. 2014 Jun;40(5):636-47 [24629273.001]
  • [Cites] Eur J Endocrinol. 2015 Jan;172(1):R1-8 [25117465.001]
  • [Cites] Leukemia. 2014 Apr;28(4):976-7 [24170029.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S158-64 [14600606.001]
  • [Cites] Oncogene. 2004 Aug 12;23 (36):6056-63 [15184865.001]
  • [Cites] Circulation. 2008 Jul 1;118(1):84-95 [18591451.001]
  • [Cites] Mol Cancer Ther. 2011 Dec;10(12):2298-308 [21926191.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6 [12843138.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4457-64 [15941870.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Mol Oncol. 2017 Aug;11(8):1007-1022 [28453190.001]
  • [Cites] Clin Nucl Med. 2015 Feb;40(2):123-7 [25546220.001]
  • [Cites] Cancer Res. 2010 Oct 1;70(19):7580-90 [20841479.001]
  • [Cites] Semin Nucl Med. 2016 May;46(3):215-24 [27067502.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Nucl Med Commun. 2001 Jun;22(6):673-8 [11403179.001]
  • [Cites] Clin Cancer Res. 2010 Nov 1;16(21):5260-8 [20847059.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Aug;3(8):599-606 [16033478.001]
  • [Cites] Br J Clin Pharmacol. 2014 Oct;78(4):748-62 [24661224.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):715-8 [10952773.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4708-13 [18541897.001]
  • [Cites] Cancer Treat Rev. 2016 Nov;50:89-98 [27664392.001]
  • [Cites] Medicine (Baltimore). 2015 Nov;94(45):e2016 [26559299.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2134-42 [17019736.001]
  • [Cites] J Clin Endocrinol Metab. 2014 May;99(5):E734-45 [24483157.001]
  • [Cites] PLoS One. 2017 Feb 16;12 (2):e0172315 [28207834.001]
  • [Cites] N Engl J Med. 2013 Nov 7;369(19):1783-96 [24180494.001]
  • [Cites] Ann Oncol. 1994 Oct;5(8):763-5 [7826911.001]
  • [Cites] Onco Targets Ther. 2015 May 13;8:1039-42 [25999738.001]
  • [Cites] J Natl Cancer Inst. 2010 May 5;102(9):596-604 [20351338.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1001-6 [18445656.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2496-9 [16608897.001]
  • [Cites] Acta Oncol. 2009;48(7):964-70 [19734999.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92 (4):751-9 [15685243.001]
  • [Cites] Rare Tumors. 2013 Jul 12;5(3):e37 [24179649.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702 [18006770.001]
  • [Cites] Eur Thyroid J. 2012 Apr;1(1):5-14 [24782992.001]
  • [Cites] Oncologist. 2013;18(8):900-8 [23918069.001]
  • [Cites] Nat Med. 2005 Sep;11(9):992-7 [16127434.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Am J Transl Res. 2010 Feb 10;2(1):119-25 [20182588.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Cancer Sci. 2005 Mar;96(3):143-8 [15771616.001]
  • [Cites] J Clin Endocrinol Metab. 2014 Feb;99(2):498-509 [24276455.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3455-9 [8012966.001]
  • [Cites] Ann Oncol. 2013 Dec;24(12):3089-94 [24050953.001]
  • [Cites] Endocr Relat Cancer. 2010 Jan 29;17(1):7-16 [19776290.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):356-62 [12872357.001]
  • [Cites] Thyroid. 2011 Feb;21(2):119-24 [21186953.001]
  • [Cites] Int J Endocrinol. 2015;2015:348124 [26294908.001]
  • [Cites] BMC Endocr Disord. 2014 Oct 11;14:84 [25306429.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34 [15634717.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10 ):1827-37 [18536916.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Jan;98(1):31-42 [23185034.001]
  • [Cites] Endocr Relat Cancer. 2013 Jul 12;20(4):611-9 [23780998.001]
  • [Cites] Surgery. 2017 Jan;161(1):137-146 [27842913.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):887-95 [9637552.001]
  • [Cites] Oncologist. 2005 Sep;10 (8):565-78 [16177281.001]
  • [Cites] PLoS One. 2011;6(12):e28841 [22174910.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] Thyroid. 2008 Mar;18(3):317-23 [17985985.001]
  • [Cites] J Thyroid Res. 2011;2011:985780 [22007339.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2070-5 [12727956.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7820-6 [16258084.001]
  • [Cites] J Clin Endocrinol Metab. 2014 May;99(5):1687-93 [24606083.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Apr;6(4):219-28 [19333228.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1001-10 [15573099.001]
  • [Cites] J Clin Oncol. 2011 Jul 1;29(19):2660-6 [21606412.001]
  • [Cites] Lung Cancer. 2012 Oct;78(1):8-15 [22795701.001]
  • [Cites] Thyroid. 2014 May;24(5):918-22 [24635127.001]
  • [Cites] Biochem Pharmacol. 2014 Sep 15;91(2):135-43 [24950467.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1967-76 [10595926.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60 [23979959.001]
  • [Cites] J Clin Endocrinol Metab. 2011 May;96(5):E863-8 [21325462.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Jul;95(7):3552-7 [20444924.001]
  • [Cites] J Clin Endocrinol Metab. 2011 Jun;96(6):E991-5 [21470995.001]
  • [Cites] Oncologist. 2014 Mar;19(3):251-8 [24563075.001]
  • [Cites] Ann Surg. 2008 Jun;247(6):1036-40 [18520232.001]
  • [Cites] Lancet Oncol. 2014 Jul;15(8):e315-26 [24988935.001]
  • [Cites] Horm Res. 1978;9(1):22-5 [618781.001]
  • [Cites] Clin Case Rep. 2015 Nov 09;4(1):9-18 [26783427.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3794-801 [19564535.001]
  • [Cites] Anticancer Drugs. 2001 Mar;12 (3):193-7 [11290865.001]
  • [Cites] Cancer Treat Rev. 2012 Nov;38(7):919-25 [22651902.001]
  • [Cites] Br J Clin Pharmacol. 2011 Jun;71(6):917-20 [21235620.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):111-5 [11790564.001]
  • [Cites] Eur J Cancer. 2017 May;76:110-117 [28301826.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] J Clin Oncol. 2012 Jan 10;30(2):134-41 [22025146.001]
  • [Cites] World J Surg. 2008 May;32(5):754-65 [18188643.001]
  • [Cites] Thyroid. 2006 Mar;16(3):311-6 [16571096.001]
  • [Cites] Cancer. 2014 Sep 1;120(17):2694-703 [24844950.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):299-310 [15355445.001]
  • [Cites] Thyroid. 1996 Aug;6(4):305-10 [8875751.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12 ):1788-95 [17519900.001]
  • [Cites] Trends Cancer. 2017 Jul;3(7):529-541 [28718406.001]
  • [Cites] Lancet Oncol. 2009 Oct;10 (10 ):967-74 [19767240.001]
  • [Cites] Rare Tumors. 2015 May 18;7(2):5765 [26266011.001]
  • [Cites] Eur Thyroid J. 2016 Jul;5(2):79-93 [27493881.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11 [21052661.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Endocrinol Metab (Seoul). 2015 Dec;30(4):593-603 [26485469.001]
  • [Cites] Endocrine. 2016 Jan;51(1):101-12 [25863490.001]
  • [Cites] Cancer Biother Radiopharm. 2009 Oct;24(5):527-33 [19877882.001]
  • [Cites] J Clin Endocrinol Metab. 2014 Sep;99(9):3055-9 [24617713.001]
  • [Cites] Aust Dent J. 2015 Dec;60(4):528-31 [25474298.001]
  • [Cites] Int J Dermatol. 2011 Apr;50(4):396-402 [21413947.001]
  • [Cites] Endocr Relat Cancer. 2011 Nov 14;18(6):711-9 [21946411.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2013 Oct;121(9):546-50 [23934677.001]
  • [Cites] Thyroid. 2012 Feb;22(2):125-30 [22176498.001]
  • [Cites] Cancer Res. 2014 May 1;74(9):2377-84 [24717177.001]
  • [Cites] Endocr Rev. 2006 Aug;27(5):535-60 [16849421.001]
  • [Cites] Eur J Endocrinol. 2007 Aug;157(2):215-20 [17656601.001]
  • [Cites] Cancer. 2014 Nov 1;120(21):3287-301 [24942936.001]
  • [Cites] Endocr Relat Cancer. 2016 Apr;23 (4):R185-205 [27207700.001]
  • [Cites] Immunol Cell Biol. 2012 Jan;90(1):85-94 [22124371.001]
  • [Cites] Sci Signal. 2013 Sep 24;6(294):re6 [24065147.001]
  • [Cites] Thyroid. 2013 Jan;23(1):50-7 [23240926.001]
  • [Cites] J Clin Endocrinol Metab. 2014 May;99(5):1543-55 [24423326.001]
  • [Cites] J Clin Endocrinol Metab. 2011 Aug;96(8):2296-307 [21816796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5 [18227510.001]
  • [Cites] Surgery. 1993 Dec;114(6):1090-5; discussion 1095-6 [8256212.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4183-91 [18519677.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Sep;92(9):3466-9 [17579194.001]
  • [Cites] Nature. 2012 Jan 26;483(7387):100-3 [22281684.001]
  • [Cites] Int J Endocrinol. 2016;2016:2930414 [27766105.001]
  • [Cites] J Nucl Med. 2011 Sep;52(9):1361-8 [21795361.001]
  • [Cites] Drug Discov Today. 2003 Sep 1;8(17):775-7 [12946636.001]
  • [Cites] Clin Cancer Res. 2016 Jan 1;22(1):44-53 [26311725.001]
  • [Cites] Thyroid. 2017 Sep;27(9):1142-1148 [28635560.001]
  • [Cites] Cancer Treat Rev. 2013 Apr;39(2):199-206 [23099278.001]
  • [Cites] Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6 [23811235.001]
  • (PMID = 29057215.001).
  • [ISSN] 2234-943X
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; cabozantinib medullary thyroid / medullary thyroid cancer / peptide receptor radionuclide therapy medullary thyroid / small molecule thyroid / targeted radionuclide medullary thyroid / targeted therapy thyroid cancer / thyroid cancer recurrence / vandetanib medullary thyroid
  •  go-up   go-down


23. Mukherjee M, Lim HF, Thomas S, Miller D, Kjarsgaard M, Tan B, Sehmi R, Khalidi N, Nair P: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy Asthma Clin Immunol; 2017;13:2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.
  • CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asthma showed poor response to Mepolizumab therapy (100 mg subcutaneous dose/monthly) and subsequent worsening of symptoms.
  • The treatment response to Mepolizumab was monitored using both blood and sputum eosinophil counts.
  • The latter was superior in assessing deterioration in symptoms, suggesting that normal blood eosinophil count may not always indicate amelioration or adequate control of the ongoing eosinophil-driven disease process.
  • This perplexing situation of persistent airway eosinophilia and increased steroid insensitivity despite an anti-eosinophil therapy can be explained if the administered dose of the mAb was inadequate in comparison to the target antigen.
  • The resultant immune complexes could act as 'cytokine depots', protecting the potency of the 'bound' IL-5, thereby sustaining the eosinophilic inflammation within the target tissue.
  • CONCLUSIONS: While anti-IL5 mAb therapy is an exciting novel option to treat patients with severe asthma, there is the rare possibility of worsening of asthma as observed in this case study, due to local autoimmune mechanisms precipitated by potential inadequate airway levels of the monoclonal antibody.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28070196.001).
  • [ISSN] 1710-1484
  • [Journal-full-title] Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
  • [ISO-abbreviation] Allergy Asthma Clin Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Autoantibodies / Autoimmune / Eosinophilic asthma / IL-5 / Immune complex / Mepolizumab / Sputum
  •  go-up   go-down


24. Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P: Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer; 2017;5:4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
  • Histology studies of regressing tumors at 1 week after therapy, revealed extensive tumor destruction and a heavy infiltration of CD45<sup>+</sup> leukocytes including F4/80<sup>+</sup> macrophages, CD8<sup>+</sup> cytotoxic T cells and CD4<sup>+</sup> helper T cells.
  • The generation of tumor-specific T cells by combined therapy was confirmed by IFN-γ secretion in tumor-stimulated splenocytes.
  • CONCLUSIONS: These findings suggest that cancer vaccine given prior to local tumor irradiation augments an immune response targeted at tumor antigens that results in specific anti-tumor immunity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Jan;33(1):60-7 [11823974.001]
  • [Cites] Nat Rev Cancer. 2012 Mar 22;12(4):237-51 [22437869.001]
  • [Cites] Cancer Prev Res (Phila). 2013 Jan;6(1):18-26 [23248097.001]
  • [Cites] Nat Med. 2009 Oct;15(10 ):1170-8 [19767732.001]
  • [Cites] J Thorac Oncol. 2015 Dec;10 (12 ):1703-12 [26709479.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] Radiat Res. 2014 Aug;182(2):126-38 [24960415.001]
  • [Cites] Cancer Gene Ther. 2004 Jan;11(1):61-72 [14681727.001]
  • [Cites] Curr Opin Mol Ther. 2004 Apr;6(2):160-5 [15195928.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1259-71 [16636135.001]
  • [Cites] Hum Gene Ther. 2005 Feb;16(2):187-99 [15761259.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3132-9 [18292536.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2010 Dec;15(4):411-21 [21161342.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7516-23 [15944250.001]
  • [Cites] Front Oncol. 2014 Nov 28;4:325 [25506582.001]
  • [Cites] Cancer Immunol Res. 2013 Aug;1(2):92-8 [24777500.001]
  • [Cites] Nat Med. 2007 Jan;13(1):54-61 [17187072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1543-52 [9816331.001]
  • [Cites] Nat Rev Cancer. 2015 Jul;15(7):409-25 [26105538.001]
  • [Cites] Cancer Biother Radiopharm. 2012 Feb;27(1):12-22 [22283603.001]
  • [Cites] Int J Urol. 2005 Jul;12(7):654-61 [16045558.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3099-107 [18713980.001]
  • [Cites] Immunity. 2015 Apr 21;42(4):767-77 [25888260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):252-4 [25636751.001]
  • [Cites] Oncoimmunology. 2012 Aug 1;1(5):791-792 [22934285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):924-32 [21398051.001]
  • [Cites] Cancer Immunol Res. 2015 Apr;3(4):345-55 [25527358.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5323-37 [19723653.001]
  • [Cites] J Clin Invest. 2014 Feb;124(2):687-95 [24382348.001]
  • [Cites] Cancer Immunol Immunother. 2011 Feb;60(2):261-71 [21069322.001]
  • [Cites] Expert Rev Vaccines. 2008 Sep;7(7):889-93 [18767940.001]
  • [Cites] Expert Rev Vaccines. 2005 Aug;4(4):493-502 [16117706.001]
  • [Cites] Front Oncol. 2012 Aug 17;2:90 [22912933.001]
  • [Cites] Cell Immunol. 1995 Oct 15;165(2):243-51 [7553889.001]
  • [Cites] Crit Rev Oncol Hematol. 2013 Mar;85(3):278-87 [23036459.001]
  • [Cites] J Clin Invest. 2013 Jul;123(7):2756-63 [23863633.001]
  • [Cites] J Gene Med. 2003 Aug;5(8):690-9 [12898638.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5379-88 [19706802.001]
  • [Cites] Semin Radiat Oncol. 2015 Jan;25(1):46-53 [25481266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1306-10 [22208977.001]
  • [Cites] Lancet Oncol. 2015 Jul;16(7):795-803 [26095785.001]
  • [Cites] Hum Gene Ther. 2003 May 20;14(8):763-75 [12804139.001]
  • [Cites] Cancer Res. 2010 Apr 1;70(7):2697-706 [20215523.001]
  • [Cites] Lancet Oncol. 2011 Nov;12(12):1125-33 [22019520.001]
  • [Cites] J Natl Cancer Inst. 2013 Feb 20;105(4):256-65 [23291374.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3880-6 [8358713.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9 [23462419.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35 [21093169.001]
  • [Cites] Curr Opin Biotechnol. 2004 Dec;15(6):506-12 [15560976.001]
  • [Cites] Lancet Oncol. 2016 Feb;17(2):212-23 [26727163.001]
  • [Cites] Immunity. 2014 Nov 20;41(5):843-52 [25517616.001]
  • [Cites] Invest New Drugs. 2009 Aug;27(4):379-86 [18931824.001]
  • [Cites] Front Oncol. 2012 Aug 06;2:89 [22888475.001]
  • [Cites] J Immunother. 2004 May-Jun;27(3):240-53 [15076142.001]
  • (PMID = 28116088.001).
  • [ISSN] 2051-1426
  • [Journal-full-title] Journal for immunotherapy of cancer
  • [ISO-abbreviation] J Immunother Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; IL-2 / MUC1 / MVA vector / Radiation / Renal Cell Carcinoma
  •  go-up   go-down


25. Lusk KA, Snoga JL, Benitez RM, Sarbacker GB: Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding. J Pharm Pract; 2017 Jan 01;:897190017707126
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding.
  • The purpose of this article is to review the available evidence regarding how to safely manage direct-acting oral anticoagulant (DOAC) therapy in patients requiring dental procedures with low-to-moderate risk of bleeding.
  • Articles were eligible for inclusion if the participants were taking DOAC therapy surrounding a dental procedure known to have low-to-moderate risk of bleeding.
  • Variation in the management of DOAC therapy surrounding these procedures was found.
  • Among patients undergoing low-to-moderate risk dental procedures while receiving DOAC therapy, bleeding rates were low regardless of whether the DOAC was held or continued surrounding the procedure.
  • Documented bleeding was mild and easily controlled by local hemostatic measures.
  • Patients can safely continue DOAC therapy surrounding these dental procedures.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28506106.001).
  • [ISSN] 1531-1937
  • [Journal-full-title] Journal of pharmacy practice
  • [ISO-abbreviation] J Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; anticoagulation / cardiology / direct-acting oral anticoagulant / medication safety
  •  go-up   go-down


26. Sam-Agudu NA, Pharr JR, Bruno T, Cross CL, Cornelius LJ, Okonkwo P, Oyeledun B, Khamofu H, Olutola A, Erekaha S, Menson WNA, Ezeanolue EE: Adolescent Coordinated Transition (ACT) to improve health outcomes among young people living with HIV in Nigeria: study protocol for a randomized controlled trial. Trials; 2017 Dec 14;18(1):595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent Coordinated Transition (ACT) to improve health outcomes among young people living with HIV in Nigeria: study protocol for a randomized controlled trial.
  • METHODS: Using a two-arm cluster randomized control design, the Adolescent Coordinated Transition (ACT) trial will measure the comparative effectiveness of a graduated transition and organized support group intervention against the usual practice of abrupt transfer of Nigerian ALHIV from pediatric to adult care.
  • This study will be conducted at 12 secondary and tertiary healthcare facilities (six intervention, six control) across all six of Nigeria's geopolitical zones.
  • The study population is 13- to 17-year-old ALHIV (N = 216, n = 108 per study arm) on antiretroviral therapy.
  • Secondary outcome measures are proportions of ALHIV achieving viral suppression and demonstrating increased psychosocial wellbeing and self-efficacy measured by psychometric tests including health locus of control, functional social support, perceived mental health, and sexual risk and behavior.
  • DISCUSSION: We hypothesize that the ACT intervention will significantly increase psychosocial wellbeing, retention in care and ultimately viral suppression among ALHIV.
  • ACT's findings have the potential to facilitate the development of standard guidelines for transitioning ALHIV and improving health outcomes in this population.
  • The engagement of a consortium of local implementing partners under the Nigeria Implementation Science Alliance allows for nationwide study implementation and expedient results dissemination to program managers and policy-makers.
  • Ultimately, ACT may also provide evidence to inform transitioning guidelines not only for ALHIV but for adolescents living with other chronic diseases in resource-limited settings.
  • TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03152006 .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29237487.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Grant] United States / Eunice Kennedy Shriver National Institute of Child Health and Human Development / / R01HD089871
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Adolescent / HIV / Healthcare transition / Mental health / Nigeria / Retention / Viral suppression
  •  go-up   go-down


27. Binda C, Tortora A, Garcovich M, Annicchiarico BE, Siciliano M: Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C. Eur Rev Med Pharmacol Sci; 2017 Mar;21(1 Suppl):102-111
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new direct acting antivirals (DAAs), defined as those drugs that are effective in combinations without interferon, have totally changed HCV treatment and probably in few years will also totally change global landscape of advanced liver diseases.
  • [MeSH-major] Antiviral Agents / adverse effects. Antiviral Agents / therapeutic use. Drug Interactions. Hepatitis C, Chronic / drug therapy
  • [MeSH-minor] Anti-Infective Agents, Local / therapeutic use. Antihypertensive Agents / therapeutic use. Hepatitis C / drug therapy. Humans

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28379589.001).
  • [ISSN] 2284-0729
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Antihypertensive Agents; 0 / Antiviral Agents
  •  go-up   go-down


28. Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L: Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology; 2017;6(11):e1363139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alongside, the impressive benefits obtained by patients with advanced melanoma who received adoptively transferred tumor-infiltrating lymphocytes (TILs) have encouraged the scientific community to pursue adoptive cell transfer (ACT)-based immunotherapy.
  • ACT involves autologous or allogenic effector lymphocytes that are generally obtained from the peripheral blood or resected tumors, expanded and activated <i>ex vivo</i>, and administered to lymphodepleted patients.
  • ACT may be optionally associated with chemo- and/or immunotherapeutics, with the overall aim of enhancing the proliferation, persistence and functionality of infused cells, as well as to ensure their evolution in an immunological permissive local and systemic microenvironment.
  • Accordingly, the US Food and Drug Administration (FDA) has recently granted 'breakthrough therapy' designation to a CAR-based T-cell therapy (CTL019) for patients with B-cell malignancies.
  • Considerable efforts are now being devoted to the development of efficient ACT-based immunotherapies for non-hematological neoplasms.
  • In this Trial Watch, we summarize recent clinical advances on the use of ACT for oncological indications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sci Transl Med. 2015 May 20;7(288):288ra78 [25995224.001]
  • [Cites] Blood. 1993 May 15;81(10):2658-63 [8490175.001]
  • [Cites] Blood. 2012 Jun 28;119(26):6198-208 [22286199.001]
  • [Cites] Cancer Lett. 1994 Sep 30;85(1):31-7 [7923099.001]
  • [Cites] Oncoimmunology. 2016 Nov 8;5(12 ):e1254856 [28123899.001]
  • [Cites] Oncogene. 2007 Oct 11;26(46):6577-92 [17486079.001]
  • [Cites] Oncoimmunology. 2015 Dec 21;5(4):e1119354 [27141401.001]
  • [Cites] Ann Surg Oncol. 2010 Jul;17(7):1747-57 [20119674.001]
  • [Cites] J Immunother. 2013 Feb;36(2):133-51 [23377668.001]
  • [Cites] J Clin Invest. 2016 Jan;126(1):318-34 [26657860.001]
  • [Cites] J Immunother. 2015 Feb-Mar;38(2):54-61 [25658614.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):907-12 [16203864.001]
  • [Cites] J Immunother. 2010 Jan;33(1):1-7 [19952961.001]
  • [Cites] Blood. 2016 Mar 3;127(9):1117-27 [26813675.001]
  • [Cites] Cancer Immunol Res. 2013 Jul;1(1):43-53 [24409448.001]
  • [Cites] Blood. 2014 Jul 10;124(2):188-95 [24876563.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] Oncoimmunology. 2015 Feb 25;4(4):e998538 [26137416.001]
  • [Cites] Oncotarget. 2016 Jun 7;7(23):34070-83 [27083001.001]
  • [Cites] Cancer Lett. 2015 Jul 1;362(2):192-8 [25843292.001]
  • [Cites] Trends Mol Med. 2008 Apr;14(4):141-51 [18353726.001]
  • [Cites] Semin Intervent Radiol. 2014 Jun;31(2):111-7 [25053862.001]
  • [Cites] Adv Drug Deliv Rev. 2017 May 15;114:222-239 [28625827.001]
  • [Cites] Clin Cancer Res. 2014 Jul 1;20(13):3401-10 [24987109.001]
  • [Cites] PLoS One. 2015 Jun 22;10(6):e0130620 [26098948.001]
  • [Cites] J Exp Med. 2016 Jun 27;213(7):1133-9 [27242164.001]
  • [Cites] Oncoimmunology. 2015 Feb 03;4(1):e954829 [25949858.001]
  • [Cites] Leukemia. 2017 May;31(5):1059-1068 [27795558.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1551-7 [16034093.001]
  • [Cites] Oncoimmunology. 2016 Apr 25;5(6):e1163462 [27471638.001]
  • [Cites] Oncoimmunology. 2015 Dec 8;5(2):e1115942 [27057468.001]
  • [Cites] Exp Hematol. 1993 Dec;21(13):1673-9 [7694868.001]
  • [Cites] Clin Cancer Res. 2017 Jan 15;23 (2):351-362 [28093487.001]
  • [Cites] J Innate Immun. 2015;7(6):557-62 [25823611.001]
  • [Cites] Cancer Cell. 2017 Apr 10;31(4):476-485 [28366678.001]
  • [Cites] J Hematol Oncol. 2017 Apr 7;10 (1):81 [28388955.001]
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1884-9 [7175442.001]
  • [Cites] Lancet. 2015 Feb 7;385(9967):517-528 [25319501.001]
  • [Cites] Nature. 2014 Nov 27;515(7528):568-71 [25428505.001]
  • [Cites] Gastroenterology. 2015 Jun;148(7):1383-91.e6 [25747273.001]
  • [Cites] Mol Ther. 2011 Mar;19(3):620-6 [21157437.001]
  • [Cites] Oncoimmunology. 2015 Feb 03;4(1):e985940 [25949870.001]
  • [Cites] Blood. 2011 Aug 4;118(5):1255-63 [21653320.001]
  • [Cites] Oncoimmunology. 2013 Jan 1;2(1):e22059 [23483796.001]
  • [Cites] Immunol Rev. 2017 Nov;280(1):175-193 [29027217.001]
  • [Cites] N Engl J Med. 2012 Jun 28;366(26):2443-54 [22658127.001]
  • [Cites] J Clin Oncol. 2017 Jul 1;35(19):2117-2124 [28375787.001]
  • [Cites] Nat Rev Clin Oncol. 2011 Aug 02;8(10):577-85 [21808266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74 [19805141.001]
  • [Cites] Oncoimmunology. 2015 Jan 22;4(3):e994398 [25949919.001]
  • [Cites] Cell Stem Cell. 2015 Apr 2;16(4):357-66 [25842976.001]
  • [Cites] J Clin Oncol. 2015 May 20;33(15):1688-96 [25800760.001]
  • [Cites] Nat Rev Immunol. 2014 Jan;14(1):24-35 [24336101.001]
  • [Cites] Nat Immunol. 2004 May;5(5):508-15 [15064759.001]
  • [Cites] Immunity. 2013 Apr 18;38(4):729-41 [23562161.001]
  • [Cites] N Engl J Med. 2016 Sep 15;375(11):1044-53 [27626518.001]
  • [Cites] J Transl Med. 2015 Aug 25;13:277 [26303618.001]
  • [Cites] N Engl J Med. 2016 Dec 29;375(26):2561-9 [28029927.001]
  • [Cites] Oncoimmunology. 2016 Sep 20;5(11):e1235107 [27999753.001]
  • [Cites] J Exp Med. 1982 Apr 1;155(4):1063-74 [6460831.001]
  • [Cites] Oncoimmunology. 2016 Oct 28;5(12 ):e1251539 [28123893.001]
  • [Cites] Blood. 2017 Feb 23;129(8):1039-1041 [28031179.001]
  • [Cites] Lancet Oncol. 2017 Jun;18(6):792-802 [28395880.001]
  • [Cites] J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87 [23852952.001]
  • [Cites] Oncoimmunology. 2015 Dec 3;5(4):e1115940 [27141398.001]
  • [Cites] J Hematol Oncol. 2017 Mar 29;10 (1):78 [28356156.001]
  • [Cites] Front Oncol. 2013 Sep 11;3:231 [24062984.001]
  • [Cites] Oncoimmunology. 2016 Jul 25;5(9):e1214790 [27757313.001]
  • [Cites] Nat Rev Clin Oncol. 2016 Jan;13(1):25-40 [26525683.001]
  • [Cites] Oncoimmunology. 2016 Aug 19;5(9):e1214788 [27757312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6 [18987320.001]
  • [Cites] Front Immunol. 2015 Nov 20;6:588 [26635802.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):843-51 [20179677.001]
  • [Cites] Clin Cancer Res. 2011 Jul 1;17(13):4550-7 [21498393.001]
  • [Cites] J Clin Oncol. 2016 Sep 10;34(26):3119-25 [27269937.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6948-55 [14583496.001]
  • [Cites] Blood. 2012 Mar 22;119(12):2709-20 [22160384.001]
  • [Cites] J Transl Med. 2013 Mar 28;11:83 [23536996.001]
  • [Cites] Sci Transl Med. 2015 Mar 25;7(280):280ps7 [25810311.001]
  • [Cites] Gynecol Oncol. 2017 Jun;145(3):420-425 [28392127.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Pathol. 1999 Jun;188(2):201-6 [10398165.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):541-51 [16254188.001]
  • [Cites] Oncoimmunology. 2016 May 31;5(7):e1176653 [27622026.001]
  • [Cites] Oncoimmunology. 2017 Jan 19;6(3):e1283462 [28405510.001]
  • [Cites] Oncoimmunology. 2015 Mar 2;4(4):e1008866 [26137404.001]
  • [Cites] Oncoimmunology. 2016 Nov 8;5(12 ):e1253656 [28180032.001]
  • [Cites] Oncoimmunology. 2015 Oct 29;5(1):e1106127 [26942094.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Adv Immunol. 2016;130:279-94 [26923004.001]
  • [Cites] Oncoimmunology. 2016 Mar 10;5(5):e1139274 [27467959.001]
  • [Cites] Lancet Oncol. 2016 Mar;17(3):299-308 [26858122.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):299-308 [18354418.001]
  • [Cites] Clin Sarcoma Res. 2017 Jun 15;7:11 [28630682.001]
  • [Cites] Clin Cancer Res. 2015 Jul 15;21(14):3149-59 [25850950.001]
  • [Cites] Cancer Immunol Immunother. 2015 Sep;64(9):1083-93 [25990075.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5818-24 [15313925.001]
  • [Cites] N Engl J Med. 2011 Nov 3;365(18):1673-83 [22047558.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):157-64 [16365406.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):711-23 [20525992.001]
  • [Cites] Cancer Immunol Immunother. 2015 Jul;64(7):805-15 [25846669.001]
  • [Cites] Blood. 2011 Jan 20;117(3):808-14 [20971955.001]
  • [Cites] Nat Rev Immunol. 2012 Nov;12(11):749-61 [23080391.001]
  • [Cites] Nat Med. 2013 Jun;19(6):747-52 [23644516.001]
  • [Cites] Trends Mol Med. 2014 Jun;20(6):332-42 [24667139.001]
  • [Cites] Cancer Res. 2010 Aug 1;70(15):6171-80 [20631075.001]
  • [Cites] Oncoimmunology. 2016 May 31;5(7):e1191732 [27622047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3029-34 [14981245.001]
  • [Cites] N Engl J Med. 1988 Dec 22;319(25):1676-80 [3264384.001]
  • [Cites] N Engl J Med. 2015 Jan 22;372(4):320-30 [25399552.001]
  • [Cites] Nat Rev Immunol. 2017 Feb;17 (2):97-111 [27748397.001]
  • [Cites] Nature. 2017 Jan 18;541(7637):321-330 [28102259.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):4773-7 [11045997.001]
  • [Cites] Nat Immunol. 2001 Oct;2(10 ):962-70 [11577350.001]
  • [Cites] Semin Cancer Biol. 2014 Dec;29:21-31 [25068995.001]
  • [Cites] J Immunol. 2014 Jun 15;192(12):5451-8 [24907378.001]
  • [Cites] N Engl J Med. 2011 Jun 30;364(26):2517-26 [21639810.001]
  • [Cites] Oncoimmunology. 2015 Sep 2;5(3):e1088631 [27141345.001]
  • [Cites] Oncoimmunology. 2016 Nov 1;5(12 ):e1249559 [28123888.001]
  • [Cites] Cancer J. 2014 Mar-Apr;20(2):127-33 [24667958.001]
  • [Cites] Oncoimmunology. 2016 Mar 30;5(6):e1168556 [27471646.001]
  • [Cites] J Clin Oncol. 2015 May 10;33(14):1543-50 [25823737.001]
  • [Cites] J Immunol. 2012 Dec 1;189(11):5147-54 [23100512.001]
  • [Cites] Expert Rev Clin Immunol. 2017 Feb;13(2):151-155 [27546707.001]
  • [Cites] Clin Cancer Res. 2011 May 1;17(9):2987-96 [21385924.001]
  • [Cites] Nat Med. 2014 Nov;20(11):1301-9 [25344738.001]
  • [Cites] J Clin Invest. 2016 Aug 1;126(8):3130-44 [27454297.001]
  • [Cites] Oncoimmunology. 2016 Feb 18;5(7):1136045 [27622012.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Int Immunopharmacol. 2011 Apr;11(4):449-56 [21215350.001]
  • [Cites] Oncoimmunology. 2016 Oct 7;5(12 ):e1240859 [28123878.001]
  • [Cites] Oncoimmunology. 2015 Apr 1;4(7):e1016700 [26140242.001]
  • [Cites] J Clin Invest. 2016 Aug 1;126(8):3036-52 [27427982.001]
  • [Cites] Ann Surg. 1891 Sep;14(3):199-220 [17859590.001]
  • [Cites] Cytometry. 2001 Feb 15;46(1):23-7 [11241503.001]
  • [Cites] Blood. 2016 Jun 30;127(26):3321-30 [27207799.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Oncoimmunology. 2015 May 5;4(11):e1046673 [26451319.001]
  • [Cites] Oncoimmunology. 2016 Oct 7;5(12 ):e1237327 [28123872.001]
  • [Cites] Nat Rev Cancer. 2016 Aug 23;16(9):566-81 [27550819.001]
  • [Cites] Mol Ther. 2015 Aug;23 (8):1401-1409 [26017177.001]
  • [Cites] N Engl J Med. 2011 Jun 2;364(22):2119-27 [21631324.001]
  • [Cites] Science. 2015 Apr 3;348(6230):62-8 [25838374.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Immunotherapy. 2015;7(5):573-84 [26065481.001]
  • [Cites] Cytotherapy. 2016 Jan;18(1):91-8 [26549382.001]
  • [Cites] Cancer Immunol Res. 2016 Nov;4(11):895-902 [27803050.001]
  • [Cites] Oncoimmunology. 2015 Mar 24;4(4):e1001232 [26137400.001]
  • [Cites] Clin Cancer Res. 2013 Oct 15;19(20):5636-46 [23873688.001]
  • [Cites] Clin Cancer Res. 2015 May 15;21(10):2268-77 [25855804.001]
  • [Cites] Clin Cancer Res. 2015 Sep 15;21(18):4062-72 [26059190.001]
  • [Cites] Int J Cancer. 1975 Aug 15;16(2):230-9 [1080480.001]
  • [Cites] Hepatology. 2009 May;49(5 Suppl):S56-60 [19399807.001]
  • [Cites] Mol Ther. 2016 Jun;24(6):1135-1149 [27019998.001]
  • [Cites] Cytotherapy. 2015 Jul;17(7):979-88 [25890480.001]
  • [Cites] Oncoimmunology. 2016 May 19;5(7):e1188243 [27622042.001]
  • [Cites] Cancer Cell. 2015 Dec 14;28(6):690-714 [26678337.001]
  • [Cites] Cancer Discov. 2015 Jun;5(6):OF5 [25851859.001]
  • [Cites] Cell. 2016 Feb 11;164(4):770-9 [26830879.001]
  • [Cites] Nature. 2011 Dec 21;480(7378):480-9 [22193102.001]
  • [Cites] Clin Cancer Res. 2016 Apr 15;22(8):1914-21 [26787753.001]
  • [Cites] Oncoimmunology. 2015 Jan 9;4(4):e974411 [26137405.001]
  • [Cites] Curr Opin Pharmacol. 2017 May 24;:null [28551360.001]
  • [Cites] Oncoimmunology. 2013 May 1;2(5):e24238 [23762803.001]
  • [Cites] Blood. 2014 Apr 10;123(15):2293-301 [24578502.001]
  • [Cites] N Engl J Med. 2017 Jul 13;377(2):122-131 [28581356.001]
  • [Cites] Nat Rev Immunol. 2016 Mar;16(3):149-63 [26875830.001]
  • [Cites] J Clin Invest. 2002 May;109(10):1335-44 [12021249.001]
  • [Cites] J Cancer Res Clin Oncol. 2017 May;143(5):861-871 [28108815.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):89-97 [12851874.001]
  • [Cites] J Immunother Cancer. 2016 Feb 16;4:6 [26885368.001]
  • [Cites] Cancer Res. 1973 Aug;33(8):1837-44 [4720795.001]
  • [Cites] N Engl J Med. 2015 May 21;372(21):2018-28 [25891174.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):313-9 [16699374.001]
  • [Cites] Cytotherapy. 2015 Aug;17(8):1130-8 [25963952.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2199-204 [15026363.001]
  • [Cites] Cancer Lett. 1994 Sep 30;85(1):39-46 [7923100.001]
  • [Cites] Oncoimmunology. 2015 Oct 29;5(4):e1100790 [27141382.001]
  • [Cites] Cancers (Basel). 2016 Oct 19;8(10 ): [27775564.001]
  • [Cites] FASEB J. 2006 Apr;20(6):621-30 [16581970.001]
  • [Cites] Science. 2015 Nov 20;350(6263):972-8 [26516201.001]
  • [Cites] Cancer Cell. 2017 Aug 14;32(2):135-154 [28810142.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] Oncoimmunology. 2016 Sep 27;5(10 ):e1219828 [27853643.001]
  • [Cites] Cancer J. 2015 Nov-Dec;21(6):465-9 [26588677.001]
  • [Cites] Oncoimmunology. 2015 Feb 18;4(4):e1005521 [26137402.001]
  • [Cites] Mol Ther. 2017 Jan 4;25(1):285-295 [28129122.001]
  • [Cites] J Clin Invest. 2016 Jun 1;126(6):2123-38 [27111235.001]
  • [Cites] Oncogene. 2007 Oct 4;26(45):6469-87 [17471238.001]
  • [Cites] N Engl J Med. 2014 Oct 23;371(17):1609-18 [25337750.001]
  • [Cites] Hum Immunol. 2000 Jan;61(1):65-73 [10658979.001]
  • [Cites] Oncoimmunology. 2016 Dec 7;6(1):e1257453 [28197376.001]
  • [Cites] Oncotarget. 2015 Dec 1;6(38):41339-49 [26515587.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):440-3 [3940209.001]
  • [Cites] Cancer J. 2014 Mar-Apr;20(2):141-4 [24667960.001]
  • [Cites] Oncoimmunology. 2016 Oct 18;5(12 ):e1248327 [28123885.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6551-8 [15475443.001]
  • [Cites] Mol Ther. 2015 Feb;23(2):330-8 [25373520.001]
  • [Cites] J Clin Invest. 2012 Jun;122(6):2066-78 [22585577.001]
  • [Cites] Immunol Rev. 2014 Jan;257(1):56-71 [24329789.001]
  • [Cites] Nat Rev Cancer. 2010 Mar;10 (3):213-21 [20168320.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] Breast Cancer Res Treat. 2012 Jun;133(2):799-804 [22418702.001]
  • [Cites] J Clin Oncol. 2015 Jan 1;33(1):74-82 [25403209.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):804-14 [16547468.001]
  • [Cites] Cancer Cell. 2014 Mar 17;25(3):304-17 [24651012.001]
  • [Cites] J Immunother. 2016 Apr;39(3):140-8 [26938947.001]
  • [Cites] Oncoimmunology. 2016 Jun 21;5(7):e1190061 [27622046.001]
  • [Cites] J Clin Invest. 2007 Aug;117(8):2197-204 [17657310.001]
  • (PMID = 29147628.001).
  • [ISSN] 2162-4011
  • [Journal-full-title] Oncoimmunology
  • [ISO-abbreviation] Oncoimmunology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; NK cell / PD-1 / PD-L1 / chimeric antigen receptor / cytotoxic T lymphocyte / immune checkpoint blockers
  •  go-up   go-down


29. ACTwatch Group, Newton PN, Hanson K, Goodman C: Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries. Malar J; 2017 May 25;16(1):204

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries.
  • BACKGROUND: Quality of artemisinin-based combination therapy (ACT) is important for ensuring malaria parasite clearance and protecting the efficacy of artemisinin-based therapies.
  • The extent to which non quality-assured ACT (non-QAACT), or those not granted global regulatory approval, are available and used to treat malaria in endemic countries is poorly documented.
  • Given the variation in non-QAACT markets observed across the eight study countries, active efforts to limit registration, importation and distribution of non-QAACT must be tailored to the country context, and will involve addressing complex and challenging aspects of medicine registration, private sector pharmaceutical regulation, local manufacturing and drug importation.
  • These efforts may be critical not only to patient health and safety, but also to effective malaria control and protection of artemisinin drug efficacy in the face of spreading resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2014 Jul 31;371(5):411-23 [25075834.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):455-67 [19641202.001]
  • [Cites] Malar J. 2011 Oct 31;10:325 [22039780.001]
  • [Cites] Malar J. 2014 Feb 04;13:46 [24495691.001]
  • [Cites] Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):75-86 [25897065.001]
  • [Cites] Lancet. 2012 Dec 1;380(9857):1916-26 [23122217.001]
  • [Cites] Am J Trop Med Hyg. 2015 Jun;92(6 Suppl):119-26 [25897068.001]
  • [Cites] PLoS One. 2015 May 27;10(5):e0125577 [26018221.001]
  • [Cites] Lancet Infect Dis. 2012 Jun;12(6):488-96 [22632187.001]
  • [Cites] Malar J. 2015 Jul 15;14:273 [26169915.001]
  • [Cites] Malar J. 2013 Jun 28;12:220 [23809666.001]
  • [Cites] Trop Med Int Health. 2004 Apr;9(4):451-60 [15078263.001]
  • [Cites] Malar J. 2012 Oct 29;11:356 [23107021.001]
  • [Cites] J Pharm Policy Pract. 2015 Sep 25;8:23 [26413304.001]
  • [Cites] Trop Med Int Health. 2014 Jan;19(1):23-36 [24134396.001]
  • [Cites] Malar J. 2014 Apr 08;13:139 [24712972.001]
  • [Cites] Malar J. 2013 Feb 05;12:52 [23383972.001]
  • [Cites] Health Policy Plan. 2010 Jan;25(1):61-9 [19726560.001]
  • [Cites] Malar J. 2010 Feb 11;9:50 [20149246.001]
  • [Cites] Lancet. 2010 May 8;375(9726):1597-8 [20458781.001]
  • [Cites] Malar J. 2010 Jun 11;9:157 [20537190.001]
  • [Cites] Malar J. 2016 Jun 01;15:302 [27251199.001]
  • [Cites] PLoS One. 2014 May 09;9(5):e95607 [24816649.001]
  • [Cites] Health Policy Plan. 2016 Dec;31(10 ):1448-1466 [27311827.001]
  • [Cites] Malar J. 2011 Dec 13;10:352 [22152094.001]
  • [Cites] Antimicrob Agents Chemother. 2015 Aug;59(8):4366-74 [26014953.001]
  • [Cites] BMJ Open. 2013 Aug 17;3(8):e002923 [23955188.001]
  • [Cites] Malar J. 2011 Oct 31;10:326 [22039838.001]
  • [Cites] Malar J. 2009 Oct 12;8 Suppl 1:S7 [19818174.001]
  • [Cites] Malar J. 2003 May 7;2:10 [12812525.001]
  • (PMID = 28539125.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ACT / Anti-malarial / Medicine quality / Regulation
  • [Investigator] Akulayi L; Alum A; Andrada A; Archer J; Arogundade ED; Auko E; Badru AR; Bates K; Bouanchaud P; Bruce M; Bruxvoort K; Buyungo P; Camilleri A; Carter ED; Chapman S; Charman N; Chavasse D; Cyr R; Duff K; Esch K; Evance I; Fulton A; Gataaka H; Guedegbe G; Haslam T; Harris E; Hong C; Hurley C; Isenhower W; Kaabunga E; Kaaya BD; Kabui E; Kangwana B; Kapata L; Kaula H; Kigo G; Kyomuhangi I; Lailari A; LeFevre S; Littrell M; Martin G; Michael D; Monroe E; Mpanya G; Mpasela F; Mulama F; Musuva A; Ngigi J; Ngoma E; Norman M; Nyauchi B; O'Connell KA; Ochieng C; Ogada E; Ongwenyi L; Orford R; Phanalasy S; Poyer S; Rahariniaina J; Raharinjatovo J; Razafindralambo L; Razakamiadana S; Riley C; Rodgers J; Rusk A; Shewchuk T; Sensalire S; Smith J; Sochea P; Solomon T; Sudoi R; Tassiba ME; Thanel K; Thompson R; Toda M; Ujuju C; Valensi MA; Vasireddy V; Whitman CB; Zinsou C
  •  go-up   go-down


30. Chanawong A, Mackenzie PI, McKinnon RA, Hu DG, Meech R: Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells. J Pharmacol Exp Ther; 2017 Jun;361(3):482-491
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exemestane (EXE) is an aromatase inhibitor indicated for endocrine therapy of breast cancer in postmenopausal women.
  • We recently reported that <i>UGT2B17</i> could be induced by both estrogenic and androgenic ligands in breast cancer cells via binding of the estrogen receptor <i>α</i> (ER<i>α</i>) or the androgen receptor (AR) to a complex regulatory unit in the proximal <i>UGT2B17</i> promoter.
  • Using antagonists of ER<i>α</i> and AR as well as inhibition mediated by small interfering RNA (siRNA) we demonstrate that EXE and 17-HE induce <i>UGT2B17</i> expression primarily via the AR.
  • This result is consistent with previous reports that 17-HE can act as an AR ligand.
  • The up-regulation of <i>UGT2B17</i> by EXE and 17-HE in breast cancer cells might enhance the local metabolism of 17-HE as well as that of endogenous androgens, hence impacting potentially on treatment outcomes.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.
  • (PMID = 28404691.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Minor Histocompatibility Antigens; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.17 / UGT2B17 protein, human; NY22HMQ4BX / exemestane
  •  go-up   go-down


31. Shou K, Niu Y, Zheng X, Ma Z, Jian C, Qi B, Hu X, Yu A: Enhancement of Bone-Marrow-Derived Mesenchymal Stem Cell Angiogenic Capacity by NPWT for a Combinatorial Therapy to Promote Wound Healing with Large Defect. Biomed Res Int; 2017;2017:7920265

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of Bone-Marrow-Derived Mesenchymal Stem Cell Angiogenic Capacity by NPWT for a Combinatorial Therapy to Promote Wound Healing with Large Defect.
  • Negative pressure wound therapy (NPWT) has been demonstrated to be effective for enhancing wound healing, especially for the promotion of angiogenesis within wounds.
  • Here we utilized combinatory strategy using the transplantation of BMSCs and NPWT to investigate whether this combinatory therapy could accelerate angiogenesis in wounds.
  • In vivo, rat full-thickness cutaneous wounds treated with BMSCs combined with NPWT exhibited better viability of the cells and enhanced angiogenesis and maturation of functional blood vessels than did local BMSC injection or NPWT alone.
  • Expression of angiogenesis markers (NG2, VEGF, CD31, and <i>α</i>-SMA) was upregulated in wounds treated with combined BMSCs with NPWT.
  • Our data suggest that NPWT may act as an inductive role to enhance BMSCs angiogenic capacity and this combinatorial therapy may serve as a simple but efficient clinical solution for complex wounds with large defects.
  • [MeSH-major] Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / cytology. Negative-Pressure Wound Therapy. Neovascularization, Physiologic. Wound Healing
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Differentiation. Cell Proliferation. Cell Shape. Cell Survival. Combined Modality Therapy. Cytokines / metabolism. Male. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):948-53 [17521616.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Tissue Eng. 2007 Dec;13(12):3003-10 [17988192.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Ostomy Wound Manage. 2004 Apr;50(4B Suppl):3S-27S [15311482.001]
  • [Cites] Biomaterials. 2015 Jun;53:58-75 [25890707.001]
  • [Cites] Stem Cells. 2010 May;28(5):905-15 [20474078.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1704-10 [16291063.001]
  • [Cites] Wound Repair Regen. 2011 Nov;19(6):727-33 [22092843.001]
  • [Cites] Int Wound J. 2009 Aug;6 Suppl 1:1-26 [19614789.001]
  • [Cites] J Biomech. 2010 Apr 19;43(6):1176-81 [20022602.001]
  • [Cites] J Vasc Surg. 2006 Jan;43(1):134-41 [16414400.001]
  • [Cites] Tissue Eng. 2007 Jun;13(6):1299-312 [17518741.001]
  • [Cites] PLoS One. 2014 Sep 12;9(9):e107339 [25216182.001]
  • [Cites] J Bone Joint Surg Am. 2014 Aug 20;96(16):1378-85 [25143498.001]
  • [Cites] Injury. 2014 May;45(5):890-3 [22377275.001]
  • [Cites] Ann Plast Surg. 2013 Jan;70(1):23-9 [23249474.001]
  • [Cites] Am J Physiol Cell Physiol. 2009 Mar;296(3):C535-43 [19109527.001]
  • [Cites] Ann Vasc Surg. 2003 Nov;17(6):645-9 [14534844.001]
  • [Cites] Stem Cells. 2008 May;26(5):1307-14 [18308943.001]
  • [Cites] Ann Surg. 2011 Feb;253(2):402-9 [21217515.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):782-8 [18355797.001]
  • [Cites] Cytotherapy. 2011 Jul;13(6):705-11 [21284564.001]
  • [Cites] J Dermatol. 2003 Aug;30(8):596-601 [12928528.001]
  • [Cites] J Bone Joint Surg Br. 2007 Oct;89(10 ):1382-6 [17957083.001]
  • [Cites] Curr Opin Hematol. 2006 Nov;13(6):419-25 [17053453.001]
  • [Cites] Ann Plast Surg. 2001 Nov;47(5):547-51 [11716268.001]
  • [Cites] Acta Biomater. 2015 Dec;28:64-75 [26432440.001]
  • [Cites] J Control Release. 2011 Jun 30;152(3):411-7 [21435363.001]
  • [Cites] Biomaterials. 2015;53:379-91 [25890736.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2648-59 [17615264.001]
  • [Cites] Stem Cells Dev. 2011 Aug;20(8):1297-308 [21303266.001]
  • [Cites] Am J Cardiol. 2004 Jul 1;94(1):92-5 [15219514.001]
  • [Cites] Stem Cell Res Ther. 2010 Sep 24;1(4):30 [20863417.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):510-6 [12707099.001]
  • [Cites] Expert Rev Med Devices. 2006 May;3(3):373-85 [16681458.001]
  • [Cites] Am J Surg. 2011 Apr;201(4):544-56 [21421104.001]
  • [Cites] Stem Cells Dev. 2009 Nov;18(9):1299-308 [19508152.001]
  • [Cites] Ostomy Wound Manage. 2000 Aug;46(8):28-32, 34 [11189545.001]
  • [Cites] Wound Repair Regen. 2009 Mar-Apr;17(2):200-5 [19320888.001]
  • (PMID = 28243602.001).
  • [ISSN] 2314-6141
  • [Journal-full-title] BioMed research international
  • [ISO-abbreviation] Biomed Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines
  •  go-up   go-down


32. Nikan M, Osborn MF, Coles AH, Godinho BM, Hall LM, Haraszti RA, Hassler MR, Echeverria D, Aronin N, Khvorova A: Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain. Mol Ther Nucleic Acids; 2016;5:e344

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain.
  • Importantly, DHA-hsiRNAs do not induce neural cell death or measurable innate immune activation following administration of concentrations over 20 times above the efficacious dose.
  • Thus, DHA conjugation is a novel strategy for improving siRNA activity in mouse brain, with potential to act as a new therapeutic platform for the treatment of neurodegenerative disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28131259.001).
  • [ISSN] 2162-2531
  • [Journal-full-title] Molecular therapy. Nucleic acids
  • [ISO-abbreviation] Mol Ther Nucleic Acids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; drug delivery / neurodegenerative disease / siRNA
  •  go-up   go-down


33. Wolfensberger TJ: Macular Edema - Rationale for Therapy. Dev Ophthalmol; 2017;58:74-86
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macular Edema - Rationale for Therapy.
  • When macular edema is caused by a generalized health problem such as diabetes, high blood pressure, or generalized inflammatory conditions, treatment of these generalized diseases can in many cases cure macular edema directly.
  • In ocular diseases, the local exudation of fluid from blood vessels is governed by Starling's law as well as by intricate cellular mechanisms linked to the tight junctions in the inner and outer blood-retinal barrier.
  • Drugs used in clinical practice, such as nonsteroidal anti-inflammatory drugs, corticosteroids, carbonic anhydrase inhibitors, and anti-vascular endothelial growth factor agents, all act in one way or another through these cellular mechanisms.
  • Successful surgical treatment of macular edema using vitrectomy and peeling relies, apart from the evident release of vitreomacular traction, on many other cellular and biochemical mechanisms activated by the surgery such as oxygenation of the inner retina, removal of the posterior hyaloid as a growth factor sink, and possible Müller cell remodeling with fluid redirection after internal limiting membrane peeling.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Macular Edema / therapy. Neuroprotective Agents / therapeutic use. Visual Acuity. Vitrectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28351053.001).
  • [ISSN] 1662-2790
  • [Journal-full-title] Developments in ophthalmology
  • [ISO-abbreviation] Dev Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Neuroprotective Agents; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


34. Lombardi M, Mantione ME, Baccellieri D, Ferrara D, Castellano R, Chiesa R, Alfieri O, Foglieni C: P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels. Sci Rep; 2017 Jul 07;7(1):4872
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleiotropic P2X purinoceptor 7 (P2X7), expressed in the carotid plaque (PL), is involved in interleukin 1 beta (IL-1β) release that may influence MMP9 generation, thus their possible modulation through acting on P2X7 was investigated.
  • Acting downstream P2X7 by MMPs inhibitors, diminished IL-1β mRNA without transcriptional effect at MMP9, possibly because the assumption of statin by patients.
  • These data firstly demonstrated A740003 suitability as a specific tool to decrease inflammatory status in human vessels and might support the design of studies applying P2X7 antagonists for the local targeting and tailored therapy of atherosclerosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cardiol. 2013 Oct 3;168(3):2863-6 [23602287.001]
  • [Cites] J Immunol. 1998 Oct 1;161(7):3340-6 [9759850.001]
  • [Cites] Immunobiology. 2009;214(7):543-53 [19250700.001]
  • [Cites] J Cardiovasc Pharmacol Ther. 2004 Dec;9(4):291-8 [15678248.001]
  • [Cites] Med Hypotheses. 2010 Dec;75(6):517-21 [20674184.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3877-83 [16547218.001]
  • [Cites] Expert Opin Investig Drugs. 2011 Jul;20(7):897-915 [21510825.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1376-85 [16982702.001]
  • [Cites] Blood. 2006 Jun 15;107(12 ):4946-53 [16514055.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2000 May;19(5):461-7 [10828225.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75 [10807742.001]
  • [Cites] Eur J Immunol. 2011 May;41(5):1203-17 [21523780.001]
  • [Cites] Mediators Inflamm. 2014;2014:720987 [24648660.001]
  • [Cites] Cardiovasc Res. 2012 Jul 15;95(2):156-64 [22406749.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2108-14 [18772495.001]
  • [Cites] Pharmacol Rev. 2014 Jul;66(3):638-75 [24928329.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2831-7 [18441195.001]
  • [Cites] Atherosclerosis. 2002 May;162(1):55-61 [11947897.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):59-69 [16374516.001]
  • [Cites] Purinergic Signal. 2016 Mar;12 (1):25-57 [26545760.001]
  • [Cites] J Clin Invest. 2012 Jan;122(1):70-9 [22201681.001]
  • [Cites] Front Pharmacol. 2016 Oct 10;7:369 [27777559.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2015 Nov;24(11):2455-66 [26381780.001]
  • [Cites] J Cell Physiol. 2007 Jun;211(3):759-70 [17311279.001]
  • [Cites] FASEB J. 2015 Oct;29(10 ):4162-73 [26116704.001]
  • [Cites] Circulation. 2011 Dec 13;124(24):2725-34 [22082680.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):250-6 [16339501.001]
  • [Cites] Nature. 2006 Mar 9;440(7081):228-32 [16407890.001]
  • [Cites] FASEB J. 2010 Sep;24(9):3393-404 [20453110.001]
  • [Cites] FASEB J. 2015 Jun;29(6):2450-61 [25690658.001]
  • [Cites] EXS. 2012;103:209-79 [22642194.001]
  • [Cites] J Endocrinol. 2012 Aug;214(2):145-53 [22619232.001]
  • [Cites] Am Heart J. 2011 Oct;162(4):597-605 [21982649.001]
  • [Cites] Sci Rep. 2016 Mar 03;6:22586 [26935289.001]
  • [Cites] Atherosclerosis. 2003 Oct;170(2):269-76 [14612207.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 24;332(1):17-27 [15896293.001]
  • [Cites] Chest. 2004 May;125(5):1853-8 [15136400.001]
  • [Cites] Mol Cells. 2014 Jun;37(6):441-8 [24850149.001]
  • [Cites] J Am Heart Assoc. 2016 May 20;5(5):null [27207962.001]
  • [Cites] Clin Sci (Lond). 2013 Aug;125(3):131-41 [23469860.001]
  • [Cites] Atherosclerosis. 2016 Aug;251:445-453 [27320174.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2568-74 [11709424.001]
  • [Cites] Br J Pharmacol. 2002 Feb;135(4):831-42 [11861311.001]
  • [Cites] Cardiovasc Diabetol. 2012 Jul 24;11:86 [22828168.001]
  • (PMID = 28687781.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Chen YW, Shieh JP, Liu KS, Wang JJ, Hung CH: Naloxone prolongs cutaneous nociceptive block by lidocaine in rats. Fundam Clin Pharmacol; 2017 Dec;31(6):636-642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to investigate the local anesthetic properties of naloxone alone or as an adjunct for the local anesthetic lidocaine.
  • The relative potency in inducing cutaneous analgesia was lidocaine [22.6 (20.1 - 25.4) μmol/kg] > naloxone [43.2 (40.3 - 46.4) μmol/kg] (P < 0.05).
  • On an equianesthetic basis [50% effective dose (ED<sub>50</sub> ), ED<sub>25</sub> , and ED<sub>75</sub> ], naloxone displayed a greater duration of cutaneous analgesic action than lidocaine (P < 0.01).
  • Coadministration of lidocaine (ED<sub>95</sub> or ED<sub>50</sub> ) and ineffective-dose naloxone (13.3 μmol/kg) intensifies sensory block (P < 0.01) with prolonged duration of action (P < 0.001) compared with lidocaine (ED<sub>95</sub> or ED<sub>50</sub> ) alone or naloxone (13.3 μmol/kg) alone on infiltrative cutaneous analgesia.
  • Furthermore, naloxone prolongs lidocaine analgesia, acting synergistically for nociceptive block.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Société Française de Pharmacologie et de Thérapeutique.
  • (PMID = 28677297.001).
  • [ISSN] 1472-8206
  • [Journal-full-title] Fundamental & clinical pharmacology
  • [ISO-abbreviation] Fundam Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; coadministration / infiltrative cutaneous analgesia / lidocaine / naloxone / subcutaneous injection
  •  go-up   go-down


36. Workman ER, Niere F, Raab-Graham KF: Engaging homeostatic plasticity to treat depression. Mol Psychiatry; 2017 Nov 14;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major depressive disorder (MDD) is a complex and heterogeneous mood disorder, making it difficult to develop a generalized, pharmacological therapy that is effective for all who suffer from MDD.
  • NMDAR antagonists act as rapid-acting antidepressants such that relief from depressive symptoms occurs within hours of a single injection.
  • Herein, we review critical studies that shed light on the action of NMDAR antagonists as rapid-acting antidepressants and how they engage a neuron's or neural network's homeostatic mechanisms to self-correct.
  • Recent studies notably demonstrate that a shift in γ-amino-butyric acid receptor B (GABA<sub>B</sub>R) function, from inhibitory to excitatory, is required for mTORC1-dependent translation with NMDAR antagonists.
  • Finally, we discuss how GABA<sub>B</sub>R activation of mTORC1 helps resolve key discrepancies between rapid-acting antidepressants and local homeostatic mechanisms.Molecular Psychiatry advance online publication, 14 November 2017; doi:10.1038/mp.2017.225.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29133952.001).
  • [ISSN] 1476-5578
  • [Journal-full-title] Molecular psychiatry
  • [ISO-abbreviation] Mol. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Harvey M, Cave G: Lipid emulsion in local anesthetic toxicity. Curr Opin Anaesthesiol; 2017 Oct;30(5):632-638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid emulsion in local anesthetic toxicity.
  • Despite widespread awareness and improved techniques (including the increasing use of ultrasound guidance for block placement), intravascular sequestration and the attendant risk of local anesthetic systemic toxicity (LAST) remains.
  • RECENT FINDINGS: Although incompletely elucidated the mechanism of action for ILE in LAST seemingly involves beneficial effects on initial drug distribution (i.e., pharmacokinetic effects) and positive cardiotonic and vasoactive effects (i.e., pharmacokinetic effects) acting in concert.
  • Recent systematic review by collaborating international toxicologic societies have provided reserved endorsement for ILE in bupivacaine-induced toxicity, weak support for ILE use in toxicity from other local anesthetics, and largely neutral recommendation for all other drug poisonings.
  • SUMMARY: Lipid emulsion remains first-line therapy (in conjunction with standard resuscitative measures) in LAST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28692439.001).
  • [ISSN] 1473-6500
  • [Journal-full-title] Current opinion in anaesthesiology
  • [ISO-abbreviation] Curr Opin Anaesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Thomas JG, Al-Holou WN, de Almeida Bastos DC, Ghia AJ, Li J, Bishop AJ, Amini B, Rhines LD, Tatsui CE: A Novel Use of the Intraoperative MRI for Metastatic Spine Tumors: Laser Interstitial Thermal Therapy for Percutaneous Treatment of Epidural Metastatic Spine Disease. Neurosurg Clin N Am; 2017 Oct;28(4):513-524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Novel Use of the Intraoperative MRI for Metastatic Spine Tumors: Laser Interstitial Thermal Therapy for Percutaneous Treatment of Epidural Metastatic Spine Disease.
  • Spinal laser interstitial thermal therapy (LITT) appears to be a promising novel modality for treatment of epidural metastatic spine disease in patients who are poor candidates for larger-scale oncologic spinal surgery and can act synergetically with spinal stereotactic radiosurgery to maximize local control and palliate pain.
  • This technique is ideally suited for the intraoperative MRI suite to monitor the extent of the ablation in the epidural space.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28917280.001).
  • [ISSN] 1558-1349
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Laser interstitial thermal therapy / Metastatic spine tumors / Spinal stereotactic radiosurgery
  •  go-up   go-down


39. Cheng P, Zeng W, Li L, Huo D, Zeng L, Tan J, Zhou J, Sun J, Liu G, Li Y, Guan G, Wang Y, Zhu C: PLGA-PNIPAM Microspheres Loaded with the Gastrointestinal Nutrient NaB Ameliorate Cardiac Dysfunction by Activating Sirt3 in Acute Myocardial Infarction. Adv Sci (Weinh); 2016 Dec;3(12):1600254

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nutrients supplied by the blood are the main source of cellular energy for cardiomyocytes.
  • Sodium butyrate (NaB), a gastrointestinal nutrient, is a short-chain fatty acid (butyric acid) that may act as an energy source in AMI therapy.
  • Poly(lactic-co-glycolic acid)-Poly (<i>N</i>-isopropylacrylamide) microspheres loaded with NaB (PP-N) are synthesized to prolong the release of NaB and are injected into ischemic zones in a Sprague-Dawley rat AMI model.
  • The results indicate that NaB, acting as a nutrient, can protect cardiomyocytes in AMI.
  • These results suggest that the gastrointestinal nutrient NaB may be a new therapy for AMI treatment, and PP-N may be the ideal therapeutic regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2016 Apr;24(4):805-11 [26782638.001]
  • [Cites] J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66 [24361318.001]
  • [Cites] Lancet. 2013 Jun 8;381(9882):1987-2015 [23746901.001]
  • [Cites] Theranostics. 2016 Jun 15;6(9):1393-402 [27375787.001]
  • [Cites] Acta Biomater. 2016 Mar 1;32:10-23 [26689467.001]
  • [Cites] Rep Prog Phys. 2014 May;77(5):056601 [24801604.001]
  • [Cites] J Control Release. 2015 Feb 28;200:167-78 [25575863.001]
  • [Cites] Chem Soc Rev. 2013 Sep 7;42(17):7214-43 [23450220.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Acta Biomater. 2014 Dec;10(12):5090-8 [25152354.001]
  • [Cites] J Am Chem Soc. 2004 Oct 20;126(41):13226-7 [15479068.001]
  • [Cites] Circulation. 1978 Dec;58(6):1072-83 [709763.001]
  • [Cites] Drug Dev Ind Pharm. 2016;42(5):737-46 [26472259.001]
  • [Cites] Acta Biomater. 2013 Feb;9(2):4976-84 [23063555.001]
  • [Cites] Biomaterials. 2009 Sep;30(26):4357-68 [19487021.001]
  • [Cites] ACS Nano. 2012 Apr 24;6(4):3327-38 [22435911.001]
  • [Cites] J Biomed Nanotechnol. 2015 Dec;11(12 ):2124-36 [26510307.001]
  • [Cites] Science. 2001 Mar 30;291(5513):2613-6 [11283375.001]
  • [Cites] Circ Res. 2010 May 28;106(10 ):1570-81 [20378859.001]
  • [Cites] J Control Release. 2014 Nov 10;193:324-40 [25218676.001]
  • [Cites] Nature. 1952 Sep 27;170(4326):541 [13002353.001]
  • [Cites] Nat Mater. 2008 Nov;7(11):863-8 [18931671.001]
  • [Cites] J Biomed Mater Res A. 2010 Dec 15;95(4):1055-66 [20878934.001]
  • [Cites] Nano Lett. 2014 Oct 8;14(10):5792-6 [25176294.001]
  • [Cites] Endocr Rev. 2010 Apr;31(2):194-223 [20007326.001]
  • [Cites] Circ Res. 2000 Sep 1;87(5):392-8 [10969037.001]
  • [Cites] Biomaterials. 2012 Jun;33(16):4069-77 [22386922.001]
  • [Cites] Cell. 1975 Jul;5(3):319-22 [1056809.001]
  • [Cites] Nanomedicine. 2010 Oct;6(5):672-80 [20172050.001]
  • [Cites] Oncogene. 2011 Jun 30;30(26):2986-96 [21358671.001]
  • [Cites] Physiol Rev. 1990 Apr;70(2):567-90 [2181501.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2108-18 [16075055.001]
  • [Cites] Adv Mater. 2011 Mar 25;23(12):H57-77 [21433103.001]
  • [Cites] Biomaterials. 2014 Jul;35(22):5679-88 [24746964.001]
  • [Cites] Angew Chem Int Ed Engl. 2015 Dec 14;54(51):15342-67 [26612195.001]
  • [Cites] ACS Nano. 2015 Jan 27;9(1):279-89 [25493575.001]
  • [Cites] Science. 2013 Nov 1;342(6158):1243417 [24051248.001]
  • (PMID = 27981013.001).
  • [ISSN] 2198-3844
  • [Journal-full-title] Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  • [ISO-abbreviation] Adv Sci (Weinh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Sirt3 / fatty acids / ischemia / microspheres
  •  go-up   go-down


40. Petri M, Stoffels I, Griewank K, Jose J, Engels P, Schulz A, Pötzschke H, Jansen P, Schadendorf D, Dissemond J, Klode J: Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term Therapy. Mol Imaging Biol; 2017 Jul 12;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term Therapy.
  • PURPOSE: Chronic leg ulcers can be a challenge to treat and long-term therapy a significant cost factor in western public health budgets.
  • Objective wound assessment assays enabling selection of appropriate wound therapy regimes would be desirable.
  • The aims were to determine if changes in tissue oxygenation can be measured after topical application of hemoglobin on chronic wounds and to evaluate the findings in terms of therapy strategies.
  • PROCEDURES: Photoacoustic imaging was used to measure the local oxygen saturation (StO<sub>2</sub>) in leg ulcers before and after hemoglobin spray treatment.
  • RESULTS: Measuring 49 patients, an increase in StO<sub>2</sub> after topical hemoglobin application from on average 66.1 to 71 % (p = 0.017) after 20 min was observed.
  • Depending on the increase in StO<sub>2</sub> (>10 % or <10 %) patients were stratified into a Responder and a Non-Responder group.
  • CONCLUSION: Our findings suggest that the likelihood of wound healing under conservative therapy can be predicted by measuring changes in StO<sub>2</sub> after topical hemoglobin application.
  • This assay may reduce treatment time and costs by avoiding ineffective conservative long-term therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28702902.001).
  • [ISSN] 1860-2002
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Chronic wounds / Hemoglobin treatment / Photoacoustic imaging
  •  go-up   go-down


41. Stoeckle E, Michot A, Rigal L, Babre F, Sargos P, Henriques de Figueiredo B, Brouste V, Italiano A, Toulmonde M, Le Loarer F, Kind M: The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series. Eur J Surg Oncol; 2017 Jun;43(6):1117-1125
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At five years, overall survival was 80% and local recurrences 11%.
  • They may be reduced by acting on comorbidity factors and careful tumor evaluation prior to surgery.
  • [MeSH-major] Activities of Daily Living. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Extremities / surgery. Postoperative Complications / epidemiology. Radiotherapy, Adjuvant / methods. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Torso / surgery
  • [MeSH-minor] Abdominal Wall. Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Male. Mesna / therapeutic use. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy / methods. Retrospective Studies. Risk Factors. Survival Rate. Thoracic Wall. Tumor Burden. Young Adult


42. Bezerra AN, Massing LT, de Oliveira RB, Mourão RH: Standardization and anti-inflammatory activity of aqueous extract of Psittacanthus plagiophyllus Eichl. (Loranthaceae). J Ethnopharmacol; 2017 Apr 18;202:234-240
Hazardous Substances Data Bank. CARRAGEENAN GUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ETHNOPHARMACOLOGICAL IMPORTANCE: The hemiparasitic species Psittacanthus plagiophyllus Eichl. (Loranthaceae), also known as erva de passarinho, is used in folk medicine in the Santarém region in the state of Pará, Brazil, to treat gastritis and a variety of inflammatory disorders.
  • In view of the lack of pharmacological studies on this species in the literature and the fact that it is used constantly by the local population, this study sought to standardize the extract of the leaves of P. plagiophyllus (AEPp) and to assess its anti-inflammatory potential in in vivo tests.
  • MATERIAL AND METHODS: Quality control and standardization of AEPp were performed following the 5th edition of the Brazilian Pharmacopeia.
  • Measurement of phenolics revealed the following percentages in the extract: 12.62±0.18% total phenolics, 5.39±0.01% total tannins, 12.54±0.24% hydrolyzable tannins, 8.37±0.32% condensed tannins and 1.23±0.02% total flavonoids.
  • ) AEPp had significant edema-inhibiting activity (p<0.01) in both the models used, suggesting that the extract may act in vascular and cell events in the inflammatory response and exert an inhibitory effect on mediators responsible for edema.
  • Both effects were statistically significant (p<0.01).
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Brazil. Carrageenan. Edema / chemically induced. Edema / prevention & control. Exudates and Transudates. Inflammation / drug therapy. Inflammation / pathology. Leukocyte Count. Male. Neutrophil Infiltration / drug effects. Plant Leaves / chemistry. Quality Control. Rats. Rats, Wistar. Reference Standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 28330723.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antioxidants; 0 / Plant Extracts; 9000-07-1 / Carrageenan
  •  go-up   go-down


43. Rajurkar SP, Singh T, Arora M, Saha S, Gayar H, Talwar N, Nettleton J: Concurrent weekly taxane (T) and radiation therapy (RT) in the adjuvant treatment of breast cancer (BrCa). J Clin Oncol; 2004 Jul 15;22(14_suppl):858

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent weekly taxane (T) and radiation therapy (RT) in the adjuvant treatment of breast cancer (BrCa).
  • : 858 Background: High-risk BrCa pts receive adriamycin(A) + cyclophosphamide(C) followed by a T given every 3 wks × 4 followed by radiation therapy (RT).
  • T is suggested to act as radiosensitisers.
  • Then they received A + C every 3 wks × 4 followed by either Paclitaxel (P)(80 mg/m<sup>2</sup>/wk) or Docetaxel (D)(30 mg/m<sup>2</sup>/wk) every wk with concurrent RT 5 days/wk for 6 wks followed by a T alone every wk for 6 wks.
  • No local recurrences have occurred.
  • CONCLUSIONS: Although there have been no local recurrences, an interruption in RT of 10 days in 22% patients is concerning.
  • At this point, we cannot recommend concurrent weekly Taxane and Radiation therapy in the adjuvant treatment of breast cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014278.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Ogawa R, Akaishi S: Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders. Med Hypotheses; 2016 Nov;96:51-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathogenesis of these scars clearly involves local conditions such as delayed wound healing, wound depth, and the tension of the skin around the scars.
  • Scar severity is also shaped by interactions between these local factors and genetic and systemic factors such as hypertension and sex hormones.
  • Our studies show that tension on the skin around the wound results in prolonged and/or repeated bouts of inflammation in the reticular layer of the dermis and that this inflammation generates abnormal numbers of blood vessels (as well as collagen and nerve fibers) in the dermal reticular layer.
  • We hypothesize that local factors, such as the mechanobiology of the dermis and blood vessels, along with genetic and systemic factors promote pathological scar development by inducing endothelial dysfunction (i.e., vascular hyperpermeability) during the inflammatory stage of wound healing.
  • Evidence for this hypothesis includes the fact that all effective treatments of keloids, namely, radiotherapy, compression therapy, steroid administration, and long-pulsed Nd:YAG laser therapy, act, at least partly, by suppressing blood vessels.
  • Thus, primary scars are caused by congenital endothelial dysfunction (e.g., a mutation prevents endothelial gaps from closing smoothly) while secondary scars are caused by endothelial dysfunction that results from aging, arterial sclerosis, and/or repeated/very strong local mechanical forces.
  • Thus, abnormal blood vessel regulation may underlie keloid and hypertrophic scar pathogenesis, which suggests that inhibiting abnormal angiogenesis and vascular hyperpermeability may be an important therapeutic approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
  • (PMID = 27959277.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


45. d'Elbée M, Baumevieille M, Dumartin C: [Cooperation according to French Law "hospital, patients, health and territories": Pharmacists' involvement in Aquitaine region]. Rev Epidemiol Sante Publique; 2017 Jun;65(3):231-239

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Missions de coopération introduites par la loi « hôpital, patients, santé et territoires » : participation des pharmaciens d’officine en Aquitaine.
  • BACKGROUND: In 2009, the French Act "Hospital, Patients, Health and Territories" (loi "Hôpital, Patients, Santé et Territoires") reorganized the outpatient care pathway and defined missions aimed at improving cooperation between pharmaceutical and medical professionals.
  • METHODS: In partnership with the local health authorities "Agence régionale de santé", we conducted a survey via an online questionnaire sent to pharmacy holders in July 2014 in Aquitaine region.
  • Regarding collaborative activities, the majority of pharmacists (78%) had conducted interviews with their patients taking vitamin K antagonist therapy and they were willing to continue (87%).
  • The main obstacles for engaging in these activities were the lack of time, lack of knowledge about these missions and the lack of remuneration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Masson SAS. All rights reserved.
  • (PMID = 28262371.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'epidemiologie et de sante publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Prescription Drugs
  • [Keywords] NOTNLM ; Enquête sur les services de santé / Health care survey / Parcours de soins coordonnés / Partnership practice / Pharmacies / Pharmacist / Public health / Santé publique
  •  go-up   go-down


46. Cheng KJ, Wang SQ, Xu YY: Different roles of <i>Staphylococcus aureus</i> enterotoxin in different subtypes of nasal polyps. Exp Ther Med; 2017 Jan;13(1):321-326

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different roles of <i>Staphylococcus aureus</i> enterotoxin in different subtypes of nasal polyps.
  • This study was designed to investigate the role of inflammation and <i>Staphylococcus aureus</i> enterotoxin (SE) in this disease.
  • The supernatant ECP and MPO levels were elevated in the CRSwNP group compared with the control group, but no significant difference in the serum total IgE and ECP levels were observed between the CRSwNP and control groups.
  • In addition, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in supernatant total IgE, SEA and SEB levels compared with the control group.
  • Additionally, local indicators reflect the inflammatory status more accurately than do serum indicators.
  • SEs may act as an infection factor rather than as a superantigen in Chinese non-eosinophilic CRSwNP patients.
  • Thus, long-term antibiotic therapy may be an option for Chinese non-eosinophilic CRSwNP patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Allergy Asthma Rep. 2003 Nov;3(6):505-12 [14531972.001]
  • [Cites] Acta Otolaryngol. 2011 Sep;131(9):997-1001 [21612504.001]
  • [Cites] J Otolaryngol Head Neck Surg. 2010 Feb;39(1):45-51 [20122344.001]
  • [Cites] J Allergy Clin Immunol. 2006 Nov;118(5 Suppl):S17-61 [17084217.001]
  • [Cites] Rhinology. 2012 Mar;50(1):1-12 [22469599.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Nov;135(5):680-3 [17071293.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2013;75(1):37-45 [23571727.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2010 Jul;119(7):455-9 [20734966.001]
  • [Cites] Rhinology. 2007 Jun;45(2):97-101 [17708455.001]
  • [Cites] Otolaryngol Head Neck Surg. 2010 Jul;143(1):147-51 [20620634.001]
  • [Cites] Am J Rhinol Allergy. 2013 Sep-Oct;27(5):367-71 [23601202.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jan;121(1):110-5 [17980412.001]
  • [Cites] Allergy. 2011 Oct;66(10):1296-303 [21575009.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Sep;129(3 Suppl):S1-32 [12958561.001]
  • [Cites] Allergol Int. 2012 Mar;61(1):115-22 [22377524.001]
  • [Cites] Laryngoscope. 2013 Nov;123(11):E1-9 [23670893.001]
  • [Cites] Clin Exp Allergy. 2014;44(5):690-700 [24597471.001]
  • [Cites] J Laryngol Otol. 2009 May;123(5):509-16 [18492304.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2005 Feb;13(1):39-44 [15654214.001]
  • [Cites] Laryngoscope. 2012 Mar;122(3):498-503 [22252861.001]
  • [Cites] J Allergy Clin Immunol. 2010 Nov;126(5):962-8, 968.e1-6 [20810157.001]
  • [Cites] Laryngoscope. 2004 Oct;114(10 ):1822-6 [15454779.001]
  • [Cites] Allergy. 2006 Nov;61(11):1275-9 [17002702.001]
  • [Cites] Ann Allergy Asthma Immunol. 2001 Mar;86(3):283-5 [11289325.001]
  • [Cites] Pediatr Allergy Immunol. 2012 Aug;23 Suppl 22:2-4 [22762847.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2002 Mar;1(1):117-26 [14561211.001]
  • [Cites] Am J Rhinol. 2007 Nov-Dec;21(6):686-90 [17883886.001]
  • [Cites] Am J Rhinol. 2006 Jul-Aug;20(4):445-50 [16955777.001]
  • [Cites] J Allergy Clin Immunol. 2008 Nov;122(5):961-8 [18804271.001]
  • [Cites] Clin Exp Allergy. 2007 Dec;37(12):1840-7 [17941912.001]
  • [Cites] J Allergy Clin Immunol. 2009 Sep;124(3):478-84, 484.e1-2 [19541359.001]
  • [Cites] Am J Rhinol. 2006 Jan-Feb;20(1):95-100 [16539303.001]
  • [Cites] Am J Rhinol. 2005 Jul-Aug;19(4):327-33 [16171163.001]
  • [Cites] J Allergy Clin Immunol. 2013 Jun;131(6):1479-90 [23587334.001]
  • (PMID = 28123509.001).
  • [ISSN] 1792-0981
  • [Journal-full-title] Experimental and therapeutic medicine
  • [ISO-abbreviation] Exp Ther Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Keywords] NOTNLM ; Staphylococcus aureus enterotoxin / chronic rhinosinusitis with nasal polyps / eosinophil cationic protein / myeloperoxidase / superantigen
  •  go-up   go-down


47. Yu B, Ma Z, Guan C, Liu G, Ding H, Yin Y, Han W, Taimei Baofa Cancer Hospital: Clinical introtumoral chemoimmunotherapy for late stages of lung cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e21001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21001 Background: Currently cancer therapy is not satisfied with the effectiveness of available treatment.
  • Therefore, it resulted in one year survial rate is 36%(treated) compared 14%(control) with P<0.05.in addition to the innovation for sustained drug release, more importantly, ChemoVac provides a new option for cancer treatment by integrating local chemotherapeutic effect with systemic anti-tumor immunity; cell death induced by chemotherapeutic drugs is a priming event and allows the injected tumor act as its own vaccine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Klug TE: Peritonsillar abscess: clinical aspects of microbiology, risk factors, and the association with parapharyngeal abscess. Dan Med J; 2017 Mar;64(3)
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment consists of abscess drainage and antimicrobial therapy.
  • There are three accepted methods of surgical intervension: needle aspiration, incision and drainage (ID), and acute tonsillectomy (á chaud).
  • Internationally, there is a strong trend towards less invasive surgical approach to PTA treatment with avoidance of acute tonsillectomy, needle aspiration instead of ID, and in some cases even antibiotic treatment without surgical drainage.
  •   The trend towards de-escalated surgical intervention and increasing reliance on antibiotic treatment, require studies defining the significant pathogens in PTA in order to determine optimal antibiotic regimens.
  • FN-positive patients displayed significantly higher infection markers (CRP and neutrophil counts) than patients infected with other bacteria (P = 0.01 and P < 0.001, respectively).
  • We found increasing levels (at least two-fold) of anti-FN antibodies in eight of 11 FN-positive (in the tonsillar cultures) PTA patients, which was significantly more frequent compared to none of four FN-negative PTA patients and nine of 47 electively tonsillectomized controls (P = 0.026 and P < 0.001, respectively).
  • Blood cultures obtained during acute tonsillectomy mirrored the bacterial findings in the tonsillar specimens with 22% of patients having bacteremia with FN.
  • Conclusions on causality cannot be drawn from this retrospective study, but the pathophysiology behind the increased risk of PTA in smokers may be related to, previously shown, alterations in the tonsillar, bacterial flora or the local and systemical inflammatory and immunological milieu.
  • This finding suggests that FN is not a subsequent overgrowth phenomenon after abscess development, but that FN can act as pathogen in severe acute tonsillitis.

  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28260599.001).
  • [ISSN] 2245-1919
  • [Journal-full-title] Danish medical journal
  • [ISO-abbreviation] Dan Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  •  go-up   go-down


49. Li J, Yang F, Wei F, Ren X: The role of toll-like receptor 4 in tumor microenvironment. Oncotarget; 2017 Jul 08;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides, substances, released from both tissue cells attacked by exogenous etiologies, also act on local cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28722681.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TLR4 / immune cells / tumor cells / tumor microenvironment
  •  go-up   go-down


50. Wagner RH, Savir-Baruch B, Gabriel MS, Halama JR, Bova D: Managing Written Directives: A Software Solution to Streamline Workflow. J Nucl Med Technol; 2017 Jun;45(2):96-101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nuclear Regulatory Commission for any use of <sup>131</sup>I above 1.11 MBq (30 μCi) and for patients receiving radiopharmaceutical therapy.
  • As the introduction of new radiopharmaceuticals increases therapeutic options in nuclear medicine, time spent on regulatory paperwork also increases.
  • The pressure of managing these time-consuming regulatory requirements may heighten the potential for inaccurate or incomplete directive data and subsequent regulatory violations.
  • To improve on the paper-trail method of directive management, we created a software tool using a Health Insurance Portability and Accountability Act (HIPAA)-compliant database.
  • This software allows for secure data-sharing among physicians, technologists, and managers while saving time, reducing errors, and eliminating the possibility of loss and duplication.
  • <b>Methods:</b> The software tool was developed using Visual Basic, which is part of the Visual Studio development environment for the Windows platform.
  • Patient data are deposited in an Access database on a local HIPAA-compliant secure server or hard disk.
  • <b>Results:</b> The software has been used at our institution for over 2 y and has reliably kept track of all directives.
  • <b>Conclusion:</b> We have developed a software solution for the management of written directives that streamlines and structures the departmental workflow.
  • This solution saves time, centralizes the information for all staff to share, and decreases confusion about the creation, completion, filing, and retrieval of directives.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
  • (PMID = 28280130.001).
  • [ISSN] 1535-5675
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; regulatory compliance / software / written directive
  •  go-up   go-down


51. Haddad RI, Gokhale AS, Wirth L, Weeks L, Faucher J, Hallar M, Cavacini LA, Posner MR: Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol; 2004 Jul 15;22(14_suppl):9716

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These cytokines act through pro-angiogenic and mitogenic effects.
  • Active co-morbid illnesses, addictions, use of steroids or NSAIDS, or active anticancer therapy immediately prior to sampling were exclusion criteria.
  • 7/7 NV and 4/5 NED had levels < 20 pg/ml (mean of 13 and 15, respectively).
  • In the RD group, 12/15 with metastatic disease (MD) and 4/5 with local regional recurrence (LRR) had IL-8 levels of > 20 (mean 44 and 29, respectively).
  • It is possible that serum IL-8 can be used as a prognostic test in patients with ND or at risk for recurrence.
  • IL-8 may also be a potential therapeutic target to control tumor growth and metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016407.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Bochis OV, Fekete Z, Vlad C, Fetica B, Leucuta DC, Busuioc CI, Irimie A: The importance of a multidisciplinary team in rectal cancer management. Clujul Med; 2017;90(3):279-285
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Concerning the time between surgery and CRT, we did not observe a statistically significantly difference in OS if the radiotherapy started after the first 6 weeks (p=0.701).
  • CONCLUSIONS: In rectal cancer, the importance of the first therapeutic act is crucial.
  • In case of adjuvant treatment, it is recommended to start this treatment as soon as the local infrastructure allows it.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2009 Apr;249(4):559-63 [19300237.001]
  • [Cites] Int J Colorectal Dis. 2010 Sep;25(9):1103-10 [20544208.001]
  • [Cites] Tumori. 2009 Nov-Dec;95(6):675-82 [20210228.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5124-30 [19770376.001]
  • [Cites] Asian Pac J Cancer Prev. 2014;15(13):5337-41 [25040998.001]
  • [Cites] Anticancer Res. 2013 Oct;33(10):4557-66 [24123031.001]
  • [Cites] Can J Surg. 2015 Aug;58(4):237-44 [26022151.001]
  • [Cites] Oncol Lett. 2014 Jan;7(1):10-16 [24348812.001]
  • [Cites] Eur J Surg Oncol. 2015 May;41(5):647-52 [25800934.001]
  • [Cites] Strahlenther Onkol. 2000 Mar;176(3):112-7 [10742831.001]
  • [Cites] J Cancer Res Clin Oncol. 2014 Oct;140(10):1651-60 [24880919.001]
  • [Cites] Med Princ Pract. 2014;23(5):465-70 [25012611.001]
  • [Cites] Ann Surg Oncol. 2015 Mar;22(3):916-23 [25190129.001]
  • [Cites] Tech Coloproctol. 2014 Sep;18(9):805-11 [24643761.001]
  • [Cites] Cancer Res Treat. 2012 Sep;44(3):187-94 [23091445.001]
  • [Cites] Cancer Treat Rev. 2010 Nov;36(7):539-49 [20334979.001]
  • [Cites] Medicine (Baltimore). 2015 Aug;94(31):e1291 [26252304.001]
  • [Cites] J Gastrointest Cancer. 2008;39(1-4):86-99 [19294536.001]
  • [Cites] CA Cancer J Clin. 2013 Jan;63(1):11-30 [23335087.001]
  • [Cites] Rep Pract Oncol Radiother. 2013 Oct 03;18(6):353-62 [24416579.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Radiat Oncol. 2014 Jul 22;9:159 [25052511.001]
  • [Cites] Int J Colorectal Dis. 2014 Oct;29(10):1237-43 [25024041.001]
  • [Cites] PLoS One. 2015 Apr 22;10(4):e0123657 [25902069.001]
  • [Cites] Recent Results Cancer Res. 2014;203:41-6 [25102998.001]
  • (PMID = 28781524.001).
  • [ISSN] 1222-2119
  • [Journal-full-title] Clujul medical (1957)
  • [ISO-abbreviation] Clujul Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Keywords] NOTNLM ; adjuvant therapy / chemoradiotherapy / prognosis / rectal neoplasms
  •  go-up   go-down


53. Palamà IE, Arcadio V, D'Amone S, Biasiucci M, Gigli G, Cortese B: Therapeutic PCL scaffold for reparation of resected osteosarcoma defect. Sci Rep; 2017 Oct 04;7(1):12672
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcomas are highly malignant tumors, which develop rapid growth and local infiltration, inducing metastases that spread primarily in the lung.
  • Medicine regenerative grafts that act as both tumor therapy with constant local drug delivery and tissue regeneration may provide a new prospect to address this need.
  • In this study microporous poly-ε-caprolactone (PCL) scaffolds have been developed for sustained local release of anti-inflammatory drug dexamethasone (DXM), used as drug model, in cancer medicine regenerative field.
  • These microporous scaffolds demonstrate the ability to deliver DXM as a localized tumor therapy and to promote proliferation and differentiation of osteoblast-like cells in vitro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomaterials. 2005 Sep;26(27):5500-8 [15860206.001]
  • [Cites] Nature. 2009 Nov 26;462(7272):433-41 [19940913.001]
  • [Cites] Clin Orthop Relat Res. 2005 Aug;(437):105-10 [16056034.001]
  • [Cites] J Cell Physiol. 2007 Jun;211(3):661-72 [17348033.001]
  • [Cites] Acta Biomater. 2012 Jan;8(1):218-24 [21878398.001]
  • [Cites] Biomaterials. 2008 Sep;29(27):3662-70 [18547638.001]
  • [Cites] Cancer. 1972 Dec;30(6):1627-31 [4539306.001]
  • [Cites] Pharm Res. 2009 Jul;26(7):1561-80 [19415467.001]
  • [Cites] Integr Biol (Camb). 2012 Feb;4(2):228-36 [22146870.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):1883-9 [16880258.001]
  • [Cites] Biomaterials. 1996 Jul;17 (14 ):1417-22 [8830969.001]
  • [Cites] Int J Nanomedicine. 2012;7:4285-97 [22904634.001]
  • [Cites] J Biomed Mater Res. 1998 Mar 15;39(4):536-8 [9492212.001]
  • [Cites] J Clin Oncol. 2015 Sep 20;33(27):3029-35 [26304877.001]
  • [Cites] Tissue Eng. 2001 Dec;7(6):679-89 [11749726.001]
  • [Cites] J Biomed Mater Res A. 2006 Dec 15;79(4):954-62 [16941588.001]
  • [Cites] Leukemia. 2014 Jul;28(7):1467-71 [24441288.001]
  • [Cites] Acta Biomater. 2015 May;18:21-9 [25686557.001]
  • [Cites] Integr Biol (Camb). 2012 Oct;4(10):1299-309 [22899167.001]
  • [Cites] Adv Drug Deliv Rev. 2007 May 30;59(4-5):234-48 [17478007.001]
  • [Cites] Nanoscale. 2012 Aug 7;4(15):4426-9 [22688679.001]
  • [Cites] Plast Reconstr Surg. 2006 Dec;118(7):1664-5; author reply 1665 [17102751.001]
  • [Cites] Handchir Mikrochir Plast Chir. 2010 Dec;42(6):369-73 [20221990.001]
  • [Cites] Oper Orthop Traumatol. 2012 Jul;24(3):247-62 [22743634.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2A):995-1002 [9137440.001]
  • [Cites] Biomaterials. 2007 Aug;28(22):3273-83 [17466368.001]
  • [Cites] J Cell Sci Suppl. 1987;8:251-72 [3141431.001]
  • [Cites] Chirurg. 2003 Feb;74(2):145-8 [12599033.001]
  • [Cites] Acta Biomater. 2010 Jul;6(7):2467-76 [20144914.001]
  • [Cites] ACS Appl Mater Interfaces. 2017 Jul 12;9(27):22950-22958 [28636315.001]
  • [Cites] Biomaterials. 2006 Jun;27(18):3413-31 [16504284.001]
  • [Cites] J R Soc Interface. 2010 Feb 6;7(43):209-27 [19864265.001]
  • [Cites] Nanomedicine (Lond). 2010 Apr;5(3):419-31 [20394535.001]
  • [Cites] Biomaterials. 2000 Dec;21(24):2615-21 [11071611.001]
  • [Cites] Cell. 2006 Aug 25;126(4):677-89 [16923388.001]
  • [Cites] J Biomater Sci Polym Ed. 2014;25(2):150-67 [24138179.001]
  • [Cites] J Biomater Sci Polym Ed. 2007;18(3):241-68 [17471764.001]
  • [Cites] Ann Biomed Eng. 2010 Jan;38(1):2-20 [19816774.001]
  • [Cites] Sarcoma. 2011;2011:545104 [21559264.001]
  • [Cites] J Orthop Res. 1993 Mar;11(2):250-5 [8483037.001]
  • (PMID = 28978922.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Read P, Lothian R, Chronister K, Gilliver R, Kearley J, Dore GJ, van Beek I: Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy; 2017 Sep;47:209-215

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
  • From March 2016, the Australian Government has provided access to direct-acting antivirals (DAA) for adults with chronic HCV, without liver disease stage or drug and alcohol use restrictions.
  • All had a lifetime history of injecting drug use, with 75% having injected within the last six months, and 44% injecting at least weekly; 25% were also enrolled in opioid substitution therapy.
  • It also demonstrates feasibility to upscale DAA therapy in high-risk PWID populations, with potential individual and population-level public health benefits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28587943.001).
  • [ISSN] 1873-4758
  • [Journal-full-title] The International journal on drug policy
  • [ISO-abbreviation] Int. J. Drug Policy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Antivirals / Harm reduction / Hepatitis C / People who inject drugs / Targeted primary health care / Treatment
  •  go-up   go-down


55. Haussen DC, Doppelheuer S, Schindler K, Grossberg JA, Bouslama M, Schultz M, Perez H, Hall A, Frankel M, Nogueira RG: Utilization of a Smartphone Platform for Electronic Informed Consent in Acute Stroke Trials. Stroke; 2017 Nov;48(11):3156-3160
MedlinePlus Health Information. consumer health - Stroke.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The e-Consent tool consists of a secure/Health Insurance Portability and Accountability Act compliant smartphone platform based on REDCap (Research Electronic Data Capture; Vanderbilt University, TN) that uses a survey project located on a static webpage.
  • The e-Consent form is filled and a freehand electronic signature added in the smartphone browser; a record ID and an e-Consent Process Attestation form are automatically generated.
  • The e-Consent application was piloted in a randomized trial comparing endovascular versus medical therapy in late presenting patients (DAWN [Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo]).
  • Trial enrollment began in January 2015; e-Consent was approved by the local institutional review board in December 2016, and the study was stopped in February 2017.
  • Enrolled e-Consented patients (n=4) had similar age (73±14 versus 69±12 years; <i>P</i>=0.65) and National Institutes of Health Stroke Scale (16±5 versus 16±5; <i>P</i>=0.88) as compared with conventionally consented (n=25).
  • Time from door-to-randomization was decreased with e-Consenting (28±9 versus 57±24 minutes; <i>P</i>=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Heart Association, Inc.
  • (PMID = 28986425.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Keywords] NOTNLM ; consent forms / electronic mail / smartphone / stroke / thrombectomy
  •  go-up   go-down


56. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C, Rete Sicilia Selezione Terapia - HCV (RESIST-HCV): Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther; 2017 Oct;46(7):688-695

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
  • BACKGROUND: Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal.
  • [MeSH-minor] Aged. Catheter Ablation. Female. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / drug therapy. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 28791711.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Investigator] Craxì A; Di Marco V; Cammà C; Calvaruso V; Petta S; Colletti P; Mazzola G; Licata A; Giannitrapani L; Corrao S; Prestileo T; Di Lorenzo F; Fecarotta R; Sanfilippo P; Madonia S; Tinè F; Malizia G; Latteri F; Maida M; Cartabellotta F; Vassallo R; Cacciola I; Caccamo G; Maimone S; Saitta C; Squadrito G; Raimondo G; Mondello L; Smedile A; Bertino G; Ardiri AL; Montineri A; Larocca LN; Cacopardo B; Benanti F; Russello M; Benigno R; Cannavò MR; Bellia A; Iacobello C; Davì A; Di Rosolini MA; Digiacomo A; Fuduli G; Scifo G; Distefano M; Portelli V; Savalli F; Scalici I; Gioia G; Magro A; Alaimo G; Salvo A; Averna A; Lomonaco F; Quattrocchi U; Guarneri L; Maffeo F
  •  go-up   go-down


57. Li M, Wu H, Wang Y, Yin T, Gregersen H, Zhang X, Liao X, Wang G: Immobilization of heparin/poly-l-lysine microspheres on medical grade high nitrogen nickel-free austenitic stainless steel surface to improve the biocompatibility and suppress thrombosis. Mater Sci Eng C Mater Biol Appl; 2017 Apr 01;73:198-205
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thrombosis formation, restenosis, and delayed endothelium regeneration continue to be a challenge for coronary artery stent therapy.
  • Furthermore, for plasma coagulation tests, the activated partial thromboplastin time and thrombin time were prolonged and depended on the heparinfunction.
  • [MeSH-major] Biocompatible Materials / pharmacology. Heparin / pharmacology. Microspheres. Nickel / pharmacology. Nitrogen / pharmacology. Polylysine / pharmacology. Stainless Steel / pharmacology. Thrombosis / prevention & control
  • [MeSH-minor] Animals. Antioxidants / metabolism. Blood Platelets / drug effects. Blood Platelets / ultrastructure. Cell Count. Cell Death / drug effects. Cell Proliferation / drug effects. Cell Shape / drug effects. Dental Alloys. Dopamine / analysis. Fibrinogen / metabolism. Hemolysis / drug effects. Human Umbilical Vein Endothelial Cells / drug effects. Humans. Nitric Oxide / metabolism. Partial Thromboplastin Time. Particle Size. Platelet Adhesiveness / drug effects. Prothrombin Time. Rabbits. Static Electricity. Surface Properties

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier B.V. All rights reserved.
  • (PMID = 28183598.001).
  • [ISSN] 1873-0191
  • [Journal-full-title] Materials science & engineering. C, Materials for biological applications
  • [ISO-abbreviation] Mater Sci Eng C Mater Biol Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biocompatible Materials; 0 / Dental Alloys; 12244-31-4 / Austenite; 12597-68-1 / Stainless Steel; 25104-18-1 / Polylysine; 31C4KY9ESH / Nitric Oxide; 7OV03QG267 / Nickel; 9001-32-5 / Fibrinogen; 9005-49-6 / Heparin; N762921K75 / Nitrogen; VTD58H1Z2X / Dopamine
  • [Keywords] NOTNLM ; Blood compatibility / Coronary stent / Heparin / High nitrogen nickel-free austenitic stainless steel / Microsphere
  •  go-up   go-down


58. Yang X, Zhang H, Kong F, Wang G, Gu Q, Zhao Z, Li T, Ren M, Li Z, Guo Y: Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer. J Thorac Dis; 2017 Jul;9(7):1891-1902

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.
  • The patients were randomly divided into study group or control group according to random number table.
  • The primary outcome was the blood test indices in both groups.
  • The patients in the study group did not receive any other anticoagulation therapy during the study period and the control group only underwent surgery.
  • The study protocol was approved by the local ethics committee of principal investigator hospital.
  • Blood samples were taken at admission (before therapy), 24 h, 72 h, 10 d (before discharge) and 24 d (first visit after discharge) after surgery.
  • Routine blood tests [red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin (HGB), and platelet (PLT) count] and coagulation function test [prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), and plasma D-dimer] were performed.
  • The changes in outcome measures over time were analyzed by repeated measures analysis of variance to compare the differences between groups and between different time points and assess the impact of tumor stage and mode of surgery on them.
  • All tests were two-tailed, and P values <0.05 were considered statistically significant.
  • In stage III-IV group, there was no significant difference in various indices between the study group and control group.
  • In addition, no adverse drug reaction was observed in both the study group and control group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):729-34 [17762339.001]
  • [Cites] Med Pediatr Oncol. 2001 Apr;36(4):429-33 [11260565.001]
  • [Cites] Thromb Res. 2012 Apr;129 Suppl 1:S80-4 [22682140.001]
  • [Cites] Arch Intern Med. 2002 Apr 8;162(7):747-56 [11926847.001]
  • [Cites] Hepatology. 2016 Sep;64(3):785-96 [26940227.001]
  • [Cites] Clin Appl Thromb Hemost. 2003 Apr;9(2):151-4 [12812385.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):355-62 [17097558.001]
  • [Cites] N Engl J Med. 2009 Dec 10;361(24):2342-52 [19966341.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Aug 29;(8):CD008500 [25171736.001]
  • [Cites] Thromb Res. 2010 Mar;125(3):e71-5 [19818470.001]
  • [Cites] JAMA. 2008 Nov 19;300(19):2277-85 [19017914.001]
  • [Cites] Yao Xue Xue Bao. 2014 Sep;49(9):1304-9 [25518330.001]
  • [Cites] JAMA Oncol. 2016 Jun 1;2(6):762-9 [26940135.001]
  • [Cites] Indian J Pharmacol. 2013 Jul-Aug;45(4):359-64 [24014911.001]
  • [Cites] Multidiscip Respir Med. 2015 Sep 15;10(1):28 [26380084.001]
  • [Cites] Oncol Lett. 2014 Jan;7(1):87-94 [24348827.001]
  • [Cites] J Thromb Thrombolysis. 2011 May;31(4):407-16 [21359646.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2272-3 [12229885.001]
  • [Cites] Cochrane Database Syst Rev. 2011 Apr 13;(4):CD006652 [21491396.001]
  • [Cites] Thromb J. 2015 Jan 23;13(1):4 [25635172.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):166-71 [10656446.001]
  • [Cites] N Engl J Med. 2012 Feb 16;366(7):610-8 [22335738.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9 [17686822.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2192-8 [12775746.001]
  • [Cites] Int J Gynecol Cancer. 2015 Jan;25(1):24-32 [25347092.001]
  • [Cites] N Engl J Med. 2010 Dec 23;363(26):2499-510 [21128814.001]
  • [Cites] Cochrane Database Syst Rev. 2014 Jul 01;(7):CD006466 [24980743.001]
  • [Cites] Pathophysiol Haemost Thromb. 2003 Jul-2004 Aug;33(4):197-201 [15583449.001]
  • [Cites] Blood. 2012 Jan 26;119(4):933-9; quiz 1093 [21835953.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5490-505 [17968019.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Nat Rev Cancer. 2011 Feb;11(2):123-34 [21258396.001]
  • [Cites] Exp Hematol Oncol. 2015 Aug 06;4:22 [26251762.001]
  • [Cites] J Clin Oncol. 2009 Oct 10;27(29):4865-73 [19704059.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):809-15 [10737280.001]
  • [Cites] Semin Thromb Hemost. 2003 Jun;29(3):291-300 [12888933.001]
  • [Cites] Br J Haematol. 2013 Aug;162(4):433-41 [23691951.001]
  • [Cites] Thromb Res. 2010 Apr;125 Suppl 2:S108-16 [20433988.001]
  • [Cites] Thromb Res. 2010 Apr;125 Suppl 2:S120-7 [20433991.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):425-30 [12142172.001]
  • [Cites] Blood Coagul Fibrinolysis. 2004 Jan;15(1):9-13 [15166937.001]
  • (PMID = 28839987.001).
  • [ISSN] 2072-1439
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; Huisheng oral solution (HSOS) / coagulation function / primary lung cancer
  •  go-up   go-down


59. Tshingani K, Donnen P, Mukumbi H, Duez P, Dramaix-Wilmet M: Impact of Moringa oleifera lam. Leaf powder supplementation versus nutritional counseling on the body mass index and immune response of HIV patients on antiretroviral therapy: a single-blind randomized control trial. BMC Complement Altern Med; 2017 Aug 22;17(1):420
HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of Moringa oleifera lam. Leaf powder supplementation versus nutritional counseling on the body mass index and immune response of HIV patients on antiretroviral therapy: a single-blind randomized control trial.
  • BACKGROUND: To achieve effective antiretroviral therapy (ART) outcomes, adherence to an antiretroviral regimen and a good immunometabolic response are essential.
  • Food insecurity can act as a real barrier to adherence to both of these factors.
  • METHODS: A single-blind randomized control trial was carried out from May to September 2013 at an outpatient clinic for HIV-infected patients in Kinshasa (DRC).
  • After random allocation, 30 patients in the Moringa intervention group (MG) received the M.O. Lam. leaf powder daily over 6 months, and 30 in the control group (CG) received nutritional counseling over the same period.
  • CONCLUSIONS: Under medical supervision, M.O. Lam. leaf powder supplementation may represent a readily available and effective local solution to improve the nutritional intake and nutritional status of PLHIV undergoing ART.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Dietary Supplements. HIV Infections / therapy. Moringa oleifera. Plant Extracts / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ethnopharmacol. 2008 Mar 28;116(3):439-46 [18249514.001]
  • [Cites] Gerontologist. 2006 Dec;46(6):781-90 [17169933.001]
  • [Cites] J Nutr. 2003 Apr;133(4):1143-6 [12672933.001]
  • [Cites] Food Chem. 2014 Mar 15;147:51-4 [24206684.001]
  • [Cites] Phytother Res. 2007 Jan;21(1):17-25 [17089328.001]
  • [Cites] J Am Soc Nephrol. 1993 May;3(11):1723-37 [8329667.001]
  • [Cites] Lancet. 2013 Jun 15;381(9883):2109-17 [23541541.001]
  • [Cites] Adv Chronic Kidney Dis. 2010 Jan;17(1):59-71 [20005490.001]
  • [Cites] Am J Clin Nutr. 2011 Dec;94(6):1677S-1682S [22089443.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004536 [23450554.001]
  • [Cites] Eur J Clin Nutr. 2004 Jan;58(1):162-72 [14679382.001]
  • [Cites] Popul Rep J. 1998 Dec;(48):1-31 [10096107.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):803-5 [11017833.001]
  • [Cites] Clin Infect Dis. 2006 Mar 15;42(6):836-42 [16477562.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):491S-499S [10479221.001]
  • [Cites] PLoS One. 2014 Jan 15;9(1):e85327 [24454841.001]
  • [Cites] BMC Nutr. 2015;1:null [26702362.001]
  • [Cites] Phytother Res. 2015 Jun;29(6):796-804 [25808883.001]
  • [Cites] Diabetes Care. 1993 Aug;16(8):1071-5 [8375235.001]
  • [Cites] J Lipid Res. 2010 Mar;51(3):635-40 [19759389.001]
  • [Cites] Clin Infect Dis. 2008 Dec 1;47(11):1449-57 [18947327.001]
  • [Cites] Ecol Food Nutr. 2009 May-Jun;48(3):212-25 [20161339.001]
  • [Cites] HIV Clin Trials. 2012 Jul-Aug;13(4):189-211 [22849961.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):25-33 [20018390.001]
  • [Cites] Ig Sanita Pubbl. 2011 Jan-Feb;67(1):41-52 [21468153.001]
  • [Cites] AIDS Patient Care STDS. 2005 Apr;19(4):216-23 [15857193.001]
  • [Cites] Am J Clin Nutr. 2006 Sep;84(3):475-82 [16960159.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):507-13 [19730111.001]
  • (PMID = 28830411.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Plant Extracts
  • [Keywords] NOTNLM ; Antiretroviral therapy / Body mass index / CD4 count / DR Congo / HIV / Moringa oleifera / Supplementation
  •  go-up   go-down


60. Akahoshi K, Ochiai T, Takaoka A, Kitamura T, Ban D, Kudo A, Tanaka S, Tanabe M: Emergency Cholecystectomy for Patients on Antiplatelet Therapy. Am Surg; 2017 May 01;83(5):486-490
MedlinePlus Health Information. consumer health - Blood Thinners.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency Cholecystectomy for Patients on Antiplatelet Therapy.
  • The use of antiplatelet therapy (APT) and/or anticoagulant therapy (ACT) continues to increase due to the aging population.
  • Because the management of patients with acute cholecystitis receiving APT/ACT is still unclear, surgeons are sometimes faced with the difficult decision to delay surgery.
  • Treatment outcomes among 13 patients who underwent cholecystectomy without discontinuing APT (the cAPT group), 11 patients who discontinued APT and ACT (the D group), and 89 patients who did not receive preoperative APT and/or ACT (the No APT group) were compared.
  • There were no significant differences in intraoperative blood loss, conversion to open surgery, and bleeding-related complications.
  • However, the incidence of intraoperative blood transfusion was higher in the cAPT group (P = 0.04).
  • They presented with severe local inflammation; thus, it was difficult to stop bleeding from the gallbladder bed.
  • Hemostatic tools for liver surgery were used to control bleeding.
  • However, in case of severe local inflammation, there is a greater risk for massive hemorrhage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28541859.001).
  • [ISSN] 1555-9823
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


61. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H: Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci; 2017 10;62(10):2932-2942
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
  • BACKGROUND: Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular carcinoma (HCC).
  • PATIENTS AND METHODS: A total of 177 patients received DAA after curative manners of HCC: 89 patients underwent DAA therapy after initial HCC treatment, and the other 88 patients after repeated therapy of 2-10 times.
  • Among a cohort of HCC patients with surgery and radiofrequency ablation, 89 patients were chosen adjusting age, gender, and Barcelona Clinic Liver Cancer (BCLC) staging with 89 patients with initial HCC therapy.
  • RESULTS: HCC recurrence rates at the end of first and second year were 18.1 and 22.1% in patients with once of HCC therapy, 28.2 and 41.6% in those with 2-3 times of therapy, and 60.2 and 74.5% in those with 4 or more times of therapy, respectively (P < 0.0001).
  • Recurrence rates were compared between 89 patients with DAA therapy after initial HCC therapy and 89 age-, gender-, and BCLC staging-matched patients without antiviral therapy after initial HCC therapy.
  • HCC recurrence rates at first and second year were 18.1 and 25.0% in patients with DAA therapy and 21.8 and 46.5% in those without DAA therapy, respectively (P = 0.003).
  • Multivariate analysis showed DAA therapy significantly decreased recurrence rate with a hazard ratio of 0.353 (confidence interval: 0.191-0.651) after adjustment with covariates of tumor multiplicity, alpha-fetoprotein value, and prothrombin time.
  • CONCLUSIONS: DAA therapy significantly decreased recurrence rate when it was performed after initial HCC therapy.
  • [MeSH-major] Antiviral Agents / administration & dosage. Carcinoma, Hepatocellular / therapy. Catheter Ablation. Chemoembolization, Therapeutic. Hepatectomy. Hepatitis C / drug therapy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Liver Dis. 2010 Feb;30(1):61-74 [20175034.001]
  • [Cites] Semin Liver Dis. 2010 Feb;30(1):52-60 [20175033.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):727-33 [27349488.001]
  • [Cites] Cancer Lett. 2010 Apr 28;290(2):204-10 [19822391.001]
  • [Cites] Hepatology. 1999 Apr;29(4):1124-30 [10094956.001]
  • [Cites] J Hepatol. 2016 Nov;65(5):1070-1071 [27476768.001]
  • [Cites] Oncology. 2016;90(3):167-75 [26901157.001]
  • [Cites] Hepatology. 1998 May;27(5):1394-402 [9581697.001]
  • [Cites] J Med Virol. 2017 Mar;89(3):476-483 [27531586.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):734-40 [27288051.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):862-4 [27255582.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):719-26 [27084592.001]
  • [Cites] J Hepatol. 2016 Oct;65(4):856-8 [27318327.001]
  • [Cites] Hepatol Res. 2010 Dec;40(12):1168-75 [20849431.001]
  • [Cites] Hepatology. 2016 Jul;64(1):130-7 [26946190.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jul;59(7):1059-71 [20217081.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Hepatology. 2016 Nov;64(5):1818-1819 [27136189.001]
  • [Cites] J Hepatol. 2016 Dec;65(6):1272-1273 [27524465.001]
  • [Cites] Ann Intern Med. 1999 Aug 3;131(3):174-81 [10428733.001]
  • [Cites] Int J Oncol. 2007 Jan;30(1):201-8 [17143530.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1543-54 [17133492.001]
  • (PMID = 28884320.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Keywords] NOTNLM ; Direct-acting antivirals (DAA) (major topic) / Hepatocellular carcinoma (HCC) (major topic) / Recurrence (major topic) / Survival (major topic) / Sustained virological response (SVR) (major topic)
  •  go-up   go-down


62. Herskind C, Wenz F, Giordano FA: Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol; 2017;7:147

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment options include surgery, whole-brain radiotherapy, or stereotactic radiosurgery (SRS) while chemotherapy has only limited activity.
  • Accumulating evidence has shown that high single doses of ionizing radiation can be highly efficient in eliciting a broad spectrum of local, regional, and systemic tumor-directed immune reactions.
  • However, it is not known if a low number of residual tumor cells in the tumor bed after resection is sufficient to act as an immunizing event opening the gate for ICB therapies in the brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother Cancer. 2016 Sep 20;4:51 [27660705.001]
  • [Cites] Cancer Res. 2012 Jul 1;72(13):3163-74 [22570253.001]
  • [Cites] Science. 2006 Feb 24;311(5764):1141-6 [16497931.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):130-6 [24331659.001]
  • [Cites] Neurosurgery. 2008 Apr;62(4):817-23; discussion 823-4 [18414136.001]
  • [Cites] Int J Cancer. 2016 Aug 15;139(4):736-41 [26939583.001]
  • [Cites] Gut. 1998 Oct;43(4):575-7 [9824589.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):500-6 [16044217.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1823-35 [14966265.001]
  • [Cites] EMBO Mol Med. 2017 Feb;9(2):167-180 [27932443.001]
  • [Cites] Cancer Lett. 2015 Nov 28;368(2):275-89 [25688671.001]
  • [Cites] Acta Oncol. 2006;45(2):224-5 [16546875.001]
  • [Cites] Genes Cancer. 2011 Apr;2(4):503-16 [21779518.001]
  • [Cites] Int J Radiat Biol. 1999 Nov;75(11):1421-7 [10597915.001]
  • [Cites] Acta Neurochir (Wien). 1995;136(1-2):82-6; discussion 86-7 [8748832.001]
  • [Cites] Trends Immunol. 2013 Jan;34(1):13-21 [22959412.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] Front Immunol. 2012 Mar 21;3:51 [22566933.001]
  • [Cites] Strahlenther Onkol. 2004 Apr;180(4):187-93 [15057428.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34 [15701862.001]
  • [Cites] N Engl J Med. 2012 Jun 28;366(26):2443-54 [22658127.001]
  • [Cites] Cancer Med. 2013 Dec;2(6):899-906 [24403263.001]
  • [Cites] J Neurooncol. 1995;23(1):81-6 [7623073.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1259-71 [16636135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Jun 1;92 (2):368-75 [25754629.001]
  • [Cites] Cancer. 2016 Oct;122(19):3051-8 [27285122.001]
  • [Cites] JAMA. 2016 Jul 26;316(4):401-9 [27458945.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3132-9 [18292536.001]
  • [Cites] N Engl J Med. 2016 Jun 30;374(26):2542-52 [27093365.001]
  • [Cites] J Neurosurg. 2015 Apr;122(4):825-32 [25614945.001]
  • [Cites] Nat Immunol. 2011 Jun;12(6):492-9 [21739672.001]
  • [Cites] Melanoma Res. 2013 Jun;23 (3):191-5 [23462208.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7516-23 [15944250.001]
  • [Cites] Immunotargets Ther. 2012 Oct 1;2012(1):7-12 [24791250.001]
  • [Cites] J Immunol. 2011 Jul 15;187(2):919-31 [21670312.001]
  • [Cites] Radiat Res. 1993 Oct;136(1):37-41 [8210336.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):80-90 [7709789.001]
  • [Cites] J Radiat Res. 1995 Jun;36(2):112-24 [7473344.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):254-62 [24411596.001]
  • [Cites] Front Oncol. 2012 Oct 26;2:153 [23112958.001]
  • [Cites] Immunity. 2014 Jul 17;41(1):49-61 [25035953.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1575-81 [19028280.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Phys Med. 2015 May;31(3):224-32 [25687416.001]
  • [Cites] Strahlenther Onkol. 2010 Aug;186(8):444-51 [20803285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):655-66 [16199306.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8448-55 [17142742.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):619-26 [7558951.001]
  • [Cites] Guo Ji Fang She Yi Xue He Yi Xue Za Zhi. 2016 Mar;40(2):91-99 [27331198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):324-5 [18474308.001]
  • [Cites] Cancer Res. 2011 Apr 1;71(7):2488-96 [21300764.001]
  • [Cites] Nature. 2015 Jul 16;523(7560):337-41 [26030524.001]
  • [Cites] Prog Tumor Res. 2015;42:11-21 [26376741.001]
  • [Cites] Am Surg. 2014 Aug;80(8):805-10 [25105403.001]
  • [Cites] Neuro Oncol. 2015 Nov;17 Suppl 7:vii3-vii8 [26516224.001]
  • [Cites] J Inflamm (Lond). 2015 Feb 18;12:14 [25705130.001]
  • [Cites] Cancer Treat Rev. 2015 Jun;41(6):503-10 [25872878.001]
  • [Cites] Onkologie. 2003 Dec;26(6):596-8 [14709937.001]
  • [Cites] Cancer Immunol Immunother. 2016 Oct;65(10 ):1269-75 [27460064.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] Nat Rev Immunol. 2013 Jul;13(7):475-86 [23797063.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1188-95 [24661671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1127-33 [22981707.001]
  • [Cites] Trends Immunol. 2015 Oct;36(10 ):569-77 [26431936.001]
  • [Cites] PLoS One. 2014 Mar 31;9(3):e92572 [24686897.001]
  • [Cites] Lancet Oncol. 2012 May;13(5):459-65 [22456429.001]
  • [Cites] Nat Rev Cancer. 2012 Mar 22;12(4):252-64 [22437870.001]
  • [Cites] J Radiat Res. 1995 Jun;36(2):125-33 [7473345.001]
  • [Cites] Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):245-58 [27365375.001]
  • [Cites] PLoS One. 2014 Jul 11;9(7):e101764 [25013914.001]
  • [Cites] Radiat Res. 1993 Mar;133(3):321-6 [8383862.001]
  • [Cites] Annu Rev Immunol. 2016 May 20;34:539-73 [26927206.001]
  • [Cites] Int J Radiat Biol. 2000 Nov;76(11):1443-53 [11098847.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):342-8 [16703290.001]
  • [Cites] J Neurooncol. 2015 Jan;121(1):159-65 [25273687.001]
  • [Cites] Oncotarget. 2016 Mar 29;7(13):17035-46 [26959743.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23 (18):4127-36 [15961760.001]
  • [Cites] Radiat Environ Biophys. 2007 Mar;46(1):21-9 [17072632.001]
  • [Cites] Nat Rev Immunol. 2012 Sep;12(9):623-35 [22903150.001]
  • [Cites] J Immunol. 1996 Dec 1;157(11):4762-70 [8943377.001]
  • [Cites] J Appl Clin Med Phys. 2014 Jan 06;15(1):4502 [24423847.001]
  • [Cites] Cancer Immunol Res. 2015 Jun;3(6):610-9 [25701325.001]
  • [Cites] Semin Oncol. 2015 Aug;42(4):523-38 [26320058.001]
  • [Cites] Technol Cancer Res Treat. 2010 Dec;9(6):597-602 [21070082.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7985-94 [15520206.001]
  • [Cites] Cancer Immunol Res. 2015 Apr;3(4):345-55 [25527358.001]
  • [Cites] Cancer Med. 2015 Jan;4(1):1-6 [25164960.001]
  • [Cites] Int J Radiat Biol. 1997 Jul;72(1):33-43 [9246192.001]
  • [Cites] N Engl J Med. 2016 Nov 10;375(19):1823-1833 [27718847.001]
  • [Cites] J Clin Invest. 2014 Feb;124(2):687-95 [24382348.001]
  • [Cites] Clin Cancer Res. 2016 Jan 1;22(1):20-5 [26362999.001]
  • [Cites] Radiother Oncol. 2016 Aug;120(2):185-94 [27495145.001]
  • [Cites] Annu Rev Immunol. 2013;31:51-72 [23157435.001]
  • [Cites] Neurol Med Chir (Tokyo). 1991 Nov;31(11):702-7 [1723157.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Dec;8(12):981-6 [18058568.001]
  • [Cites] J Clin Oncol. 2011 Jan 10;29(2):134-41 [21041710.001]
  • [Cites] Front Oncol. 2016 Jun 20;6:141 [27379203.001]
  • [Cites] Cancer Res. 2014 Oct 1;74(19):5458-68 [25274032.001]
  • [Cites] Am J Clin Oncol. 2015 May 16;:null [26017484.001]
  • [Cites] Neurosurgery. 2015 Apr;76(4):411-20 [25599198.001]
  • [Cites] Br J Radiol. 1973 Mar;46(543):220-2 [4706791.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6028-32 [10626784.001]
  • [Cites] Trends Cancer. 2016 Jun;2(6):286-294 [27774519.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5379-88 [19706802.001]
  • [Cites] Clin Cancer Res. 2017 Jan 1;23 (1):124-136 [27358487.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1306-10 [22208977.001]
  • [Cites] Mol Immunol. 2013 Aug;55(1):76-82 [23207101.001]
  • [Cites] N Engl J Med. 2016 Nov 10;375(19):1856-1867 [27718784.001]
  • [Cites] Ann Oncol. 2016 Dec;27(12 ):2288-2294 [27637745.001]
  • [Cites] Nature. 2015 Apr 16;520(7547):373-7 [25754329.001]
  • [Cites] Oncoimmunology. 2014 Apr 25;3:e28518 [25071979.001]
  • [Cites] Neurosurg Focus. 2009 Dec;27(6):E7 [19951060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):710-7 [25752382.001]
  • [Cites] ScientificWorldJournal. 2012;2012:609295 [22619631.001]
  • [Cites] Ann Surg Oncol. 2013 Sep;20(9):3106-11 [23681603.001]
  • [Cites] Pract Radiat Oncol. 2012 Jul-Sep;2(3):210-25 [25925626.001]
  • [Cites] Clin Transl Oncol. 2013 Sep;15(9):683-90 [23463592.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1990-3 [12702593.001]
  • [Cites] Radiat Res. 2005 Feb;163(2):208-15 [15658897.001]
  • [Cites] Zh Vopr Neirokhir Im N N Burdenko. 2007 Jul-Sep;(3):39-40 [18041212.001]
  • [Cites] Med Pediatr Oncol. 1981;9(5):473-6 [7029238.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2167-76 [19965656.001]
  • [Cites] Carcinogenesis. 2014 Aug;35(8):1680-90 [24942866.001]
  • [Cites] Blood. 2009 Jul 16;114(3):589-95 [19349616.001]
  • [Cites] N Engl J Med. 2016 Nov 10;375(19):1845-1855 [27717298.001]
  • [Cites] Sci Transl Med. 2010 Dec 22;2(63):63ra94 [21178137.001]
  • [Cites] Front Immunol. 2014 Oct 21;5:508 [25374568.001]
  • [Cites] PLoS One. 2014 Jan 22;9(1):e84991 [24465461.001]
  • [Cites] Angiogenesis. 2008;11(1):91-9 [18264787.001]
  • [Cites] Radiat Oncol. 2017 Jan 19;12 (1):24 [28107823.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9 [23462419.001]
  • [Cites] J Neurosurg. 2012 Aug;117(2):227-33 [22702482.001]
  • [Cites] BMC Cancer. 2002;2:1 [11818027.001]
  • [Cites] Oncoimmunology. 2014 Apr 17;3:e28499 [25050217.001]
  • [Cites] J Neurosurg Sci. 2016 Sep;60(3):350-6 [26824195.001]
  • [Cites] Nat Chem Biol. 2013 Dec;9(12):769-75 [24231618.001]
  • [Cites] Semin Radiat Oncol. 2015 Jan;25(1):18-27 [25481262.001]
  • [Cites] Lancet Oncol. 2013 Oct;14(11):e457-64 [24079873.001]
  • [Cites] Annu Rev Immunol. 2011;29:621-63 [21314428.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Jul;25(9):1348-51 [9703825.001]
  • [Cites] Semin Cancer Biol. 2013 Jun;23(3):139-40 [23454237.001]
  • [Cites] J Clin Invest. 2015 Sep;125(9):3384-91 [26325035.001]
  • (PMID = 28791250.001).
  • [ISSN] 2234-943X
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; brain metastases / immune therapy / intraoperative radiotherapy / radiotherapy / stereotactic radiosurgery
  •  go-up   go-down


63. Corrigan ML, Huang S, Weaver A, Keeler D, Rahe K, Balint J, Marti M, Goodman B, Nagy T, DeLano V, Bond B, for Home and Alternate Site Care Section, American Society for Parenteral and Enteral Nutrition: Resources for the Provision of Nutrition Support to Children in Educational Environments. Nutr Clin Pract; 2017 Dec;32(6):834-843

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As these children grow and enter educational settings, there is a need for awareness of the care that these children require for nutrition support therapy.
  • Care is individualized to the specific child and may include provision of nutrition support therapy while in the school setting, maintenance of a nutrition access device, and monitoring to safely prevent or act on signs of potential complications.
  • Suggested roles and responsibilities of those involved with nutrition support care are discussed; however, all interventions and routine care must be in accordance with physician's orders, school nurse privileges and competencies, and state and local regulations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28700266.001).
  • [ISSN] 1941-2452
  • [Journal-full-title] Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • [ISO-abbreviation] Nutr Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; enteral nutrition / home nutrition support / nutrition support / parenteral nutrition / pediatrics
  •  go-up   go-down


64. Kwiatt M, Spitz FR, LaCouture TA: Early experience with robotic radiosurgery for local control of liver metastasis. J Clin Oncol; 2012 Feb;30(4_suppl):295

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early experience with robotic radiosurgery for local control of liver metastasis.
  • : 295 Background: Liver toxicity limits radiation therapy for liver metastasis; however, robotic radiosurgery delivers effective doses with limited toxicities.
  • Preradiosurgery and follow-up abdominal computed tomography (CT) scans reviewed for treatment response.
  • Our primary endpoint was local recurrence, defined as increased enhancement or tumor progression within the treatment field on follow-up CT scan.
  • Prior to radiosurgery 27 of 33 patients (81.8%) had undergone surgical resection of primary tumor, 26 of 33 patients (78.8%) were treated with chemotherapy for metastatic disease, and 15 of 33 patients (45.5%) had non-liver radiation therapy.
  • Median time from primary diagnosis to radiosurgery treatment was 33.3 months (5.7 to 320 months).
  • Sixteen patients had disease progression outside the treatment field (15 liver, 6 systemic) with a median time to progression of 4.6 months (0.9 to 17.6).
  • Five lesions (13.5%) had in field progression with a median time to progression of 10 months (2.6 to 13.1).
  • CONCLUSIONS: Robotic radiosurgery offers a potential local therapy for patients with metastatic liver disease with limited toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27982843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Vialu C, Doyle M: Determining Need for School-Based Physical Therapy Under IDEA: Commonalities Across Practice Guidelines. Pediatr Phys Ther; 2017 Oct;29(4):350-355

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining Need for School-Based Physical Therapy Under IDEA: Commonalities Across Practice Guidelines.
  • BACKGROUND AND PURPOSE: The Individuals with Disabilities Education Act (IDEA) includes physical therapy (PT) as a related service that may be provided to help students with disabilities benefit from their education.
  • The authors examined 22 state and local education agency guidelines available online to find commonalities related to the determination of a student's need for PT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28953182.001).
  • [ISSN] 1538-005X
  • [Journal-full-title] Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association
  • [ISO-abbreviation] Pediatr Phys Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Bockel S, Antoni D, Deutsch É, Mornex F: [Immunotherapy and radiotherapy]. Cancer Radiother; 2017 May;21(3):244-255
MedlinePlus Health Information. consumer health - Cancer Immunotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By an immunologic cell death, tumor cells exposed to radiation release a large amount of neoantigenes and pro-inflammatory mediators, acting as an in situ vaccine, resulting in an tumor regression within the primary irradiated site, but also in the distant "out of field" secondary tumors.
  • Over the last years, many scientific data and preclinical studies have demonstrated that the combination of local irradiation with immune therapy has a synergistic action in inducing an antitumoral immunity, thus enhancing an abscopal effect.
  • In this article, we summarize the main mechanisms cancer harnesses to evade the control of the immune system and how ionising radiations can induce an antitumor immunity.
  • A focus reports then on recent preclinical and clinical research built on this background of combined radiation and immune therapy, which bear the great potential to further improve anticancer therapies.
  • [MeSH-major] Immunotherapy. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier SAS.
  • (PMID = 28522277.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Keywords] NOTNLM ; Abscopal / Immunotherapy / Immunothérapie / Radiotherapy / Radiothérapie
  •  go-up   go-down


67. Smyth D, Francheville JW, Rankin R, Beck J, Hoare C, Materniak S, German G, Barrett L, Bunimov-Wall N: Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island. Ann Hepatol; 2017 Sep-Oct;16(5):749-758

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model.
  • Primary analysis assessed the time from referral to assessment/treatment, as well as the number of referrals, assessments, and treatment initiations.
  • RESULTS: During the study period 242 referrals were received, 123 patients were seen for intake assessments, and 93 initiated direct-acting antiviral therapy based on medical need.
  • The median time from assessment to treatment initiation was 3 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Hepatol. 2017 Aug 8;16(5):696-698 [28809738.001]
  • (PMID = 28809740.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  • [Keywords] NOTNLM ; Direct-acting antivirals / Health plan implementation / Hepatitis C virus / Real-world / SVR
  •  go-up   go-down


68. Sarmento-Cabral A, L-López F, Gahete MD, Castaño JP, Luque RM: Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways. Mol Cancer Res; 2017 Jul;15(7):862-874
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the beneficial antitumoral effects of metformin on prostate cancer progression/aggressiveness and the relative contribution of high-fat diet (HFD; independently of obesity), we used HFD-fed immunosuppressed mice inoculated with PC3 cells (which exhibited partial resistance to diet-induced obesity) compared with low-fat diet (LFD)-fed control mice.
  • The results demonstrate that HFD is associated with enhanced prostate cancer growth irrespective of body weight gain and endocrine metabolic dysregulations and that metformin can reduce prostate cancer growth under LFD but more prominently under HFD, acting through the modulation of several tumoral-associated processes (e.g., cell cycle, apoptosis, and/or necrosis).
  • Moreover, the actions observed <i>in vivo</i> could be mediated by the modulation of the local expression of GH/IGF1 axis components.
  • <b>Implications:</b> The current study linking dietary influence on metformin-regulated signaling pathways and antitumoral response provides new and critical insight on environment-host interactions in cancer and therapy.
  • <i>Mol Cancer Res; 15(7); 862-74.
  • ©2017 AACR</i>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2017 American Association for Cancer Research.
  • (PMID = 28385910.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Mutschelknaus L, Azimzadeh O, Heider T, Winkler K, Vetter M, Kell R, Tapio S, Merl-Pham J, Huber SM, Edalat L, Radulović V, Anastasov N, Atkinson MJ, Moertl S: Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci Rep; 2017 Sep 29;7(1):12423
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation is a highly efficient therapy in squamous head and neck carcinoma (HNSCC) treatment.
  • However, local recurrence and metastasis are common complications.
  • We conclude that exosomes may act as driver of HNSCC progression during radiotherapy and are therefore attractive targets to improve radiation therapy strategies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Transl Med. 2016 Mar;5(1):7 [26943717.001]
  • [Cites] Laryngoscope. 2004 Dec;114(12):2243-8 [15564854.001]
  • [Cites] Acta Biochim Pol. 2015;62(2):265-72 [26098714.001]
  • [Cites] Cancer Discov. 2013 Jul;3(7):761-9 [23619167.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]
  • [Cites] J Mol Biol. 2016 Feb 22;428(4):688-692 [26434508.001]
  • [Cites] J Extracell Vesicles. 2012 Apr 16;1:null [24009886.001]
  • [Cites] Nat Med. 2012 Jun;18(6):883-91 [22635005.001]
  • [Cites] Genome Biol. 2010;11(5):R53 [20482850.001]
  • [Cites] Laryngoscope. 2011 Nov;121(11):2359-65 [22020886.001]
  • [Cites] Oral Oncol. 2013 Apr;49(4):287-92 [23182398.001]
  • [Cites] Cell Mol Life Sci. 2016 Aug;73(16):2999-3007 [27022944.001]
  • [Cites] Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52 [25352553.001]
  • [Cites] Oncotarget. 2016 Apr 26;7(17):24228-41 [27015118.001]
  • [Cites] Oncotarget. 2017 Mar 28;8(13):22203-22217 [28108737.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Am J Surg. 1978 Oct;136(4):494-500 [360853.001]
  • [Cites] Carcinogenesis. 2013 Jan;34(1):10-9 [22948179.001]
  • [Cites] J Gene Med. 2012 Aug;14(8):549-60 [22887595.001]
  • [Cites] BMC Cancer. 2011 Sep 06;11:388 [21896192.001]
  • [Cites] Cancers (Basel). 2014 Feb 13;6(1):396-415 [24531055.001]
  • [Cites] J Circ Biomark. 2015 Jul 17;4:7 [28936243.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1489-96 [17641014.001]
  • [Cites] Proteomes. 2013 Sep 1;1(2):87-108 [24860738.001]
  • [Cites] Sci Rep. 2016 Dec 08;6:38750 [27929118.001]
  • [Cites] IUBMB Life. 2013 Oct;65(10):807-18 [24030926.001]
  • [Cites] Cancer Res. 2016 May 15;76(10 ):3036-44 [26896280.001]
  • [Cites] Semin Cancer Biol. 2017 Jun;44:170-181 [28215970.001]
  • [Cites] Transl Oncol. 2013 Dec 01;6(6):638-48 [24466366.001]
  • [Cites] Int J Oncol. 2013 Sep;43(3):793-802 [23807724.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8511-9 [16951163.001]
  • [Cites] Semin Cancer Biol. 2014 Oct;28:3-13 [24769058.001]
  • [Cites] Mol Cell Proteomics. 2013 Feb;12 (2):343-55 [23161513.001]
  • [Cites] Crit Rev Oncol Hematol. 2014 Nov;92(2):133-42 [24908570.001]
  • [Cites] CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215 [12139232.001]
  • [Cites] ISRN Otolaryngol. 2012 Oct 18;2012:953089 [23762622.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):634-40 [14760086.001]
  • [Cites] Sci Rep. 2016 Sep 23;6:34134 [27658723.001]
  • [Cites] PLoS One. 2016 Mar 23;11(3):e0152213 [27006994.001]
  • [Cites] BMC Cancer. 2010 Jun 16;10:294 [20553606.001]
  • [Cites] Nat Cell Biol. 2008 Dec;10(12):1470-6 [19011622.001]
  • [Cites] Oncotarget. 2016 Mar 22;7(12):14259-78 [26893360.001]
  • [Cites] Clin Cancer Res. 2016 Aug 1;22(15):3884-93 [26936917.001]
  • [Cites] Biochem J. 2012 Jan 1;441(1):1-21 [22168436.001]
  • [Cites] Neuro Oncol. 2014 Oct;16(10):1313-23 [24811392.001]
  • [Cites] Biochem Biophys Res Commun. 2015 Oct 23;466(3):327-32 [26362179.001]
  • [Cites] Clin Cancer Res. 2011 Jul 15;17(14):4629-41 [21642380.001]
  • [Cites] Expert Opin Ther Targets. 2013 Feb;17(2):203-16 [23252422.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):288-96 [18308254.001]
  • [Cites] Int J Radiat Biol. 2017 Jun;93(6):569-580 [28264626.001]
  • [Cites] Oral Oncol. 2012 Dec;48(12):1208-19 [22748451.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 16;102(12 ):866-80 [20484105.001]
  • [Cites] J Biol Chem. 2016 Mar 4;291(10 ):5128-37 [26769968.001]
  • [Cites] Curr Protein Pept Sci. 2011 Feb;12(1):30-42 [21190521.001]
  • (PMID = 28963552.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Cho JJ, Stewart JM, Drashansky TT, Brusko MA, Zuniga AN, Lorentsen KJ, Keselowsky BG, Avram D: An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis. Biomaterials; 2017 Oct;143:79-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.
  • A novel antigen-specific therapy has been developed which, when administered semi-therapeutically, is highly efficacious in the treatment of the mouse model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE).
  • Disease blocking was associated with a reduction of infiltrating CD4<sup>+</sup> T cells, inflammatory cytokine-producing pathogenic CD4<sup>+</sup> T cells, and activated macrophages and microglia in the central nervous system.
  • Furthermore, CD4<sup>+</sup> T cells isolated from dMP-treated mice were anergic in response to disease-specific, antigen-loaded splenocytes.
  • Additionally, the frequency of CD86<sup>hi</sup>MHCII<sup>hi</sup> dendritic cells in draining lymph nodes of EAE mice treated with Ag-specific dMPs was reduced.
  • Our findings highlight the efficacy of microparticle-based drug delivery platform to mediate antigen-specific tolerance, and suggest that such a multi-factor combinatorial approach can act to block autoimmunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28772190.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Ag-specific / Drug delivery / EAE / Immunotherapy / Multiple sclerosis / PLGA-microparticles
  •  go-up   go-down


71. Li J, Yang F, Wei F, Ren X: The role of toll-like receptor 4 in tumor microenvironment. Oncotarget; 2017 Sep 12;8(39):66656-66667

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides, substances, released from both tissue cells attacked by exogenous etiologies, also act on local cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2015 Aug;19(4):232-8 [26071054.001]
  • [Cites] PLoS One. 2013 May 29;8(5):e65906 [23734265.001]
  • [Cites] PLoS One. 2011 Jan 26;6(1):e16333 [21298114.001]
  • [Cites] Mol Oncol. 2016 Nov;10 (9):1473-1484 [27590684.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1696-703 [9635852.001]
  • [Cites] Mol Carcinog. 2009 Aug;48(8):713-23 [19142898.001]
  • [Cites] J Control Release. 2013 Nov 28;172(1):190-200 [23933525.001]
  • [Cites] Toxicol In Vitro. 2017 Jun;41:75-82 [28242239.001]
  • [Cites] Int J Clin Exp Pathol. 2015 Jun 01;8(6):7034-9 [26261595.001]
  • [Cites] Am J Transplant. 2009 Sep;9(9):2034-47 [19681826.001]
  • [Cites] Int J Clin Exp Pathol. 2014 Oct 15;7(11):8087-95 [25550856.001]
  • [Cites] Front Immunol. 2017 Feb 23;8:194 [28280496.001]
  • [Cites] Clin Cancer Res. 2012 Jul 15;18(14):3762-71 [22645050.001]
  • [Cites] PLoS One. 2012;7(11):e50394 [23185615.001]
  • [Cites] Cell Mol Immunol. 2014 Mar;11(2):150-9 [24362470.001]
  • [Cites] Annu Rev Immunol. 2002;20:197-216 [11861602.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] J Exp Med. 2012 Jan 16;209(1):157-71 [22184635.001]
  • [Cites] Sci Transl Med. 2012 Feb 29;4(123):123ra25 [22378925.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2011 May;31(5):1024-32 [21372296.001]
  • [Cites] PLoS One. 2014 Aug 07;9(8):e104351 [25102137.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3339-46 [16116226.001]
  • [Cites] Leuk Lymphoma. 2013 Nov;54(11):2418-25 [23432688.001]
  • [Cites] Innate Immun. 2015 Apr;21(3):242-54 [24648487.001]
  • [Cites] Biochem Biophys Res Commun. 2014 Apr 18;446(4):836-42 [24631687.001]
  • [Cites] Cancer Biol Ther. 2012 Jul;13(9):727-36 [22617774.001]
  • [Cites] Oncotarget. 2016 Sep 13;7(37):59957-59964 [27494867.001]
  • [Cites] Int Immunopharmacol. 2015 Sep;28(1):450-8 [26202806.001]
  • [Cites] J Immunother. 2010 Jan;33(1):73-82 [19952954.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2622-35 [17049055.001]
  • [Cites] Oncotarget. 2016 Aug 9;7(32):51840-51853 [27322081.001]
  • [Cites] Innate Immun. 2014 May;20(4):423-30 [23941760.001]
  • [Cites] J Immunol. 2010 Jan 15;184(2):1022-30 [20018613.001]
  • [Cites] Int Immunol. 2000 Nov;12(11):1539-46 [11058573.001]
  • [Cites] PLoS One. 2015 Feb 27;10(2):e0116191 [25723174.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5784-9 [17908969.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5708-16 [17575137.001]
  • [Cites] J Transl Med. 2014 Nov 29;12:322 [25432242.001]
  • [Cites] Microbiol Immunol. 2014 Jan;58(1):61-7 [24236732.001]
  • [Cites] J Biol Chem. 2011 Feb 4;286(5):3418-28 [21127066.001]
  • [Cites] Oncol Rep. 2013 Sep;30(3):1249-56 [23836405.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7370-7 [14660645.001]
  • [Cites] Biochem Biophys Res Commun. 2014 May 30;448(2):212-7 [24780395.001]
  • [Cites] PLoS One. 2011;6(12):e29363 [22195048.001]
  • [Cites] Int J Cancer. 2014 Jun 1;134(11):2633-45 [24443321.001]
  • [Cites] Int J Oncol. 2000 Sep;17(3):445-51 [10938382.001]
  • [Cites] Nat Rev Immunol. 2009 Mar;9(3):162-74 [19197294.001]
  • [Cites] J Exp Clin Cancer Res. 2010 Jul 10;29:92 [20618976.001]
  • [Cites] Int Immunopharmacol. 2007 Jan;7(1):78-87 [17161820.001]
  • [Cites] Cancer Lett. 2015 Mar 28;358(2):136-43 [25511737.001]
  • [Cites] Nature. 1997 Jul 24;388(6640):394-7 [9237759.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5009-14 [15958541.001]
  • [Cites] Cell Biochem Biophys. 2015 Apr;71(3):1341-7 [25388837.001]
  • [Cites] Mol Cancer Ther. 2013 Aug;12(8):1676-87 [23720768.001]
  • [Cites] Stem Cells. 2008 Jan;26(1):279-89 [17962701.001]
  • [Cites] Cancer Res. 2014 Mar 1;74(5):1329-37 [24448240.001]
  • [Cites] Stem Cell Rev. 2015 Apr;11(2):280-7 [25592610.001]
  • [Cites] Clinics (Sao Paulo). 2013 Jun;68(6):858-64 [23778475.001]
  • [Cites] Immunology. 2007 Jun;121(2):238-47 [17462078.001]
  • [Cites] PLoS One. 2012;7(7):e40677 [22815789.001]
  • [Cites] Cell. 2006 Feb 24;124(4):783-801 [16497588.001]
  • [Cites] Ann Rheum Dis. 2009 Sep;68(9):1428-32 [18801761.001]
  • [Cites] Anesthesiology. 2011 Mar;114(3):603-13 [21270629.001]
  • [Cites] J Immunol. 2015 Oct 1;195(7):3190-7 [26297758.001]
  • [Cites] Oncotarget. 2016 Jun 28;7(26):40106-40114 [27223258.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5791-802 [18832739.001]
  • [Cites] Biochem Biophys Res Commun. 2015 Aug 21;464(2):541-7 [26159925.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):78-83 [11544529.001]
  • [Cites] Biochem Biophys Res Commun. 2011 Jun 17;409(4):675-80 [21616060.001]
  • [Cites] PLoS One. 2014 Oct 31;9(10):e111639 [25360699.001]
  • [Cites] J Cell Physiol. 2010 Feb;222(2):268-77 [19847802.001]
  • [Cites] J Immunol. 1991 Jul 1;147(1):22-8 [1711076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17390-5 [17088530.001]
  • [Cites] PLoS One. 2014 Oct 09;9(10):e109980 [25299052.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Virchows Arch. 2011 Oct;459(4):361-6 [21874508.001]
  • [Cites] Mol Med Rep. 2013 Oct;8(4):1074-8 [23982165.001]
  • [Cites] Chin Med J (Engl). 2007 Oct 5;120(19):1685-8 [17935670.001]
  • [Cites] J Immunol. 2010 Sep 1;185(5):2773-82 [20675592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5664-9 [24706787.001]
  • [Cites] Oncotarget. 2015 Sep 29;6(29):27751-62 [26336989.001]
  • [Cites] J Immunol. 2011 Jul 1;187(1):118-25 [21642542.001]
  • [Cites] Cancer Lett. 2011 Dec 27;313(2):226-34 [21974804.001]
  • [Cites] Circ Res. 2007 Feb 2;100(2):204-12 [17218606.001]
  • [Cites] J Leukoc Biol. 2009 Jun;85(6):996-1004 [19261929.001]
  • [Cites] Cancer Res. 2010 Dec 15;70(24):10044-50 [21159629.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5243-8 [17875751.001]
  • [Cites] J Cell Mol Med. 2015 Sep;19(9):2128-35 [26099505.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Eur J Immunol. 2006 Dec;36(12):3198-206 [17109473.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1107-13 [10353745.001]
  • [Cites] J Exp Clin Cancer Res. 2014 May 22;33:45 [24887394.001]
  • [Cites] Cancer Res. 2011 Mar 1;71(5):1637-46 [21343392.001]
  • [Cites] Cell Biol Toxicol. 2012 Aug;28(4):269-77 [22648782.001]
  • [Cites] Clin Cancer Res. 2011 Jun 15;17(12):3984-92 [21543518.001]
  • [Cites] Int Immunol. 2012 Aug;24(8):485-94 [22473704.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):615-22 [18199559.001]
  • [Cites] Acta Histochem. 2013 Mar;115(2):151-7 [22749378.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1439-45 [10193932.001]
  • [Cites] J Infect Dis. 2014 Nov 15;210(10):1605-15 [24872326.001]
  • (PMID = 29029545.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TLR4 / immune cells / tumor cells / tumor microenvironment
  •  go-up   go-down


72. Rutter GA, Hodson DJ, Chabosseau P, Haythorne E, Pullen TJ, Leclerc I: Local and regional control of calcium dynamics in the pancreatic islet. Diabetes Obes Metab; 2017 Sep;19 Suppl 1:30-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and regional control of calcium dynamics in the pancreatic islet.
  • Ca<sup>2+</sup> is the key intracellular regulator of insulin secretion, acting in the β-cell as the ultimate trigger for exocytosis.
  • In response to high glucose, ATP-sensitive K<sup>+</sup> channel closure and plasma membrane depolarization engage a sophisticated machinery to drive pulsatile cytosolic Ca<sup>2+</sup> changes.
  • Voltage-gated Ca<sup>2+</sup> channels, Ca<sup>2+</sup> -activated K<sup>+</sup> channels and Na<sup>+</sup> /Ca<sup>2+</sup> exchange all play important roles.
  • The use of targeted Ca<sup>2+</sup> probes has revealed that during each cytosolic Ca<sup>2+</sup> pulse, uptake of Ca<sup>2+</sup> by mitochondria, endoplasmic reticulum (ER), secretory granules and lysosomes fine-tune cytosolic Ca<sup>2+</sup> dynamics and control organellar function.
  • For example, changes in the expression of the Ca<sup>2+</sup> -binding protein Sorcin appear to provide a link between ER Ca<sup>2+</sup> levels and ER stress, affecting β-cell function and survival.
  • Across the islet, intercellular communication between highly interconnected "hubs," which act as pacemaker β-cells, and subservient "followers," ensures efficient insulin secretion.
  • New insights into the control of both the intra- and intercellular Ca<sup>2+</sup> dynamics may thus shed light on T2D pathology and provide novel opportunities for therapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 28466490.001).
  • [ISSN] 1463-1326
  • [Journal-full-title] Diabetes, obesity & metabolism
  • [ISO-abbreviation] Diabetes Obes Metab
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ca2+ / connectivity / imaging / insulin / organelle
  •  go-up   go-down


73. Yamamoto T, Schindler E: Short title: Anaesthetic mechanisms in the CNS Where and how do anaesthetics act? Mec. Anaesthesiol Intensive Ther; 2017;49(4):288-293

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short title: Anaesthetic mechanisms in the CNS Where and how do anaesthetics act? Mec.
  • Local anaesthesia implements the latter two elements in a conscious patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28953311.001).
  • [ISSN] 1731-2515
  • [Journal-full-title] Anaesthesiology intensive therapy
  • [ISO-abbreviation] Anaesthesiol Intensive Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; anaesthetic action mechanism / anaesthetics / analgesia / intraoperative patient immobility
  •  go-up   go-down


74. Khlopas A, Elmallah RK, Chughtai M, Yakubek GA, Faour M, Klika AK, Higuera CA, Molloy RM, Mont MA: The Learning Curve Associated with the Administration of Intra-Articular Liposomal Bupivacaine for Total Knee Arthroplasty: A Pilot Study. Surg Technol Int; 2017 Feb 07;30:314-320

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Liposomal bupivacaine is a long-acting, local, injectable anesthetic that is used to potentially mitigate post-operative pain after total knee arthroplasty (TKA).
  • Pain scores were calculated using the visual analogue scale (VAS), obtained from the first post-operative physical therapy note.
  • We used an ANOVA test for continuous and X2-square test for categorical variables.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28182826.001).
  • [ISSN] 1090-3941
  • [Journal-full-title] Surgical technology international
  • [ISO-abbreviation] Surg Technol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Péter Z, Rókusz L, Schneider F, Szalay F, Tornai I, Werling K, Makara M: [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016]. Orv Hetil; 2017 Feb;158(Suppl 1):3-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Treatment of hepatitis C is based on a national consensus guideline updated six-monthly according to local availability and affordability of approved therapies through a transparent allocation system in Hungary.
  • This updated guideline incorporates some special new aspects, including recommendations for screening, diagnostics, use and allocation of novel direct acting antiviral agents.
  • Indication of therapy in patients with no contraindication is based on demonstration of viral replication with consequent inflammation and/or fibrosis in the liver.
  • Therefore, expensive novel direct acting antiviral combinations as first line treatment are reimbursed only, if the freely available, but less effective and more toxic pegylated interferon plus ribavirin dual therapy deemed to prone high chance of adverse events and/or low chance of cure.
  • Interferon-free treatments and shorter therapy durations are preferred. Orv.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28218867.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Keywords] NOTNLM ; direct acting antiviral drug / direkt ható antivirális szer / genotype / genotípus / hepatitis C virus / hepatitis C-vírus / hepatocellular carcinoma / interferon / liver cirrhosis / májrák / májzsugor / polimerázgátló / polymerase inhibitor / protease inhibitor / proteázgátló / replication complex inhibitor / replikációskomplex-gátló / viral hepatitis / vírushepatitis
  •  go-up   go-down


76. Aznar MA, Tinari N, Rullán AJ, Sánchez-Paulete AR, Rodriguez-Ruiz ME, Melero I: Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally. J Immunol; 2017 Jan 01;198(1):31-39
MedlinePlus Health Information. consumer health - Cancer Immunotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.
  • Immune mechanisms have evolved to cope with local entry of microbes acting in a confined fashion but eventually inducing systemic immune memory.
  • Indeed, in situ delivery of a number of agents into tumors can mimic in the malignant tissue the phenomena that control intracellular infection leading to the killing of infected cells.
  • Intratumoral therapy with pathogen-associated molecular patterns or recombinant viruses is being tested in the clinic.
  • Local delivery means less systemic toxicity while focusing the immune response on the malignancy and the affected draining lymph nodes.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Immunotherapy / methods. Neoplasms / immunology. Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 by The American Association of Immunologists, Inc.
  • (PMID = 27994166.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


77. Butler SM: Changes to radiotherapy utilisation in Western NSW after the opening of a local service. J Med Radiat Sci; 2017 Dec;64(4):251-258

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes to radiotherapy utilisation in Western NSW after the opening of a local service.
  • INTRODUCTION: In 2011, the first radiotherapy centre in Western NSW Local Health District (WNSWLHD) was opened in the city of Orange.
  • METHODS: Data were collected on WNSWLHD patients, 17 years of age and above, who received radiotherapy in either 2010 or 2012 in New South Wales (NSW) or Australian Capital Territory (ACT).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.
  • [Cites] Surgery. 2000 Nov;128(5):847-61 [11056451.001]
  • [Cites] Rural Remote Health. 2008 Oct-Dec;8(4):1003 [19012470.001]
  • [Cites] Radiother Oncol. 2015 Nov;117(2):386-9 [26243679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):493-500 [27209499.001]
  • [Cites] Rural Remote Health. 2016 Jan-Mar;16(1):3640 [26960266.001]
  • [Cites] Int J Nurs Pract. 2003 Jun;9(3):176-82 [12801249.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2641-4 [19596940.001]
  • [Cites] Med J Aust. 2004 Jan 19;180(2):55-6 [14723583.001]
  • (PMID = 28160454.001).
  • [ISSN] 2051-3909
  • [Journal-full-title] Journal of medical radiation sciences
  • [ISO-abbreviation] J Med Radiat Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Health services / patient access / radiation oncology / rural / travel distance
  •  go-up   go-down


78. Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, Lockwood A: Principles of pharmacology in the eye. Br J Pharmacol; 2017 Dec;174(23):4205-4223

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both local and systemic disease may affect different anatomical regions of the eye.
  • Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre-corneal tear film, the structure and biophysiological properties of the cornea, the limited volume that can be accommodated by the cul-de-sac, the lacrimal drainage system and reflex tearing.
  • The tissue layers of the cornea and conjunctiva are further key factors that act to restrict drug delivery.
  • Novel exciting therapeutic approaches include methods for promoting transscleral delivery, sustained release devices, nanotechnology and gene therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 The British Pharmacological Society.
  • [Cites] Ophthalmology. 2012 Jul;119(7):1399-411 [22578446.001]
  • [Cites] Macromol Biosci. 2011 Jun 14;11(6):748-64 [21188688.001]
  • [Cites] Ophthalmology. 2012 Jan;119(1):66-73 [22115712.001]
  • [Cites] Eur J Pharm Biopharm. 2000 Sep;50(2):237-44 [10962233.001]
  • [Cites] Arch Ophthalmol. 1992 Feb;110(2):259-66 [1736876.001]
  • [Cites] Br J Ophthalmol. 2012 May;96(5):614-8 [22133988.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1327-35 [21790508.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 May;48(5):2230-7 [17460284.001]
  • [Cites] Expert Opin Drug Deliv. 2014 Oct;11(10):1647-60 [24975820.001]
  • [Cites] Acta Ophthalmol. 2015 Aug;93(5):411-5 [25988730.001]
  • [Cites] Mediators Inflamm. 2012;2012:126463 [22988344.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1041-6 [15037566.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):449-69 [12431694.001]
  • [Cites] J Pharm Sci. 1998 Dec;87(12):1479-88 [10189253.001]
  • [Cites] Dev Ophthalmol. 2008;41:1-20 [18453758.001]
  • [Cites] Ther Deliv. 2017 Jul;8(7):521-541 [28633591.001]
  • [Cites] Arch Ophthalmol. 1991 Feb;109(2):205-10 [1993029.001]
  • [Cites] J Biomed Opt. 2014 Jun;19(6):068001 [24887746.001]
  • [Cites] Biomaterials. 2011 May;32(14):3620-6 [21320724.001]
  • [Cites] Lancet. 1958 Dec 20;2(7060):1313-5 [13612208.001]
  • [Cites] Am J Ophthalmol. 2009 Jul;148(1):43-58.e1 [19376495.001]
  • [Cites] Curr Eye Res. 1988 May;7(5):483-6 [3409715.001]
  • [Cites] S Afr Med J. 1975 Jul 19;49(31):1259-62 [1098179.001]
  • [Cites] Nat Rev Drug Discov. 2014 Sep;13(9):655-72 [25103255.001]
  • [Cites] Ophthalmic Res. 2001 Jan-Feb;33(1):42-7 [11114604.001]
  • [Cites] Mol Ther. 2015 Aug;23 (8):1308-1319 [25896245.001]
  • [Cites] Biochem Biophys Res Commun. 2013 Feb 8;431(2):309-14 [23291166.001]
  • [Cites] Gene Ther. 2003 Mar;10(6):523-7 [12621456.001]
  • [Cites] Surv Ophthalmol. 2002 Aug;47 Suppl 1:S41-52 [12204700.001]
  • [Cites] Int Ophthalmol Clin. 2004 Summer;44(3):53-61 [15211177.001]
  • [Cites] Surv Ophthalmol. 2007 Sep-Oct;52(5):503-22 [17719372.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):154-63 [16765457.001]
  • [Cites] Br J Ophthalmol. 2006 Mar;90(3):262-7 [16488940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3896-901 [16505355.001]
  • [Cites] Biomech Model Mechanobiol. 2010 Feb;9(1):65-76 [19471979.001]
  • [Cites] Acta Pol Pharm. 2012 Jul-Aug;69(4):719-24 [22876616.001]
  • [Cites] J Ocul Pharmacol Ther. 2016 Mar;32(2):67-82 [26666398.001]
  • [Cites] Ophthalmology. 2011 Apr;118(4):663-71 [21459217.001]
  • [Cites] Int J Pharm. 2012 Jul 15;431(1-2):1-11 [22546296.001]
  • [Cites] Stem Cell Res. 2015 Jul;15(1):122-129 [26042795.001]
  • [Cites] J Pharm Sci. 2010 May;99(5):2219-39 [19894268.001]
  • [Cites] Prog Retin Eye Res. 2010 Nov;29(6):466-75 [20452456.001]
  • [Cites] Mater Sci Eng C Mater Biol Appl. 2017 Aug 1;77:895-903 [28532107.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1024-8 [11274081.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Nov 15;58(11):1131-5 [17097758.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1994 Mar;35(3):1038-45 [8125715.001]
  • [Cites] Ophthalmology. 2009 May;116(5):821-2 [19410940.001]
  • [Cites] J Clin Pharmacol. 2016 May;56(5):517-27 [26360129.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Nov;53(11):4794-800 [19687247.001]
  • [Cites] J Pharm Sci. 2015 Oct;104(10):3330-42 [26108574.001]
  • [Cites] Clin Ophthalmol. 2011;5:751-8 [21750608.001]
  • [Cites] Drug Metab Dispos. 1998 Aug;26(8):745-54 [9698288.001]
  • [Cites] Eur J Pharm Biopharm. 2010 Jun;75(2):200-5 [20144709.001]
  • [Cites] Nat Biotechnol. 2014 Nov;32(11):1121-33 [25211370.001]
  • [Cites] Pigment Cell Res. 1993 Jun;6(3):127-33 [8234197.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14 ):1432-44 [17021319.001]
  • [Cites] Curr Opin Ophthalmol. 2010 Jul;21(4):317-21 [20467317.001]
  • [Cites] Int J Pharm. 2016 Sep 10;511(1):359-366 [27436708.001]
  • [Cites] Curr Eye Res. 2013 Mar;38(3):342-52 [23216079.001]
  • [Cites] Clin Exp Ophthalmol. 2004 Dec;32(6):626-32 [15575833.001]
  • [Cites] Eye (Lond). 2013 Sep;27(9):1090-7 [23788205.001]
  • [Cites] Ophthalmology. 2016 Jul;123(7):1606-20 [27102010.001]
  • [Cites] Bioimpacts. 2016;6(1):49-67 [27340624.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Jan;49(1):320-32 [18172109.001]
  • [Cites] J Glaucoma. 2008 Mar;17(2):147-56 [18344762.001]
  • [Cites] Pharm Dev Technol. 2017 Mar 30;:1-7 [28300463.001]
  • [Cites] Ophthalmology. 2014 Nov;121(11):2081-90 [24974815.001]
  • [Cites] Retina. 2012 Mar;32(3):434-57 [22374154.001]
  • [Cites] Gene Ther. 2006 Aug;13(16):1191-7 [16838031.001]
  • [Cites] N Engl J Med. 2015 May 14;372(20):1887-97 [25938638.001]
  • [Cites] Clin Exp Ophthalmol. 2012 Aug;40(6):634-43 [22300341.001]
  • [Cites] Br J Pharmacol. 2015 Dec;172(24):5979-6023 [26650444.001]
  • [Cites] Biomed Microdevices. 2009 Oct;11(5):959-70 [19396548.001]
  • [Cites] J Ocul Pharmacol. 1994 Spring;10(1):83-92 [8207347.001]
  • [Cites] J Control Release. 2005 Jan 20;102(1):23-38 [15653131.001]
  • [Cites] J Ophthalmic Vis Res. 2011 Jan;6(1):36-46 [22454705.001]
  • [Cites] Exp Eye Res. 2002 Jun;74(6):719-35 [12126945.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Oct 31;52(1):37-48 [11672874.001]
  • [Cites] Am J Ophthalmol. 2017 Jul;179:32-38 [28428049.001]
  • [Cites] Phys Med Biol. 2005 Oct 7;50(19):4729-43 [16177501.001]
  • [Cites] Ther Adv Chronic Dis. 2015 Sep;6(5):234-45 [26336592.001]
  • [Cites] Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68 [26464438.001]
  • [Cites] Cell. 2014 Oct 9;159(2):428-39 [25303535.001]
  • [Cites] Mater Sci Eng C Mater Biol Appl. 2017 Aug 1;77:1275-1289 [28532005.001]
  • [Cites] Acta Biomater. 2011 Mar;7(3):921-35 [21050899.001]
  • [Cites] Drug Dev Ind Pharm. 2010 Sep;36(9):1027-35 [20545508.001]
  • [Cites] Gene Ther. 2005 Nov;12 (21):1544-50 [16034458.001]
  • [Cites] Eye Contact Lens. 2011 Jan;37(1):16-9 [21139501.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):1023-34 [21051703.001]
  • [Cites] Biomaterials. 2004 Mar-Apr;25(7-8):1339-48 [14643608.001]
  • [Cites] AAPS J. 2010 Sep;12(3):348-60 [20437123.001]
  • [Cites] Mol Ther. 2013 Mar;21(3):509-19 [23358189.001]
  • [Cites] Br J Clin Pharmacol. 2014 Oct;78(4):699-706 [24602183.001]
  • [Cites] J Control Release. 2010 Oct 15;147(2):225-31 [20655965.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):1-3 [17150014.001]
  • [Cites] Med Hypotheses. 2017 Jun;103:5-9 [28571808.001]
  • [Cites] Clin Exp Ophthalmol. 2007 Nov;35(8):713-8 [17997773.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1911-20 [24777708.001]
  • [Cites] Int J Pharm. 2013 Aug 30;453(1):167-80 [22771733.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):576-86 [17332885.001]
  • [Cites] Antiviral Res. 1996 Jan;29(1):73-5 [8721551.001]
  • [Cites] Eur J Pharm Biopharm. 2015 Sep;95(Pt B):203-14 [25960331.001]
  • [Cites] Clin Ophthalmol. 2011;5:633-43 [21629568.001]
  • [Cites] Pharm Res. 2013 Jan;30(1):41-59 [23054085.001]
  • [Cites] Prog Retin Eye Res. 2000 May;19(3):323-44 [10749380.001]
  • [Cites] Acta Ophthalmol. 2012 Nov;90(7):603-8 [22269010.001]
  • [Cites] Pharm Res. 2010 Oct;27(10):2043-53 [20535532.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):584-7 [3884542.001]
  • [Cites] Curr Opin Chem Biol. 2002 Aug;6(4):466-71 [12133722.001]
  • [Cites] Prog Retin Eye Res. 2005 Sep;24(5):537-59 [15955719.001]
  • [Cites] PLoS One. 2014 Apr 30;9(4):e95461 [24788066.001]
  • [Cites] Prog Retin Eye Res. 2017 Mar;57:134-185 [28028001.001]
  • [Cites] Doc Ophthalmol. 1997;93(1-2):149-57 [9476613.001]
  • [Cites] Curr Opin Ophthalmol. 2015 May;26(3):233-9 [25759965.001]
  • [Cites] N Engl J Med. 2011 May 19;364(20):1897-908 [21526923.001]
  • [Cites] Retina. 2004 Oct;24(5):676-98 [15492621.001]
  • [Cites] Prog Retin Eye Res. 2009 Mar;28(2):117-44 [19114125.001]
  • [Cites] Eur J Pharm Biopharm. 2015 Sep;95(Pt B):343-52 [25615882.001]
  • [Cites] J Control Release. 2014 Sep 28;190:157-71 [24798478.001]
  • [Cites] Expert Opin Pharmacother. 2012 Apr;13(5):723-45 [22348427.001]
  • [Cites] Biomed Mater. 2013 Oct;8(5):055007 [24057809.001]
  • [Cites] Drug Discov Today. 2011 Mar;16(5-6):270-7 [21167306.001]
  • [Cites] J Ocul Pharmacol Ther. 2014 Nov;30(9):729-51 [25073069.001]
  • [Cites] Curr Opin Ophthalmol. 2016 May;27(3):268-73 [26918787.001]
  • [Cites] Eur J Pharm Biopharm. 2015 Sep;95(Pt B):407-17 [26032291.001]
  • [Cites] Expert Opin Drug Deliv. 2012 Jul;9(7):837-61 [22703523.001]
  • [Cites] Exp Eye Res. 2003 Jun;76(6):643-52 [12742346.001]
  • [Cites] Mol Pharm. 2016 Apr 4;13(4):1251-7 [26820602.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1419-31 [17021318.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12 ):1023-35 [15573101.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Feb;46(2):641-6 [15671294.001]
  • [Cites] Drug Discov Today. 2008 Feb;13(3-4):135-43 [18275911.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2013 Apr 03;54(4):2483-92 [23532526.001]
  • [Cites] Retina. 2013 Mar;33(3):522-31 [22990317.001]
  • [Cites] J Oleo Sci. 2010;59(8):423-30 [20625234.001]
  • [Cites] Br J Ophthalmol. 2007 Sep;91(9):1244-6 [17431015.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164-81 [17069929.001]
  • [Cites] Eur J Pharm Biopharm. 2017 Apr;113:34-49 [27914235.001]
  • [Cites] Int J Pharm. 2015 Sep 30;493(1-2):86-95 [26220650.001]
  • [Cites] Arch Ophthalmol. 1972 Sep;88(3):308-13 [5053256.001]
  • [Cites] Acta Ophthalmol. 2014 Dec;92(8):e689-90 [25262598.001]
  • [Cites] Br J Ophthalmol. 2011 Dec;95(12 ):1631-7 [21546514.001]
  • [Cites] Surv Ophthalmol. 2004 Mar-Apr;49(2):197-213 [14998692.001]
  • [Cites] Trans Am Ophthalmol Soc. 2008;106:138-45; discussion 145-8 [19277229.001]
  • [Cites] Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26 [25603198.001]
  • [Cites] Acta Biomater. 2010 Apr;6(4):1370-9 [19900594.001]
  • [Cites] J Drug Target. 2010 Aug;18(7):489-98 [20192653.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):977-84 [15258595.001]
  • [Cites] J Adv Pharm Technol Res. 2010 Jul;1(3):291-6 [22247860.001]
  • [Cites] Exp Eye Res. 2012 May;98:23-7 [22440812.001]
  • [Cites] Br J Ophthalmol. 2011 May;95(5):604-12 [20733027.001]
  • [Cites] Prog Retin Eye Res. 2008 Nov;27(6):622-47 [18940262.001]
  • [Cites] Eur J Med Chem. 2010 Jan;45(1):326-34 [19889480.001]
  • [Cites] Intractable Rare Dis Res. 2012 Aug;1(3):103-14 [25343081.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Dec 13;57(14):2063-79 [16310884.001]
  • [Cites] Chem Rev. 2012 May 9;112(5):2853-88 [22360637.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):80-6 [20702826.001]
  • [Cites] Cancer Genomics Proteomics. 2013 Jan-Feb;10(1):1-18 [23382582.001]
  • [Cites] J Biomater Sci Polym Ed. 2011;22(1-3):59-75 [20540835.001]
  • [Cites] J Pharm Sci. 1996 Aug;85(8):819-23 [8863270.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Oct;47(10 ):4513-22 [17003447.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5403-20 [20980702.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Nov 3;57(11):1713-23 [16183163.001]
  • [Cites] J Pharm Biomed Anal. 2011 Dec 5;56(4):825-9 [21831555.001]
  • [Cites] Langmuir. 2009 Feb 17;25(4):2437-42 [19166277.001]
  • [Cites] Ann Intern Med. 1980 Nov;93(5):655-64 [6259979.001]
  • [Cites] Int J Pharm. 2017 Aug 7;528(1-2):395-405 [28624658.001]
  • [Cites] Adv Healthc Mater. 2016 Nov;5(21):2823-2831 [27616466.001]
  • [Cites] Br Med Bull. 2008;85:47-61 [18292605.001]
  • [Cites] J Pharm Pharmacol. 2011 Sep;63(9):1119-35 [21827484.001]
  • [Cites] Pharmacol Ther. 1983;21(1):35-51 [6353438.001]
  • [Cites] Drug Deliv Transl Res. 2016 Dec;6(6):735-754 [27798766.001]
  • [Cites] J Clin Pharmacol. 2007 Jan;47(1):121-6 [17192510.001]
  • [Cites] Ophthalmic Res. 2007;39(5):244-54 [17851264.001]
  • [Cites] J Pharm Sci. 1997 Jun;86(6):716-20 [9188054.001]
  • [Cites] Int J Pharm. 2017 Apr 30;522(1-2):119-127 [28232270.001]
  • [Cites] Mol Ther. 2001 Feb;3(2):241-8 [11237681.001]
  • [Cites] Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:529-540 [27987741.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4532-9 [17003449.001]
  • [Cites] Chem Soc Rev. 2016 Mar 7;45(5):1457-501 [26776487.001]
  • [Cites] BMB Rep. 2015 Apr;48(4):193-9 [25560700.001]
  • [Cites] Arch Ophthalmol. 2008 Aug;126(8):1143-6 [18695113.001]
  • [Cites] Expert Opin Drug Deliv. 2014 Oct;11(10):1575-90 [24931577.001]
  • [Cites] Nanomedicine (Lond). 2017 Mar;12 (6):683-702 [28186436.001]
  • [Cites] Arch Ophthalmol. 1972 Nov;88(5):549-52 [4634795.001]
  • [Cites] World J Biol Chem. 2012 Apr 26;3(4):73-92 [22558487.001]
  • [Cites] Eur J Pharm Biopharm. 2015 Nov;97(Pt B):338-49 [26614556.001]
  • [Cites] Eye (Lond). 2011 Nov;25(11):1504-11 [21921952.001]
  • [Cites] AAPS PharmSciTech. 2011 Dec;12 (4):1335-47 [21979886.001]
  • [Cites] Nat Methods. 2014 Aug;11(8):855-60 [24930130.001]
  • [Cites] Int Ophthalmol Clin. 1980 Fall;20(3):33-49 [6998899.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Nov 15;58(11):1224-42 [17095114.001]
  • [Cites] Pharm Res. 2011 Oct;28(10):2379-85 [21744171.001]
  • [Cites] Optometry. 2011 Jan;82(1):38-43 [21146792.001]
  • [Cites] N Engl J Med. 1997 Jul 10;337(2):83-90 [9211677.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Oct 10;52(11):7944-8 [21896859.001]
  • [Cites] Regen Med. 2006 Sep;1(5):715-9 [17465740.001]
  • [Cites] J Control Release. 2002 Jan 17;78(1-3):211-8 [11772462.001]
  • [Cites] Hong Kong Med J. 2012 Dec;18(6):488-95 [23223649.001]
  • [Cites] Ophthalmology. 2012 Jul;119(7):1388-98 [22555112.001]
  • [Cites] Am J Ophthalmol. 2012 May;153(5):939-48 [22310078.001]
  • [Cites] Ophthalmology. 2008 Oct;115(10):1655-62 [18538404.001]
  • [Cites] Eye (Lond). 2013 Mar;27(3):289-90 [23485959.001]
  • [Cites] Drug Discov Today. 2012 Jul;17(13-14):748-59 [22504325.001]
  • [Cites] Development. 2013 Jun;140(12):2576-85 [23715550.001]
  • [Cites] Phys Med Biol. 2007 Apr 7;52(7):2021-34 [17374925.001]
  • [Cites] J Adv Pharm Technol Res. 2011 Jul;2(3):192-4 [22171317.001]
  • [Cites] Retina. 2004 Dec;24(6):900-4 [15579987.001]
  • [Cites] Ther Deliv. 2017 Jul;8(8):685-699 [28730942.001]
  • [Cites] J Control Release. 2014 Sep 28;190:94-114 [24993429.001]
  • [Cites] Lancet. 2006 Jul 29;368(9533):365 [16876661.001]
  • [Cites] Int J Pharm. 2008 Feb 4;348(1-2):175-8 [17897799.001]
  • [Cites] Am J Ophthalmol. 1986 May 15;101(5):515-23 [3706455.001]
  • [Cites] Eye Contact Lens. 2010 May;36(3):170-6 [20351555.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Feb;36(2):442-53 [7843913.001]
  • [Cites] J Control Release. 2015 Dec 10;219:652-668 [26435454.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2714-30 [24777644.001]
  • [Cites] Int J Pharm. 2001 Feb 1;213(1-2):75-81 [11165095.001]
  • [Cites] J Pharm Sci. 2015 Nov;104(11):3814-23 [26227825.001]
  • [Cites] Invest Ophthalmol. 1966 Jun;5(3):264-76 [5947945.001]
  • [Cites] Blood. 2001 Jan 15;97(2):388-92 [11154213.001]
  • (PMID = 28865239.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


79. Fu Y, Karbaat L, Wu L, Leijten J, Both SK, Karperien M: Trophic Effects of Mesenchymal Stem Cells in Tissue Regeneration. Tissue Eng Part B Rev; 2017 Dec;23(6):515-528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal stem cells (MSCs) are considered to hold great therapeutic value for cell-based therapy and for tissue regeneration in particular.
  • These bioactive factors have diverse actions like modulating the local immune system, enhancing angiogenesis, preventing cell apoptosis, and stimulating survival, proliferation, and differentiation of resident tissue specific cells.
  • We will also highlight the various underlying mechanisms used by MSCs to act as trophic mediators.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28490258.001).
  • [ISSN] 1937-3376
  • [Journal-full-title] Tissue engineering. Part B, Reviews
  • [ISO-abbreviation] Tissue Eng Part B Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; apoptosis / extracellular vesicles / growth factors / membrane nanotubes / mesenchymal stem cells / trophic effects
  •  go-up   go-down


80. Wang H, Zhang M, Zhang L, Li S, Li L, Li X, Yu M, Mou Z, Wang T, Wang C, Su Z: Near-infrared light and pH-responsive Au@carbon/calcium phosphate nanoparticles for imaging and chemo-photothermal cancer therapy of cancer cells. Dalton Trans; 2017 Nov 07;46(43):14746-14751
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-infrared light and pH-responsive Au@carbon/calcium phosphate nanoparticles for imaging and chemo-photothermal cancer therapy of cancer cells.
  • A simple, mild and reproducible synthetic route was developed to fabricate the multifunctional Au@carbon/calcium phosphate core-shell nanoparticles (Au@C/CaP NPs), which act as an efficient nanoplatform for pH/near-infrared (NIR) dual-responsive drug delivery, X-ray computed tomography (CT) imaging and synergistic chemo-photothermal cancer therapy in vitro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29034940.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, Nishimura K, Shibata E, Tamaki M, Yoshimoto S, Kishi F, Kishi S, Matsuura M, Nagai K, Abe H, Doi T: A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep; 2017 May;6(1):55-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.
  • Patients with mixed cryoglobulinemic nephropathy who have a rapidly progressive glomerulonephritis should receive immunosuppressive therapy.
  • After disease stabilization, patients should receive concurrent therapy for the underlying HCV infection.
  • The standard therapy of a chronic HCV infection is IFN monotherapy or IFN combined with ribavirin; however, after the introduction of direct-acting antivirals (DAAs), the standard therapy for patients with HCV genotype 1 has dramatically changed.
  • We report a case of HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) successfully treated by daclatasvir and asunaprevir, which are IFN-free DAAs for HCV, in combination with angiotensin II receptor blocker without immunosuppressive therapy.
  • Blood examination revealed a high copy number of HCV-RNA (6.4 log IU/mL, type 1), cryoglobulinemia, paraproteinemia of IgM-κ, and hypocomplementemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2013 May 16;368(20):1878-87 [23607594.001]
  • [Cites] J Hepatol. 2013 Apr;58(4):646-54 [23178977.001]
  • [Cites] Postgrad Med. 2015 May;127(4):413-7 [25746436.001]
  • [Cites] Gastroenterology. 2014 Feb;146(2):430-41.e6 [24184810.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2011 May 10;100(5):1289-95 [21702146.001]
  • [Cites] J Hepatol. 2013 Apr;58(4):655-62 [23183526.001]
  • [Cites] N Engl J Med. 2001 Jul 5;345(1):41-52 [11439948.001]
  • [Cites] J Hepatol. 2014 Aug;61(2):219-27 [24727123.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):751-6 [8107741.001]
  • [Cites] Nephrol Dial Transplant. 2007 Jul;22(7):1840-8 [17478492.001]
  • [Cites] Rheumatology (Oxford). 2006 Jul;45(7):842-6 [16418196.001]
  • [Cites] Am J Kidney Dis. 1989 Dec;14(6):445-51 [2596471.001]
  • [Cites] Intern Med. 2010;49(14):1321-3 [20647643.001]
  • [Cites] Clin Exp Rheumatol. 2011 Nov-Dec;29(6):933-41 [22153224.001]
  • [Cites] Hepatology. 2012 Mar;55(3):742-8 [21987462.001]
  • [Cites] Hepatology. 2014 Jun;59(6):2083-91 [24604476.001]
  • [Cites] Blood. 2010 Jul 22;116(3):326-34; quiz 504-5 [20439619.001]
  • [Cites] Liver Int. 2010 Oct;30(9):1259-69 [20633102.001]
  • [Cites] J Hepatol. 2005 Mar;42(3):334-40 [15710215.001]
  • [Cites] Autoimmun Rev. 2011 Jun;10 (8):444-54 [21303705.001]
  • [Cites] Ann Rheum Dis. 2014 Oct;73(10):e64 [25038237.001]
  • [Cites] Gastroenterology. 2014 Aug;147(2):359-365.e1 [24818763.001]
  • [Cites] Ann Intern Med. 1996 Nov 1;125(9):781-2 [8929026.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4644-50 [12370404.001]
  • [Cites] Case Reports Immunol. 2015;2015:816424 [25815218.001]
  • (PMID = 28509128.001).
  • [ISSN] 2192-4449
  • [Journal-full-title] CEN case reports
  • [ISO-abbreviation] CEN Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Cryoglobulinemic membranoproliferative glomerulonephritis / Hepatitis C virus / Interferon-free direct-acting antiviral agents
  •  go-up   go-down


82. Kim DW, Cho SH: Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res; 2017 Jul;9(4):299-306
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Defining endotypes can help clinicians predict disease prognosis, select subjects suitable for a specific therapy, and assess risks for comorbid conditions, including asthma.
  • Thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, which are mainly secreted by epithelial cells in response to external stimuli, act on type 2 ILCs and T helper 2 (Th2) cells, inducing IL-4, IL-5, and IL-13.
  • Local immunoglobulin E (IgE) production is also a signature event in nasal polyps (NP).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.
  • [Cites] J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):575-82 [27393771.001]
  • [Cites] J Allergy Clin Immunol. 2010 May;125(5):1061-8 [20392482.001]
  • [Cites] N Engl J Med. 2014 May 29;370(22):2102-10 [24846652.001]
  • [Cites] Rhinol Suppl. 2012 Mar;(23):3 p preceding table of contents, 1-298 [22764607.001]
  • [Cites] J Allergy Clin Immunol. 2012 Jan;129(1):216-27.e1-6 [22119406.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):1080-7 [17617600.001]
  • [Cites] Laryngoscope. 2014 Apr;124(4):E115-22 [24122812.001]
  • [Cites] Rhinology. 2012 Mar;50(1):1-12 [22469599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8765-70 [27432971.001]
  • [Cites] Clin Exp Otorhinolaryngol. 2015 Jun;8(2):123-8 [26045910.001]
  • [Cites] Clin Exp Allergy. 2015 Feb;45(2):394-403 [25429730.001]
  • [Cites] Am J Respir Crit Care Med. 2013 Aug 15;188(4):432-9 [23805875.001]
  • [Cites] Mol Immunol. 2016 Apr;72:74-80 [26991049.001]
  • [Cites] J Allergy Clin Immunol. 2016 May;137(5):1514-24 [26684290.001]
  • [Cites] Clin Exp Allergy. 2012 Jun;42(6):883-90 [22093003.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):535-45 [14970180.001]
  • [Cites] Rhinology. 2005 Sep;43(3):162-8 [16218508.001]
  • [Cites] PLoS One. 2016 Feb 05;11(2):e0148442 [26849431.001]
  • [Cites] J Allergy Clin Immunol. 2016 Nov;138(5):1344-1353 [